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Abstract
Cervical cancer is the second most common cancer in women and is caused by a
persistent infection of the cervical epithelium by the Human Papilloma Virus (HPV). Adherens
(AJ) and tight junctions (TJ) play a key role in maintaining the apical-basolateral polarity and
cohesive structure of epithelial cells. These junctions are maintained by the interaction of
several key proteins including, claudins, catenins, cadherins and SNAIL. This study aims to
identify the expression profile of several AJ and TJ proteins and to identify and genotype HPV
DNA in several cases of cervical neoplasia. This study also aims to investigate the pathogenesis
of aberrant AJ and TJ expression using cell based models.
This study utilised a PCR based method to detect and genotype HPV DNA in 126
formalin-fixed paraffin embedded tissue samples. In tandem, tissue microarrays were produced
from cervical biopsy samples and utilised to immunohistochemically examine the expression of
several AJ and TJ proteins. The HeLa cervical cancer cell line was transfected with plasmids
containing claudin-1 and claudin-7 genes to generate cell lines stably expressing claudin-1
claudin-7 respectively. Knockdown of SNAIL expression was performed in the SiHa cervical
cancer cell line.
An aberrant expression profile of AJ and TJ proteins was observed in cases of cervical
neoplasia with increased expression of claudin-1, claudin-7, N-cadherin p120-catenin, SNAIL
and decreased expression of E-cadherin compared to normal cervical epithelium. HPV DNA was
detected and genotyped in 60 cervical tissue samples. HPV-16 was the most prevalent subtype,
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and was the subtype most associated with aberrant AJ and TJ expression. Knockdown of SNAIL
expression had no effect on E-cadherin expression in SiHa cells while overexpression of claudin1 and claudin-7 suppressed cellular motility in vitro, and decreased permeability in HeLa cells.
This study identified aberrant expression of several AJ and TJ proteins which may be of
potential use as biomarkers in the identification of pre-invasive cervical lesions. This study also
identified that claudin-1 and claudin-7 overexpression in HeLa cells reduced cell migration and
increased TEER values. This indicates the acquisition of invasive and metastatic properties in
malignant cells is likely reliant on the synergistic interaction of several AJ and TJ proteins.
.
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1. General Introduction
1.1 Cervical cancer overview
Cervical cancer is a malignancy that develops in the epithelium lining the cervix. This
epithelium consists of two major subtypes, a simple columnar type in the endocervix, and the
stratified squamous epithelium in the ectocervix. Squamous cell carcinoma arising from the
stratified squamous epithelium is the most common cervical malignancy, accounting for
approximately 85% of cervical malignancies. Adenocarcinoma, derived from the simple
columnar epithelium, constitutes around 10% of cervical malignancies with the remaining 5%
consisting of adenosquamous and other rare tumour types [1]. Cervical cancer develops from
precursor lesions called cervical intraepithelial neoplasia (CIN), also termed squamous
intraepithelial lesions (SIL), which may progress to invasive carcinomas or may also regress to
normal epithelium.

The introduction of cervical screening programmes, to detect these

premalignant lesions before they develop into invasive carcinomas, has greatly reduced the
incidence of cervical cancer. Indeed, it has been shown that in countries with established
systematic screening programmes, the number of cervical cancer deaths has been reduced by
around 70% [2]
One of the most important discoveries in the aetiological investigation of cervical cancer
over the last 25 years has been the demonstration that cervical cancer is caused by the
persistent infection by certain genotypes of the Human Papillomavirus (HPV). The important
role of HPV in the development of cervical cancer is highlighted by the fact that HPV DNA is
12

present in 99% of cervical tumours [3]. Based on their association with cervical cancer and
precursor lesions, HPVs can also be grouped to high-risk and low-risk HPV types. Low-risk HPV
types include types 6, 11, 42, 43, and 44. High-risk HPV types include types 16, 18, 31, 33, 34,
35, 39, 45, 51, 52, 56, 58, 59, 66, 68, and 70. Of these high risk types, four are most often found
within the malignant cells of cervical cancers, with type 16 accounting for about half of the
cases in the United States and Europe and types 18, 31, and 45 accounting for an additional 25
to 30% of cases [4].
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1.2 The Cervix
The cylindrical lower part of the uterus, the cervix, has a constricted opening at each end; the
os. The internal os is located at the upper end of the cervix and is the opening of the cervix
inside the uterine cavity (Figure 1.1). The external os is located at the lower end of the cervix
and opens into the vagina [5] .The passageway linking the external and internal os is termed the
endocervical canal. The lining of the endocervical canal differs completely from the rest of the
uterine endometrium as it contains large branched glands. The endocervix is lined with a single
layer of columnar, mucin-secreting simple columnar epithelium.

Figure 1.1 Diagram of the uterus, including the location of the cervix, the internal and
external os and the cervical canal [6].
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Towards the external os the columnar epithelium is gradually replaced by stratified squamous
epithelium, in an area known as the transformation zone (TZ) or the squamo-columnar
junction. The TZ is the area of the cervical epithelium most likely to be affected by disease [6].
The ectocervix is the portion of the cervix that projects into the vagina and has a convex surface
with an epithelial lining. The epithelium of the ectocervix is non-keratinised stratified squamous
epithelium which is continuous with the squamous epithelium lining the vagina [6]. The
epithelium of the ectocervix consists of several distinct layers of cells (Figure 1.2). Along the
basement membrane are the basal cells which are immature, actively dividing cells with
relatively large nuclei [7]. The layer of cells above this are termed the parabasal and
intermediate layers; with cells in this part of the epithelium showing a recognisable chromatin
pattern and often being vacuolated. In fully mature epithelium, a superficial layer lies above the
intermediate layer, with superficial cells containing small pyknotic nuclei [7].

Figure 1.2 Outline of different cell layers found in the stratified squamous epithelium of the
ectocervix. Arrows indicate the position of basal, parabasal, intermediate and superficial cell
layers within the epithelium.
15

1.3 Cervical cancer epidemiology
Cervical cancer is the second most common cancer in women worldwide, with
an estimated 528,000 new cases annually, and being responsible for approximately 266,000
deaths in 2012 (WHO 2012). A large majority, around 85%, of the global burden occurs in the
less developed regions, where it accounts for almost 12% of all female cancers, most likely as a
result of the lack of systemic cervical screening programmes in many developing countries [8]
[2]. Eastern Africa has some of the highest incidences in the world, with an age standarised rate
(ASR) of 42.7 per 100,000, meaning in these countries it is the most common cancer in women,
overtaking even breast cancer (WHO 2012). Mortality rates are also highest in developing
countries with 87% of world cervical deaths occurring in these countries. Mortality varies 18fold between the different regions of the world, with rates ranging from less than 2 per 100,000
in Western Asia, Western Europe and Australia/New Zealand to more than 20 per 100,000 in
Melanesia (20.6), Middle (22.2) and Eastern (27.6) Africa (WHO 2012).
In Ireland, cervical cancer incidence has an ASR of 15.1 per 100,000 which is above the
EU average of 11.3 and also above the UK (7.9) German (9.8) and Swedish (8.6) average.
Cervical cancer incidences in are Ireland are similar to Poland (15.3), Denmark (12.1), and
Croatia (12.1) (WHO 2012) (Figure 1.3). The highest incidences in Europe are found mostly in
eastern European countries such as Romania, Bulgaria and Serbia which all have an ASR above
20.6 (Figure 1.3). The mortality rate in Ireland at an ASR of 4.3 per 100,000 people is above the
EU average of 3.7 and the same as both the Czech Republic and Croatia (WHO 2012). In Europe
the lowest mortality rates are found in the UK, Germany, Iceland and Finland, with rates in
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these countries all below 2.5 per 100,000 (Figure 1.3). The highest mortality rates in Europe are
found mostly in the east, with Russia, Ukraine and Romania all having mortality rates above 7.5
per 100,000 (Figure 1.3).
The recent introduction of vaccines against HPV should help significantly reduced the
incidence of cervical cancer in countries with properly implemented vaccination programmes.
Early studies show that HPV vaccination, recommended for both women and men between 926 years old who have not previously been exposed to HPV, has the potential to significantly
reduce the rate of cervical cancer worldwide [9]. Two main vaccines are currently available,
Gardasil and Cervarix. The Gardasil vaccine is produced by Merck & Co., Inc. and protects
against two low risk (6 and 11) and two high risk (16 and 18) HPV subtypes. The Cervarix
vaccine is produced by GlaxoSmithKline and offers protection against high risk HPV types 16
and 18. The vaccines have been shown to provide protection against persistent cervical HPV
16/18 infections for up to 8 years, which is the maximum time of research follow-up thus far
[10]. Both vaccines are based on virus like particles (VLPs) that are composed of the viral L1
proteins, which is the main capsid protein of the virus, and elicits a strong immunogenic
response in the host immune system [11].
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Figure 1.3 Comparison of European estimated cervical cancer incidence and mortality for
2012 (WHO 2012).
The highest incidence and mortality rates in Europe are mostly found in eastern European
countries such as Romania, Lithuania and Bulgaria. Ireland has higher rates of incidence and
mortality than the EU average and of other western european countries such as the UK, France
and Germany.
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1.4 Papillomavirus background
Papillomaviruses are members of the Papillomaviridae family, which consist of a vast
group of DNA viruses that infect a wide array of animals, in a species specific manner [12].
Papillomaviruses nomenclature divides the family into genus, species, types, subtypes and
variants [12]. There are 16 genera in the Papillomavirus family, each genus is designated a letter
from the Greek alphabet e.g alpha-papillomaviruses, beta-papillomviruses etc. [13] The most
clinically important HPV types are contained within the alpha-papillomavirus genera (Figure
1.5). Different genera share less that 60% nucleotide homology in the Late gene 1 (L1) and less
than 43% sequence homology in the full length genome [13]. Contained within the 16 genera
there are 44 species. Species within genera have between 60 and 70% sequence homology in
the L1 gene. Each species is identified by a number, with each genus containing a varying
number of species. Within a species there may be several types which not only have a large
degree of genetic similarity, but also usually share biological and pathological properties.
Specific types are usually named after the host species they infect, such as Bovine
Papillomavirus or Canine Oral Papillomavirus [12]. When more than one distinct isolate of
papillomavirus occurs in a single host, each isolate is assigned a number, e.g. Human
Papillomavirus type 1, Human Papillomavirus type 2 etc. In order for a papillomavirus to be
defined as a specific type, it must have less than 90% L1 sequence homology with any other
papillomavirus type [13]. Subtypes are defined as being between 2-10% divergent in the L1
gene from a known PV type. An example of this is HPV-55 genome which is 95% homogenous to
the HPV-44 genome and therefore is classified as a sub-type of HPV-44. Lastly, variants differ in
their genomic sequence by less than 2% from another papillomavirus type [13] [14].
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Figure 1.4 Phylogenic papillomaviridae tree outlining the 16 different papillomavirus genera
[13]
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1.5 Papillomavirus life cycle
Initial infection requires access of the virion to cells in the basal layer of the cervical epithelium
usually through a micro-abrasion in the epithelium (Figure 1.5). Following infection and
uncoating, it is thought that the virus maintains its genome as a low copy number episome in
the basal cells of the epithelium [15]. In uninfected epithelium, basal cells exit the cell cycle
soon after migrating into the suprabasal cell layers and undergo a process of terminal
differentiation. During papillomavirus infection the restraint on cell cycle progression is
abolished and normal terminal differentiation is retarded [16]. For the production of infectious
virions, HPV must amplify its viral genome and package them into infectious particles. For most
HPV types this occurs in the mid or upper epithelial layers following an increase in activity of
the late promoter [17]. The late promoter is tightly regulated so as to limit the exposure of the
highly immunogenic viral capsids to the host immune system. After the viral genome is packed
into the capsid protein the newly formed viruses are not released from the cell until it reaches
the surface of the epithelium and the cells are sloughed off [15].
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Figure 1.5 HPV mediated progression from normal cervical epithelium to invasive cancer [18]
The disease begins with infection of the basal cells of the epithelium by viral particles. Viral
genes become expressed in infected cells which may lead to the proliferation of dysplastic cells
within the epithelium. When dysplastic cells make up to one third of the depth of the
epithelium the disease is classified as a low grade squamous epithelial lesion (LSIL). When
dysplastic cells make up more than one third and up to the entire depth of the epithelium the
disease is classified as a high grade squamous epithelial lesion (HSIL). Over time, with persistent
expression of viral genes, dysplastic cells may penetrate the basement membrane leading to
the development of an invasive cancer.
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1.6 HPV induced cervical abnormalities

Infection of cervix with HPV most commonly results in genital warts. These lesions occur as a
result on non-oncogenic HPV-6 and HPV-11 infection [19]. Infection with a high-risk HPV type
can lead to abnormalities in cells of cervical epithelium giving rise to initially non-invasive
neoplastic lesions, termed cervical intraepithelial neoplasia (CIN), which can in turn lead to the
development of invasive tumours [12] . Neoplastic cells are characterised by a number of
features including hyperchromasia, increase in mitotic figures and a high nuclear to cytoplasmic
ratio [20]. CIN is subdivided in three grades, with CIN 1 the lowest and CIN 3 the highest. In CIN
1 lesions abnormal cells are confined to no more than a third of the basal side of the
epithelium. In CIN 2 lesions abnormal cells are present in up to two thirds of the epithelium
with maturation only occurring in the superficial third of the epithelium, while in CIN 3 lesions
more than two thirds of the epithelium contains abnormal cells (Figure 1.5 & 1.6) [21]. More
recently a two tier system, termed the Bethesda system, for grading neoplastic lesions of the
cervix has been developed with CIN 1 now termed low grade squamous intraepithelial lesion
(LSIL) and CIN 2 and 3 being combined to form a new classification termed high grade
squamous intraepithelial lesion (HSIL) (Figure 1.5 & Figure 1.6) [22]. All grades of lesions may
either progress to a higher grade or regress over time. CIN 1 or LSIL lesions have a 60%
likelihood of regression, a 30% risk of becoming a persistent lesion, a 10% risk of progression to
a CIN3 lesion and a 1% chance of becoming an invasive carcinoma [22]. CIN 2 has 40%
likelihood of regression, 40% chance of persistence, 20% risk of progression to CIN3 and a 5 %
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risk of becoming an invasive carcinoma. CIN 3 has a 33% likelihood of regressing, a 56% chance
of persistence and a less than 12% risk of progressing to an invasive carcinoma [21] [22].

1.7 CIN Treatment
Several methods may be utilised to remove or destroy pre malignant lesions of the cervix,
including laser ablation, cold coagulation, and long loop excision of the transformation zone
(LLETZ), also referred to as loop electrosurgical excision procedure (LEEP) [23]. LLETZ is one of
the most frequently used treatments for CIN as it can be performed without general anesthetic
and generally has very few complications [24] [25]. After examination of the cervix during
colposcopy, the transformation zone and any additional dysplasia is identified using a dilute
acetic acidic solution that temporarily stains densely nucleated areas. CIN lesions contain a
larger amount of immature, proliferating cells and therefore these areas stain stronger than
normal fully mature epithelium that is more sparsely nucleated [23]. After identification of the
lesion, a physician uses a wire loop with an electrical current passing through it to excise and
caurterise the area identified [24]. One of the benefits of LEETZ compared to other techniques
is that the lesion is not destroyed and can be subsequently histologically analysed to assess the
severity and extent of dysplasia. The effect of LEETZ on fertility is still debated with previous
studies finding that it had no effect on fertility [26], whereas a more recent study found that
those with a time interval from LEEP to pregnancy of less than 12 months compared with 12
months or more were at significantly increased risk for spontaneous abortion, with risk of 18%
compared with 4.6%, respectively [27].
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Figure 1.6 Images from cervical samples used in this study showing different grades of
squamous intra-epithelial lesion in the uterine cervix. N.E.M = No evidence of malignancy. LSIL
= Low grade squamous intra-epitthelial lesion, with abnormal immature cells in the basal third
of the epithelium. HSIL = High grade squamous intra-epitthelial lesion, with diffuse atypia and
immature cells occupying the entire depth of the epithelium. SCC = Squamous cell carcinoma,
malignant cells invaded though basement membrane with complete loss of epithelial structure
and large number of proliferating cells. Stained with hematoxylin and eosin, x100 magnification
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1.8 HPV Proteins
The HPV genome is divided into early and late genes, depending on the stage the viral life cycle
they are expressed, transcribed into 6 early proteins (E1, E2, E4, E5, E6, E7) and two late
proteins (L1 and L2) (Figure 1.8) [28]. The transcription of the open reading frames (ORFs) into
functional proteins is regulated by promoters within the viral genome. The HPV-16 genome
contains two major promoters. The P97 promoter lies upstream of the E6 ORF and is
responsible for almost all early gene expression (Figure 1.7). The P670 promoter lies within the
E7 ORF region and is responsible for late gene expression [28] [29]. The HPV-16 P97 promoter,
equivalent to P99 in HPV-31 and P105 in HPV-18, is very potent and tightly controlled, primarily
by upstream cis-elements in the LCR [17]. Induction of the late P670 promoter in HPV-16, and
equivalent promoters in other HPV types, only occurs in differentiated keratinocytes [30]

Figure 1.7 Linear representation of the HPV-16 genome [28]
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Figure 1.8 Diagram showing the HPV protein expression profile in the cervical epithelium,
displaying the relative expression levels of the different HPV proteins at different stages of
the viral life cycle. [28]

1.8.1 E1 Protein

The E1 ORF is the largest ORF in the HPV genome and encodes one the most conserved proteins
in the HPV genome [12]. E1 proteins are approximately 68 kDa in size and are expressed at low
levels in HPV-positive cells [29]. E1 is the only viral protein shown to have enzymatic activity; it
can function as an ATPase and as an ATP dependent helicase. This enzymatic activity allows the
E1 protein to play a key role in viral replication by catalysing the unwinding of the DNA at the
origin of replication [31]. E1 has been shown to bind the alpha subunit of DNA polymerase,
recruiting the replication machinery to the viral origin of replication. Replication is initiated by
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the E1 protein through binding to AT-rich regions in the LCR. Binding is stabilised and
strengthened through cobinding with E2 protein [29].

1.8.2 E2 Protein

The E2 protein is required for both the replication of viral DNA and transcriptional
regulation[32]. E2 proteins are approximately 50 kDa in size and function as dimers. The C
terminus encodes a DNA binding domain that has been crystallized and shown to consist of a
dimeric β-barrel structure that binds to LCR region of HPV DNA [29]. The LCR of high-risk HPV
types contain 4 E2 binding sites, 3 of which are adjacent to the E1 binding sites and increase E1
binding affinity [16]. E2 can have a dual function depending on its concentration. At low
concentration it acts as a promoter of early gene expression, whereas while at high
concentrations it represses early gene expression by interfering with the binding of
transcription factors such as TFIID and Sp1 [33].

1.8.3 E4 Protein

The E4 ORF completely overlaps with the E2 ORF (Figure 1.8). However it is transcribed in a
different reading frame. The E4 protein is heterogenous, forming a fusion product with a 5
amino acid sequence from the N-terminus of E1. For this reason it is referred to as E1^E4 [29].
Despite its position in the genome and its ‘E’ name it is primarily expressed in the later stages of
the viral life cycle. E1^E4 proteins from high-risk types associate with keratin networks in cells
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and, when overexpressed in transient-transfection assays, can induce their collapse [34]. This
suggests a role for E1^E4 in facilitating the release of virions from the cell, but in natural
infections of high-risk types only a limited amount of collapse has been observed [16]

1.8.4 E5 Protein

The HPV E5 proteins are small hydrophobic proteins whose exact functions remain unresolved.
These proteins are localized to endosomal membranes and the Golgi but on occasion are found
in the cellular membranes. E5 has weak oncogenic properties which occur through increasing
epidermal growth factor receptor (EGFR) expression, and inhibiting the expression of major
histocompatibility complex (MHC)-I and MHC-II on the plasma membrane [35]. E5 expression
alone is not sufficient to initiate cell transformation, however it can act to increase the potency
of E6 and E7 when co-expressed with them [36]. E5 has recently been shown to initiate cell
fusion, producing genetically unstable tetraploid cells which may be more susceptible to
oncogenic transformation [37]

1.8.5 E6 Protein

The E6 protein contains approximately 160 amino acids and is one of the earliest expressed
proteins in the viral life cycle (Figure 1.8). In conjunction with other viral proteins, E6 serves to
drive the cell into an actively dividing and undifferentiated state that is more favourable for the
production and replication of new virions [31]. It is the promotion of a pro-replicative state
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within the cell that leads to the malignant transformation of infected cells and ultimately,
tumour development. The influence of E6 protein over the cell cycle is illustrated by the ability
of E6 protein from highrisk HPV being sufficient for the induction and maintenance of cellular
transformation in-vitro [38]. One of the primary methods by which E6 interferes with the cell
cycle is through its interaction with the pro-apotosis protein p53 (Figure 1.9) [31]. The p53
protein responds to DNA damage by transcriptionally activating a number of cell cycle
regulatory pathways, including the p21 and GADD 45 pathways that can arrest the cell cycle or
trigger apoptosis [29]. The degradation of p53 occurs through a trimeric complex containing E6,
E6-associated protein (E6AP) and p53. E6AP recruits a complex of enzymes called the ubiquitin
complex, which then target p53 for proteosomal degradation [39]. Low-risk HPV E6 proteins
can also bind to p53, but with very low affinity and do not degrade p53 [31]. In addition to its
effects on p53, HPV also targets a number of other pro-apoptosis proteins including Bak, Fasassociated death domain containing protein (FADD) and procaspase 8, which is degraded by
E6/E6AP furthering reducing the ability of the cell to enter apoptosis [40]
E6 in conjunction with the transcription factor Myc, can up regulate the transcription of
TERT (Telomerase reverse transcriptase) from its promoter, allowing the cell to repair the
telomere after each division and maintain telomere length [41]. Human telomerase is a
ribonucleoprotein complex composed of at least the reverse catalytic transcriptase (hTERT) and
an RNA component (hTR) [42]. hTERT is expressed only in specific germ-line cells, proliferative
stem cells of renewal tissues, and cancer cells. Because telomerase activity is hardly detected in
most somatic tissues, telomeres shorten with each cell division, eventually leading to
senescence [42]
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1.8.6 E7 Protein

E7 is a small nuclear phosphoprotein made up of approximately 100 amino acids. E7 is
known to bind to the retinoblastoma tumor suppressor gene product, pRb, and its family
members, p107 and p130 (Figure 1.10), via a binding motif conserved in its CR2 region [31]. In
the hypophosphorylated state, pRb family proteins can bind to transcription factors such as E2F
family members and repress the transcription of particular genes involved in DNA synthesis and
cell-cycle progression [31]. Phosphorylation of pRb by G1 cyclin-dependent kinases releases E2F
(Figure 1.10) leading to cell cycle progression into the S phase. As E7 is able to bind to
unphosphorylated pRb, it may prematurely induce cells to enter the S phase by disrupting pRb–
E2F complex [43]
E7 interacts with inhibitors of cyclin-dependent kinases including p21 and p27 [44] [45].
p21 is an important mediator of cell cycle arrest via its inhibition of cyclin dependent kinases
[46]. This process occurs during keratinocyte differentiation ultimately leading to cell
senescence; therefore the sequestering of p21 by E7 may be critical in allowing continued
replication of the viral genome in differentiated squamous cells where otherwise replication of
DNA has ceased [31]. In addition to the inactivation of pRb family members, other oncogenic
functions of E7 have been reported. Histone deacetylases have been shown to play an
important role in cell cycle regulation. HPV16-E7 targets chromatin remodelling histone
deacetylase complexes through its C-terminal zinc ﬁnger. This interaction potentially enables E7
to alter expression of cellular genes by modulating their chromatin structure [47].

31

E7 may play a role in helping the virus to evade the host immune system though it’s
influence on E-cadherin expression. Langerhans cells are one of the major immune cells present
in the cervical epithelium and play a role in activation of the adaptive immune response by
detecting, processing and presenting foreign antigens to other leucocytes [48]. It has previously
been observed that dysplastic cervical lesions contain fewer langerhans cells than normal
cervical epithelium [49], likely creating an environment favorable for HPV persistence. The
expression of E-cadherin on the cell membranes of keratinocytes is required for langerhans cell
migration into the epithelium [50], thus any reduction in E-cadherin expression likely
contributes to a concurrent reduction in the number of langerhans cells in the epithelium. The
role of E7 in regulating E-cadherin expression is demonstrated by experiments showing
silencing of E7 in HPV 16-transformed keratinocytes restores functional E-cadherin expression
[51]. A study by Laurson et al., 2010 [52] observed that E7 mediated repression of E-cadherin
expression occurs at the epigenetic level, through augmentation of cellular DNA
methyltransferase I (Dnmt1) activity. Interestingly Laurson et al. 2010 observed that Dmnt1
does not methylate the E-cadherin promoter directly, suggesting that E7-augmented Dnmt1
activity is directed to a cellular gene/genes whose protein acts on the E-cadherin promoter. In
this study the role of the SNAIL protein, which can bind to the E-cadherin promoter, in
repressing E-cadherin expression is examined in cervical cell lines (Chapter 5).
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Figure 1.9 Schematic presentation of the HPV viral oncoproteins E6/E7 and their interaction
with cell-cycle regulatory proteins in cervical carcinogenesis [53]

1.8.7 L1 Protein

The L1 protein is the major capsid protein and is the principal viral protein responsible for
generating an immunogenic response in the host. It is one of the most conserved proteins in
the HPV genome and is expressed late in the viral life cycle (Figure 1.9). Due to its highly
conserved structure, the L1 sequence is used as a basis for classifying Papillomaviridae into
their separate genus, type and subtypes [13]. Papillomavirus capsids contain two virally
encoded proteins L1 and L2, synthesised late in the infection cycle, which encapsulate the
histone-associated, closed circular double-stranded DNA minichromosome [16]. The viral capsid
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is primarily composed of 72 pentamers (capsomeres) of the L1 protein, in association with 12 or
more copies of the L2 protein [12] .The major late protein L1 pentamers have the intrinsic
property of self-assembly into empty capsids, referred to as virus like particles (VLPs) [54]. VLPs
are structurally and immunologically similar to infectious viruses, as determined by electron
microscopy and their ability to bind conformation-dependent monoclonal antibodies. L1 can
bind to cell surface hepran sulphates, which are thought to be site of viral attachment to the
host cell [55].

1.8.8 L2 Protein

The L2 protein is the minor capsid protein and is approximately 50 kDa in size. As well as playing
a structural role in the viral capsid it has also been suggested to play a number of other roles.
VLPs made up of L1 and L2 proteins combined show a different pattern of distribution once
taken into a cell compared to VLPs made up of L1 alone [56]. L1 VLPs remain widely and
diffusely distributed throughout the cytoplasm, whereas L1/L2 VLPs exhibit a radial distribution
across the cytoplasm and accumulate in the perinuclear region, suggesting that L2 may be
involved in the transport of the virions across the cytoplasm [57].

34

1.9 Detection of HPV
Nearly all HPV detection assays currently in use rely on the assessment of viral nucleic acids,
mostly DNA. Originally, Southern blot and Northern blot hybridizations were the methods of
choice for HPV DNA and RNA detection, respectively. These methods, however, require large
amounts of input material are time consuming and in principle can only detect one HPV type at
a time. In addition, they are not applicable to routine formalin-fixed tissue specimens that
typically contain crosslinked, severely degraded nucleic acids. The HPV detection methods that
are currently in use can broadly be subdivided into target amplification methods and signal
amplification methods. Target amplification methods utilize nucleic acid polymerases, targetspecific oligonucleotides(‘primers’), and a mixture of deoxyribonucleotides to amplify a specific
nucleic acid sequence up to a level at which it can be easily detected [58].
Signal amplification methods are based on an initial hybridization step of nucleic acids in
the specimen with target-specific probes in liquid phase or in situ on cells or tissue slides, after
which the signal (i.e. the hybridization event) is amplified and ultimately visualized with one of
the various available methodologies. The most common of these tests, and the one that has
been approved by the Federal Drug Administration, is the Hybrid Capture 2 (HC2) test. This is a
solution based hybridisation method that uses two RNA probe cocktails, one that contains
probes for 5 low-risk HPV types, and one that contains probes for 13 high-risk types, to detect
the presence of HPV [59]. The HPV DNA-RNA hybrid is immobilised on the wall of a microtiter
plate before a luminescent product is generated through a series of reactions. As the intensity
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of the signal is proportional to the amount of target that was present in the sample this is a
semi-quantative method for HPV detection [59]
PCR is widely used tool capable of amplifying very limited amounts of DNA, generating
thousands to millions of copies of a particular DNA sequence, to a level which is more easily
detectable. Since its initial development 1980s by Kary Mullis [60] it has become a widely used
tool in medical and biological labs in both research and diagnostic settings. Today PCR is one of
the most widely used tools for the detection of HPV DNA due to its ability to test samples with
low levels of tissue or cells or poor quality DNA. Given the fact that many different HPV types
exist, two different primer designs were developed to identify both the broad presence of HPV
and specific subtypes of the virus. Type-specific PCR uses a set of primers that is specific for
only one distinct type of HPV, where as consensus primers can detect a broad-spectrum of HPV
types with only one primer set. Most type-specific and consensus primers are directed against
highly conserved sequences of the HPV genome, almost exclusively within the L1 or E1 open
reading frames [61]. Some of the first consensus PCR assays designed were the MY09⁄ 11 and
GP5⁄6-PCR systems. From the latter two, which target 450 base pair and 150 base pair regions
within L1, respectively, second-generation, modified versions (i.e. PGMY from MY09⁄ 11 and
GP5+⁄6+- PCR from GP5⁄ 6-PCR, respectively) were developed. Today, these assays still belong
to the most commonly used HPV detection assays. By utilizing the conserved L1 sequences
targeted by MY09 and GP5+ primers, a short-fragment PCR assay, the SPF10, was subsequently
developed that amplifies a 65 base pair region [62]. Despite overall sequence conservation in
the viral L1 and E1 regions, these assays still had to deal with some degree of inter-type
heterogeneity at the nucleotide level, which precluded the selection of single primer pairs that
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fully match corresponding sequences of a broad spectrum of HPVs. Therefore, to ensure broadspectrum HPV detection, consensus primer assays either use low-stringency PCR conditions to
allow some degree of mismatch acceptance between primers and target sequence (as used in
GP5⁄6-PCR and GP5+⁄6+-PCR), degenerate primers with nucleotide variations at ambiguous
base positions (as used in MY09⁄ 11), or combinations of the two (as used in SPF10) [61] [63].

37

1.10 Structure and function of adherens and tight junctions
Adherens juctions and tight junctions comprise two modes of cell-cell adhesion that
provide different but complimentary functions. The presence of adherens junctions is a defining
feature of all epithelial sheets [64] with adherens junctions performing multiple vital functions
including initiation and stabilization of cell-cell adhesion, regulation of the actin cytoskeleton,
intracellular signaling and transcriptional regulation [65]. The core of the adherens junction
includes interactions among transmembrane glycoproteins of the classical cadherin
superfamily, such as E-cadherin, and the catenin family members including p120-catenin, βcatenin, and α-catenin (Figure 1.10 & Figure 1.11) [65]. Together, these proteins control the
formation, maintenance and function of adherens junctions [65]. Junctional E-cadherin–catenin
complexes exhibit several important characteristics that are critical for the proper functioning
of epithelia.

Homophilic interactions between the extracellular portions of E-cadherin

molecules help to provide mechanically strong adhesive links between cells in the tissue (Figure
1.10) [66]. In addition, AJs help to define an epithelial cell’s apical–basal axis in many systems
and, in doing so, act as a reference point for the coordination of cell polarity across the
epithelial sheet [66]. The process of AJ formation is dependent on the local activation of the
Rho family GTPase Rac following contact between neighbouring cells [67] . Rac drives the
formation of actin-based protrusions in the cell that carry E-cadherin to site of cell-cell contact
and initiate junction formation [68] [69]. This collaboration between Rho GTPases and AJ
components continues during AJ maturation, as tight junctions and apical–basal polarity are
established through the action of both Rac and Cdc42. Interaction between these activated Rho
family GTPases and Par6 leads to the activation of atypical PKC (aPKC), which has been shown
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to be required for the maturation of AJs from simple cell–cell adhesions to junctional
complexes [66] [70].

Figure 1.10 Structure and components of adherens and tight junctions [71]
Adherens and tight junctions are maintained by the interaction of a number of key proteins.
Claudins and occludin are the main intercellular proteins of the tight junction that form cell-cell
contacts between neighbouring cells, with cadherins performing a similar role in adherens
junctions. Intra-cellular domains of claudin and occludin bind to several additional proteins,
such as ZO-1, that link the junctions to the actin cytoskeleton of the cell.

Tight junctions have been proposed to have two mutually exclusive functions: a fence
function which prevents the mixing of membrane proteins between the apical and basaolateral
membanes; and a gate function which controls the paracellular passage of ions and solutes in39

between cells [72]. Tight junctions contain two types of transmembrane proteins, occludins and
claudins, which confer these functions, and associated cytoplasmic proteins that link tight
junctions to the actin-cytoskeleton (Figure 1.11) [73]. In epithelial cells, tight junctions are the
most apical component of the junctional complexes, whereas their localisation is more variable
in endothelia [73]. The two major types of integral membrane proteins are classified according
to the number of transmembrane domains they contain: four-pass transmembrane proteins
such as claudins, occludin and tricellulin, and single-span transmembrane proteins including the
junctional adhesion molecule (JAM) and the Coxsackie and adenovirus-associated receptor
(CAR) [74]. Lateral association between claudin molecules within the plasma membrane,
combined with homotypic adhesive interactions between claudin molecules on adjacent cells, is
thought to underlie the characteristic structure of tight junction strands [75]. The association of
other integral membrane proteins to the claudin-based strands provides additional complexity
to tight junction structure. Occludin, the first transmembrane component of tight junctions to
be identified also localises to the tight junction strands and has been implicated in regulating
the permeability properties of tight junctions and, in particular, has been linked to the
regulation of size-selective diffusion [76]. JAMs and related proteins function as adhesion
proteins, homotypically as well as heterotypically, and regulate various processes such as
leukocyte transmigration [77]. Underlying the membrane domain is the cytoplasmic plaque, a
network of densely packed peripheral proteins that connect the integral membrane proteins to
the underlying actin cytoskeleton as well as to different types of signaling proteins. Prominent
examples are the zona occludens proteins ZO-1, -2 and -3: each contains multiple proteininteraction domains, including three PDZ domains and an SH3 domain, through which they
40

demonstrate affinity for a number of cytoskeletal proteins, signalling molecules and membrane
proteins [78].
Tight junctions are dynamic structures and thus a wide array of growth factors,
cytokines, drugs, and hormones regulate tight junctions and barrier function. For example, the
glucocorticoid hydrocortisone, prolactin, and unsaturated fatty acids all enhance the tight
junction barrier partially by increasing the expression of occludin in endothelial and epithelial
cells [79] [80] [81]. Cytokines and growth factors, such as tumor necrosis factor-α, interferon-γ,
interleukin-1β, transforming growth factor-α also play a role in influencing TJ permeability and
many cases lead to development of disease [81]. Cytokine mediated changes in paracellular
permeability are linked to a multitude of pathologic conditions including inflammatory bowel
disease (IBD), airway inflammation in asthma and cystic fibrosis, and diseases that perturb the
blood-brain barrier (BBB) [82] [83] [84].
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1.10.1 Epithelial Cadherin (E-cadherin)

E-cadherin is a transmembrane glycoprotein that is one of the primary constituents of
adherens junctions in epithelial tissues with the protein being encoded in humans by the CDH1
gene which maps to chromosome 16q22.1. [85]. It is a member of the cadherin superfamily of
calcium dependent proteins, which each contain five extracellular repeat domains, termed
extracelluar cadherin (EC) domains. These domains are the primary areas of trans-cadherin
interactions between neighbouring cells and initiate cell-cell adhesion and formation of the
adherens junction (Figure 1.11) [86]. The intracellular portion of E-cadherin binds to several
additional proteins that play a diverse set of roles, from binding to the actin cytoskeleton of the
cell to intracellular signaling and gene regulation. On the cytoplasmic side of the membrane, a
bundle of actin filaments is linked to the E-cadherin molecules via a protein complex (Figure
1.11). Alpha-catenin and either beta- or gamma-catenins are included in this complex [87].
Beta- and gamma-catenins share significant homology and bind to a specific domain at the Ecadherin C-terminus. Alpha-catenin links the bound beta- or gamma-catenin to the actin
cytoskeleton [87]. The structure of the extracellular domain of classical E-cadherin contains five
tandem repeats of a 100-residue-amino-acid-motif, and the biggest part of the N-terminal of
these repeats contains the sites with adhesive activity [86]. This part of the molecule also has
binding sites for calcium ions situated in the pockets between the repeats. The amino acid
sequences that form the Ca2+ binding pockets are highly conserved between different
members of the cadherin family and between different species [86]. Cell-cell adhesion is
mediated through homotypic interactions of E-cadherin extracellular domains in a process of
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lateral dimerisation. Parallel dimers are able to interdigitate with dimers from neighbouring
cells forming the points of adhesion [86].
Malignant carcinoma cells are characterised in general by poor intercellular adhesion,
loss of the differentiated epithelial morphology and increased cellular motility. Downregulation
of E-cadherin expression, mutation of the E-cadherin gene, or other mechanisms that interfere
with the integrity of the adherens junctions, are often observed in carcinoma cells [88]. In
human tumours, the loss of E-cadherin mediated cell adhesion correlates with the loss of the
epithelial morphology and with the acquisition of metastatic potential by the carcinoma cells
[88]. Thus, a tumour invasion-suppressor role has been assigned to this gene [88].

Figure 1.11 Outline of the structure and components of an adherens junction between two
neighbouring epithelial cells. [89]
Adherens junctions are initiated by homotypic binding of E-cadherin between neighbouring
cells. A number of intra-cellular components, such as p-120 catenin and β-catenin, bind to intracellular domains of E-cadherin and link the junction to the actin cytoskeleton of the cell.
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1.10.2 p120-Catenin

p120 catenin (p120) is an armadillo (ARM) repeat-containing protein (Figure 1.12) that, along
with the classical cadherins, β-catenin and α-catenin, plays a crucial role in the regulation of
cell-cell adhesion at adherens junctions (AJs) [90]. p120 plays a pivotal role in both promoting Ecadherin stability and a sessile cellular phenotype or inducing cell migration and invasiveness of
E-cadherin–deficient cells through its effects on Rho GTPase activities [91]. p120 family
members share a conserved central domain composed of 9 ARM repeats and flanking N- and Cterminal regions. p120 plays a role in stabilising E-cadherin by interacting with the
juxtamembrane domain of E-cadherin, which consists of 40 amino acids at the N-terminal end.
It is believed that the binding of p120 to the juxtamembrane domain of cadherin blocks factors
such as the ubiquitin ligase Hakai and components of the endocytic machinery, which tag and
target cadherin for destruction and internalisation [92]. Both

loss of expression and

mislocalised expression of p120 have been observed in tumours [93] [94] . The role of p120 in
regulating tumours growth, likely occurs as a result of the protein’s interaction with E-cadherin
[91]. In the mammary epithelial cell line MDA-MB-231, p120 induces the transformed growth of
E-cadherin–deficient cells by activating a Rac1–MAPK signaling pathway normally activated by
the adhesion of cells to the ECM. When E-cadherin is re-expressed in this cell line, it is stabilised
by p120 association and selectively and potently inhibits the growth of epithelial cells [91].

44

Figure 1.12 Structure and functional elements of p120-catenin [90]
p120 contains 10 central Armadillo repeat domains (orange) that are essential for cadherin
binding. The carboxy-terminal tail contains at least two serine/threonine phosphorylation sites
(open lollipops), and alternatively spliced exons A and B (red). The amino-terminal end
contains two distinct regions, the coiled-coil domain (blue), and the regulatory domain (green).
The regulatory domain contains the vast majority of tyrosine (red lollipops) and
serine/threonine (open lollipops). Exact amino-acid locations of the known sites are listed. Their
individual roles are unknown, but collectively, they participate in the dynamic regulation of
p120 adhesive function.

1.10.3 Claudin family of proteins

The tight junction is an intercellular junctional structure that mediates adhesion
between epithelial cells and is required for proper epithelial cell function [95]. Tight junctions
control paracellular permeability across epithelial cell sheets and also serve as a barrier to
intramembrane diffusion of components between cells apical and basolateral membrane
domains [96]. Claudins are tetraspan transmembrane proteins of tight junctions. They
determine the barrier properties of this type of cell–cell contact existing between the plasma
membranes of two neighbouring cells. Claudins can completely tighten the paracellular cleft for
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solutes, and they can form paracellular ion pores [97]. The claudin family consists of at least 24
members (Figure 1.13), with each showing a specific organ and tissue distribution [95]. A large
degree of sequence homology is found between claudins 1–10, 14, 15, 17 and 19. Combined
with functional findings, these claudins are therefore grouped together as the classical claudins
(Figure 1.13) [98]. All other claudins are termed non-classical claudins (Figure 1.13).

Figure 1.13 Phylogenic tree of the claudin family of proteins showing levels of similarity
between different different proteins. In red are the classical claudins and in black are the nonclassic claudins. Highly similar claudins encoded by genes located in close proximity in the
human genome are highlighted in green. [95]
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Claudins are tetraspan proteins with relatively short cytoplasmic amino and carboxy
termini flanking a first extracellular loop of approximately 53 amino acids and a second shorter
loop of approximately 24 amino acids in length (Figure 1.14) [95]. The cytoplasmic C-terminus
sequence varies considerably in length (from 21–63 residues) and sequence between isoforms
[98]. All claudins have C-terminal PDZ binding motifs that enables direct interaction with tight
junction cytoplasmic proteins such as ZO-1,-2, and -3, multi-PDZ domain protein (MUPP)-1 and
PALS-1 associated TJ protein (PATJ) (Figure 1.14) [97]. In particular, interactions with the
cytoplasmic scaffolding proteins ZO-1 and ZO-2 indirectly link claudins to the actin cytoskeleton
which stabilises the tight junction and is required to maintain their permeability characteristics.
The function of the short N-terminal domain is yet to be fully elucidated [99]. Just as different
tissue types tend to have their own unique pattern of claudin expression; different tumours
have been shown to have distinct patterns of abnormal claudin expression. Claudin 3 and
claudin 4 have been shown to be overexpressed in certain types of ovarian cancer [100],
whereas Claudin-1 is overexpressed in colon tumours [101] but loss of expression is observed in
some breast tumours [102]. A small number of studies have also observed changes in claudin
expression in both pre-invasive and invasive cervical lesions. Lee et al., 2005 observed a
gradual increase in claudin-1 and claudin-7 expression in accordance with the progression from
LSIL to HSIL and invasive cancer. Sobel et al., 2005 observed an increase in claudin-2 and
claudin-4 expression as well as claudin-1 and -7, in pre-invasive and invasive cervical lesions.
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Figure 1.14 Schematic representation of the claudin monomer. The model depicts the
conserved structural features of claudins and some of the known interactions and
modifications. EL1 and EL2 denote the extracellular loops 1 and 2, respectively. The
transmembrane domains 1 to 4 (TM1 to TM4) and the regions important for hepatitis C virus
(HCV) entry and Clostridium perfringens enterotoxin (CPE) binding are shown [95]
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1.10.4 Claudin-1

Claudin-1 protein is made up of 211 amino acids and has a molecular weight of 22,744 Da. The
gene encoding the protein is located on chromosome 3q28-q29. Claudin-1 has quite a wide
distribution in normal human tissue being found in the epidermis of skin [103], distal nephron
[104] and ovarian epithelium [105], as well as several other tissues [106]. Experiments in
claudin-1 knockout nude mice have shown that Claudin-1 plays a key role in maintaining the
epidermal barrier, with claudin-1 deficient mice dying at 1 day post birth from transepidermal
water loss [107]. Claudin-1 had been observed to bind homophillically with claudin-1 proteins
on neighbouring cells and can also form heterotypic interactions with Claudin-3 proteins in cotransfected fibroblast cells [75] [108]. The role of claudin-1 controlling paracellular permeability
is further highlight by experiments that show Claudin-1 transfected epithlial cell lines display an
increase in transepithilal electric resistance [109], most likely by decreasing cation permeability
[110].
In terms of pathology, Claudin-1 has been observed to have many roles. Claudin-1 is a
co-receptor for HCV infection of human hepatoma cell lines and is the first factor to confer
susceptibility to HCV when ectopically expressed in non-hepatic cells. Discrete residues within
the first extracellular loop (EL1) of CLDN1, but not protein interaction motifs in intracellular
domains, are critical for HCV entry [111]. Dysregulation of claudin-1 expression itself has been
associated with pathogenesis in many different tumours. Studies have identified that Claudin-1
overexpression is associated with an increased invasiveness in oral carcinoma cells through
upregulation of several matrix metalloproteases [112] [113]. Claudin-1 expressing colon
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carcinoma cells that underwent siRNA mediated knockdown of Claudin-1 displayed significantly
decreased anchorage-independent growth and invasion with a significant decrease in MMP-9
activity [114]. Conversely, claudin-1 overexpression suppresses metastasis and invasion in lung
cancer cell lines [115].

1.10.5 Claudin-7

Claudin-7 is a member of the classical claudin family and is a protein made up of 211 amino
acids with a molecular weight of 22,390 Da [116]. Like other claudins, claudin-7 expression is
tissue specific with expression observed in the nephron, breast and corniel epithelium [106].
Claudin-7 is essential for NaCl homeostasis in distal nephrons, and the paracellular ion transport
pathway plays an indispensable role in keeping ionic balance in kidneys. In claudin-7 knockout
mice severe salt wasting, chronic dehydration, and growth retardation was observed; with
knockout mice surviving no longer than 12 days [117]. The role of claudin-7 in regulating
cellular paracellular permeability is further highlighted by experiments showing that claudin-7
transfected epithelial cells display increased TEER values [109] and also experiments in LLC-PK1
cells that show claudin-7 overexpression decreases paracellular permeability to Cl- and
increases paracellular permeability to Na+ [118].
The role of claudin-7 in disease and tumourigenesis is becoming clearer, with aberrant
expression observed in several different tumour types. Increased expression of claudin-7 has
been observed in gastric [119] and ovarian tumours [120]. In contrast, reduced expression has
been observed in prostate [121] and oesophageal tumours [122]. In vitro studies using cell lines
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have helped shed further light on how claudin-7 drives tumourigenesis. Knockdown of claudin7 expression in oesophageal squamous cell carcinoma cells induces loss of E-cadherin, along
with increased cell growth and enhanced cell invasion [123]. Similarly, claudin-7 inhibits the
migration and invasion of lung cancer cells through a mechanism involving the ERK/MAPK
signalling pathway [124]. In contrast claudin-7 may have tumour promoting properties in other
cell lines, with overexpression of claudin-7 promoting invasion in ovarian cell lines [125] and
also in colon carcinoma cell lines [126].

1.10.6 Neural-cadherin (N-cadherin)

N-cadherin is encoded in humans by the CDH2 gene and is similar to other members of the
classical cadherin super-family in that it is a calcium dependent cell-cell adhesion glycoprotein
comprising five extracellular cadherin repeats, a transmembrane region and a highly conserved
cytoplasmic tail [127]. In embryogenesis, N-cadherin is a key molecule during gastrulation and
neural crest development, where N-cadherin mediated contacts activate several pathways like
Rho GTPases and function in tyrosine kinase signalling [128]. N-cadherin is expressed by a group
of cells in the developing embryo known as the neural crest which are a pluripotent population
of cells that arise from the dorsal part of the neural tube during or just before closure. After an
epithelial-mesenchymal transition (EMT), they migrate over long distances along distinct
pathways to many different regions of the embryo and contribute to a diverse array of tissues
and cell types, such as the peripheral nervous system, melanocytes, some endocrine cells,
craniofacial cartilage and bone [128]. In adult tissues N-cadherin expression is restricted to
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neural tissue, retina, endothelial cells, fibroblasts, osteoblasts, mesothelium, myocytes [128]. In
neural tissue it is involved in a number of key events that range from the control of axonal
growth and guidance to synapse formation to synaptic plasticity [129].
N-cadherin has also been implicated in the tumorigenesis of several epithelial and other
malignancies [130]. One of the methods by which this process is driven is through a
downregulation of E-cadherin and upregulation of N-cadherin; termed a ‘cadherin switch’
[131]. The effect of E-cadherin downregulation is that cells can lose their cohesive structure and
can more easily detach and disseminate from their original site. N-cadherin up-regulation is
thought to promote tumourigenesis in a number of ways. Epithelial cell lines with
overexpressed N-cadherin have been shown to have increased motility and have a greater
invasive and metastatic potential [132] [133]. The increased invasiveness and metastatic
behaviour of N-cadherin over-expressing cells may in part be due to N-cadherins ability to
interact with the Fibroblast growth factor receptor and enhance its downstream signalling [132]
[134]. In addition to modulating the invasive characteristics of tumour cells, expression of Ncadherin might also promote metastasis by facilitating interactions with the endothelium.
Endothelial cells express two cadherins: VE-cadherin, which is localised in junctions and serves
to organise the junctional complex in these cells, and N-cadherin, which is extrajunctional and
has an unclear role [131]. Endothelial cells may use N-cadherin to interact with other Ncadherin-expressing cells such as vascular smooth muscle cells and/or pericytes [135]. It is
equally likely that tumour cells that express N-cadherin have an increased ability to interact
with endothelial cells and that this interaction may enable metastasis by allowing the tumour
cells access to the vasculature [131].
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N-cadherin has now been identified as potential novel target for cancer therapy. A
peptidic N-cadherin antagonist (ADH-1) has been developed and has entered clinical testing as
a potential novel cancer therapy [136]. ADH-1 has been shown to inhibit cell growth and
motility in vitro, and tumour growth and invasion in vivo [136]. In addition, Erez et al. 2004
[137] have shown that treatment of endothelial cells, which express both N-cadherin and VEcadherin, with ADH-1 induces apoptosis in a cell-density-dependent manner and suggest that
ADH-1 might be effective at preventing tumour angiogenesis.

1.10.7 Snai1 (Snail)

Snail is a part of a family of zinc fingered proteins that play an important role in the regulation
of development via its ability to downregulate the expression of ectodermal genes within the
mesoderm of the embryo [138]. The protein is encoded in humans by the SNAI1 gene localised
on the chromosome 20q13.2, and encodes a protein with 264 amino acids and 29.1kDa [138]
While the protein undoubtedly is necessary for successful embryonic development, highlighted
by the fact that Snail null mice die during embryogenesis [139], the protein may promote
tumourigenesis in a process termed epithelial to mesenchymal transition (EMT) [140]. EMT is a
hypothesised process that describes how epithelial cells can lose their normal cohesive
structure and adopt a more motile and invasive phenotype that is commonly observed in
malignant cells. Snail can drive this process by repressing the expression of proteins normally
associated with the epithelial phenotype such as E-cadherin and Claudin-1. Snail is able to
repress the expression of E-cadherin by binding to certain E-box motifs in the proximal E53

cadherin promoter and negatively regulating the expression of the gene [141]. Snail has been
shown to repress Claudin-1 expression by a similar mechanism in MDCK (Madin–Darby canine
kidney) cells, with cells overexpressing Snail showing a dramatic down-regulation of Claudin-1
protein levels and a significant reduction of Claudin-1 mRNA [142]. Additionally Snail has been
recently proposed to act as a cell survival factor and inhibitor of cellular senescence in some
prostate carcinoma cells lines, with long-term siRNA mediated knockdown of Snail inducing a
severe decline in cell numbers of transfected cells [143]. Currently there is very little known
about the role SNAIL may play in cervical neoplasia, or about it’s expression in pre-invasive and
invasive cervical lesions. An IHC based study of 144 cervical tissue samples, 28 normal tissue
116 SCC, by Zhao et al 2013., found an increase in SNAIL expression in SCC samples compared
to normal cervical tissue, but there are very few other studies published to corroborate these
findings.
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1.11 Epithelial to Mesenchymal Transition (EMT)
Epithelial tissues line the cavities and surfaces of structures throughout the body. The
cells that make up the epithelium are typically closely packed together in continuous cohesive
sheets that are attached to a basement membrane, which acts as a scaffold for the epithelial
cells to grow [144]. Epithelial cells are normally polarised, or have distinct domains at apical and
basolateral portions of their plasma membranes. Each plasma membrane domain has a distinct
protein composition, giving them distinct properties and allowing directional transport of
molecules across the epithelial sheet [144]. Mesenchymal tissue is a form of connective tissue
usually found in the mesoderm germ layer of the developing embryo. It consists of
undifferentiated, motile, non-polarised, loosely associated cells surrounded by a ground
substance ECM (Extra Cellular Matrix), containing reticular fibers [145]
Epithelial to mesenchymal transition (EMT) is a process by which an epithelial cell loses
the cohesiveness and apical-basolateral polarity normally associated with it, and adopts
characteristics usually associated with a mesenchymal phentotype, such as enhanced migratory
capacity, invasiveness, and greatly increased production of ECM components [146]. EMT is a
process that occurs normally during several phases of embryogenesis, including implantation
and placenta formation [147] and neural crest formation [148]. EMT also occurs is tissues that
have been damaged or injured and are undergoing fibrosis. In mouse models this type of EMT is
mediated by inflammatory cells and fibroblasts through secretion of pro-inflammatory
cytokines, growth factors and matrixmetaloproteases (MMPs) [149]. Epithelial cells come under
the influence of these signalling molecules and, acting together with the inflammatory cells,
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induce basement membrane damage and focal degradation of type IV collagen and laminin
[149] [150]. Although the concept of EMT was originally devised to explain various processes
that occur during embryogenesis, the concept has since been applied as a model for cancer
progression and metastasis [151]. It was observed that a number of processes that occur
during EMT in embryogenesis such as, loss of epithelial markers, loss of cell polarity,
cytoskeleton reorganisation and activation of MMPs, closely resembled those that occurred
during tumourigenesis in epithelial malignancies (Figure1.15) [151]. It is therefore possible that
the understanding of comparisons of EMT signaling pathways in embryological development
and cancer progression may make it possible to identify novel pathways specific to cancer
progression and to suggest new therapeutic strategies in cancer therapy [152] [153].

Figure 1.15 Alterations of the apical–basal and planar cell polarity pathways in epithelial–
mesenchymal transitions. The EMT signature is characterised by the convergent loss and
relocalisation of epithelial markers (e.g. E-cadherin, β-catenin), and gain of mesenchymal
markers (e.g. N-cadherin, α-SMA, vimentin and fibronectin) [154].
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Multiple complex signaling systems are required for induction of EMT because epithelial
cells undergoing EMT must undergo both functional and morphologic changes. In the case of
many carcinomas, EMT-inducing signals emanating from the tumour-associated stroma, notably
HGF, EGF, PDGF, and TGF-β, appear to be responsible for the induction or functional activation
in cancer cells of a series of EMT-inducing transcription factors [150]. Transforming growth
factor beta (TGF-β) in particular is thought to play a key role in EMT promotion [150] and was
first identified as an inducer of EMT in experiments on mammary epithelial cells by Miettinen et
al. 1994 [155]. TGF- β induces EMT through multiple signalling pathways including direct
phosphorylation of Smad 2 and Smad 3 (Figure 1.16) [153]. SMAD are small signal transduction
proteins that activate several signaling pathways in the nucleus. TGF-β also activates other
EMT-related signal pathways including the Wnt, Integrin and Notch pathways (Figure 1.16)
[153] . TGF-β and other growth factors also serve to activate a number of transcription factors
such as Snail, Slug, zinc finger E-box binding homeobox 1 (ZEB1), Twist, and FOXC2 [153]. Loss
of E-cadherin expression is a considered a key step in EMT and several of these transcriptional
factors are able suppress expression of E-cadherin. Snail and Zeb bind directly to E-box motifs in
the E-cadherin promoter [156], whereas Twist and Goosecoid, repress E-cadherin expression
indirectly [152] [157].
Loss of cell polarity is also a crucial step in EMT. In epithelial cells, three protein
complexes partake in establishing and maintaining apicobasal polarity Par, Crumbs and Scribble
[158]. SNAIL alters epithelial cell polarity by repressing the transcription of Crumbs3 and
abolishing the localisation of both Par and Crumbs complexes at tight junctions [159]. Similarly,
Zeb1 directly represses the transcription of cell polarity genes, including Crumbs3, Pals157

associated tight junction proteins (PATJ), and the member of the Scribble complex Lethal giant
larvae (Lgl2) [160]. TGF-β contributes to the loss of cell polarity during EMT in two ways,
through the canonical pathway by inducing Snail and Zeb genes expression and through a
noncanonical pathway that involves the downregulation of Par3 expression and the Par6mediated degradation of RhoA and local alteration of the actin cytoskeleton [157] [161] [162].
An additional component to the regulation of EMT is the effect of small micro RNAs
(miRNAs) that can play a role in inhibition or promotion of EMT inducers (Figure 1.16). Micro
RNAs are small non-coding RNA molecules which primarily influence post-transcriptional
regulation of gene expression. For example, microRNA 200 (miR200) and miR205 inhibit the
repressors of E-cadherin expression, ZEB1 and ZEB2, and thereby help in maintaining the
epithelial cell phenotype (Figure 1.16) [163]. Another miRNA, miR-148a, promotes the
expression of

E-cadherin and reduces the levels of mesenchymal markers (N-cadherin,

fibronectin or vimentin) in hepatoma cells by inhibiting SNAIL expression [164]. In contrast,
miR-9, a MYC/MYCN-induced miRNA, directly targets the E-cadherin-encoding mRNA leading
to increased cell motility/invasiveness in breast tumour cells [165].
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Figure 1.16 Depiction of signal pathways regulating the epithelial–mesenchymal transition
(EMT) [153]
Transforming growth factor (TGF)-β signals toward the SMAD pathway or the PI3K/AKT axis.
Wnt ligands block β-catenin degradation leading to excess β-catenin entering the nucleus and
upregulating SLUG and SNAIL transcription. In integrin signaling, overexpression of ILK leads to
nuclear translocation of β-catenin. Signals via RTK lead to EMT through the Ras-Raf-MAPK
pathway or the PI3K/AKT pathway.
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1.12 Hypothesis and aims of this study
The hypothesis of this study is that the expression of a number of tight and adherens
junction proteins are altered in HPV induced cervical lesions. Altered protein expression within
adherens and tight junctions leads to disruption of their normal structure and function leading
to a loss of cell polarity and cohesion. Loss of cell cohesion and polarity allows dysplastic cells to
adopt invasive and motile characteristics that may allow dissemination of cells from their site of
origin.



Overarching aim
o To elucidate mechanisms by which HPV induced neoplastic cervical cells invade
surrounding tissue and form distant metastases
 Discover novel biomarkers indicative of disease progression
 Discover novel tumourigenic pathways that may be of use as targets for
new cervical cancer treatments.



Specific aims
o To construct tissue microarrays containing normal and neoplastic cervical tissue
and examine the expression profile of several integral tight and adherens
junction proteins
o To detect and genotype HPV DNA in cervical samples and to look for an
association between specific HPV genotypes and aberrant expression of
adherens and tight junction proteins
o To analyse the pathogenesis of aberrant tight and adherens junctions protein
expression in cervical cancer cell models

60

2 Materials and Methods
2.1 Introduction
2.1.1 Tissue Microarrays (TMAs)

Tissue microarrays are conventional paraffin blocks containing several different tissue samples
that have been transferred from other donor tissue blocks. They are produced by using a
needle to biopsy a standard histological section and placing the core into an array on a recipient
paraffin block (Figure 2.1) [166]. The idea of studying a large number of formalin fixed and
paraffin wax embedded tissues simultaneously in a single histological section was proposed as
far back a 1986 by Battifora et al., [167], although this so called ‘sausage’ technique described
could only include a limited number of samples. The microarray technique, described by
Kononen et al. 1998 [168], elegantly eliminated this drawback by the introduction of a high
precision punching instrument, which enabled the exact and reproducible placement and
relocalisation of distinct tissue samples. Tissue microarray cores are typically between 0.6 and
2.0mm in diameter while arrays may consist of anywhere from 40 to 1000 cores, depending on
core size. Arrays can be utilised for a wide range of techniques including histochemical stains,
immunologic stains with either chromogenic or fluorescent visualisation, in situ hybridisation
(including both mRNA ISH and FISH), and even tissue micro-dissection techniques [166].
There are a number of advantages to using TMAs as compared to normal histological
tissue blocks. The technique allows a large number of samples to be examined on one slide and
a result of this it greatly reduces the amount of reagents and other materials that need to be
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used in any assay. It also reduces the variability that may be associated with an assay examining
a large number of samples, as all samples are treated in an identical manner and processed in a
single batch. This method also preserves the original tissue block should any further
examination of the tissue be necessary in the future.

Figure 2.1 Schematic diagram of tissue microarray construction [169].
A large number of individual samples from either frozen tissue, formalin fixed paraffin
embedded tissue or cell line are embedded into a single recipient tissue block. The recipient
tissue block can then be sectioned and examined using standard histological techniques.
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2.1.2 Immunohistochemistry

The publication of a paper by Coons et al. 1941 [170] describing a technique for detecting
cellular antigens in tissue sections using fluorescently labeled antibodies marked the beginning
of immunohistochemistry (IHC). Since then, IHC has become a valuable tool in both diagnosis
and research of infectious and neoplastic diseases. The basis of IHC is very simple and bridges
three scientific disciplines: immunology, histology, and chemistry. The fundamental concept
behind IHC is the demonstration of antigens (Ag) within tissue sections by means of specific
antibodies (Abs). Once antigen–antibody (Ag-Ab) binding occurs, it is demonstrated with a
coloured histochemical reaction visible by light microscopy or using fluorochromes visualised
under fluorescence microscopy [171]. There are a number of conditions that are essential for
the detection of an antigen using immunohistochemistry, the antigen must be preserved in the
tissue in the same context as it was during sampling, antibody-antigen binding must be specific
and sensitive and there must be efficient labelling and detection of the antibody [172]. Various
processes that occur during tissue processing, such as fixation and embedding can cause
antigen to be masked, depleted or lost entirely. One of the most common forms of fixation,
formalin fixation, causes inter and intra molecular protein cross linking, which can mask the
antigen present in the tissue [172]. In order to overcome this, methods of antigen-retrieval
were developed. Protease-induced epitope retrieval (PIER) was introduced by Huang et al.,
1976 [173]. Many enzymes have been used for this purpose, including trypsin, proteinase K,
and pepsin. Heat induced epitope retrieval (HIER) was introduced by Shi et al. In 1991 [174],
their method involved heating the sections in a boiling solution of a heavy metal salt. Buffer
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using heavy metals were gradually phased out in favour of less toxic alternatives such as citrate
and EDTA buffers.

2.1.3 Avidin-Biotin Conjugate Method (ABC) Method

This immunhistochemical method was developed by Hsu et al. 1981 [175] to give much greater
sensitivity than the standard avidin-biotin method. This method can be direct or indirect
depending on whether biotin is bound to the primary antibody (direct) or to a secondary
antibody (indirect). With the indirect method the primary antibody first binds to the antigen,
secondly the biotinylated secondary antibody binds to the primary. Then complexs of avidin
and biotin horseradish peroxidase conjugate bind to the biotinylated secondary. As the avidin
contains more than one biotin-horse radish peroxidase it serves to bring multiple labels to the
site of the antigen [176]. Once the enzyme label has been localised to site of the antigen the
substrate of the enzyme is added. This results in a product being formed that can be visualised
using light microscopy. An example of this process is the reaction between the enzyme horseradish peroxidase, it substrate hydrogen peroxidase and the chromogen diaminobenzadine
(Figure 2.2).
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Figure 2.2 Detection of antigen using the Avidin-biotin complex method in conjuction with
DAB
Primary antibody binds to antigen followed by a biotinylated secondary binding to the primary
antibody. Avidin-biotin-HRP complex then binds to the biotinylated antibody localising the label
to the site of the antigen. DAB and H2O2 are added leading to the development of an insoluble
brown product.
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2.1.4 Stable and transient transfection

Transfection is a procedure that involves the introduction of foreign nucleic acids into
cells to produce genetically modified cells. The process was first described in 1965 by Vaheri
and Pagano and has since become a widely used and valuable tool in biomedical research. By
selectively enhancing or inhibiting the expression of a certain gene in cells, the technique allows
the study of gene function and offers insights into the role of certain genes in many different
biological processes and diseases.
Transfection methods are broadly classified into three groups based on the nature of
the technique used to deliver foreign nucleic acids into the target cell, with the ideal method
having high transfection efficiency, low cell toxicity, minimal effects on normal physiology, and
being easy to use and reproducible [177]. Biological methods typically use a viral vector, most
commonly based on adenoviruses, to deliver nucleic acid into a target cell. Biological methods
usually have high transfection efficiency but can suffer from high cytotoxicity [178]. Chemical
methods allow entry of foreign DNA into the target cell by forming positively charged
complexes with the foreign DNA that is attracted to the negatively charged cell membrane.
Various different chemical transfection techniques are utilised including calcium phosphate
[179] and cationic lipid [180] and newer methods such as Genejuice, which uses a novel
polyamine based on a non-toxic cellular protein. Chemical methods are generally cheap and
easy to use but can suffer variable transfection efficiency based on cell type and condition and
some of the chemicals used can be cytotoxic [177]. Physical transfection methods offer several
different approaches to transfecting DNA including electroporation, biolistic particle delivery
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and direct injection [181]. Electroporation is one of the most commonly used methods of
physical transfection. First described by Neumann et al. 1982 [182] this method uses an electric
field to create small temporary destabilisations in the cell membrane that causes it to become
highly permeable to exogenous molecules, such as DNA, in the surrounding medium [181].
Optimisation of electroporation can be laborious and the equipment is expensive compared to
some chemical methods, however once optimised it offers fast and efficient method of
transfection.
Transfected nucleic acids can be expressed stably or transiently. In a transient
transfection the introduced nucleic acids are not integrated into the chromosomal DNA and
thus persist only for a limited time, usually up to 72 hrs, as the transfected nucleic acid is not
copied during cell division and becomes diluted after repeated cell division. To achieve a stable
transfection, cells which integrate the exogenous nucleic acid into the chromosomal DNA are
selected, using a selection marker present in the expression vector, ensuring long term gene
expression and inheritance in cell progeny (Figure 2.3). Foreign DNA integrates in the
chromosomal DNA randomly at one or very few sites [183] and site integration influences the
transcription rate of the gene of interest [184]. Cellular DNA in the nucleus is combined with
proteins to help protect the DNA from damage, to control gene expression and DNA replication
and to ensure its fits properly within the nucleus. This compact structure is called chromatin
and is found in two varieties: euchromatin and heterochromatin [185]. Euchromatin consists of
DNA complexed to several nucleosomes which in turn are made up of proteins called histones.
Histones have small sequences of DNA wrapped around them loosely allowing RNA polymerase
and gene regulatory proteins to bind to DNA sequences and allow gene transcription [185]. In
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heterochromatin the DNA is tightly wound and packed thus preventing any transcription of
genes present in the chromatin. The site at which transfected DNA becomes integrated is thus
of critical importance. If the transfected DNA becomes integrated into the heterochromatin, it
is unlikely that any expression of the target gene will occur, whereas if it becomes integrated
into cellular euchromatin, expression of the target gene is much more likely. If transfected DNA
successfully integrates into to cellular euchromatin, a number of factors can still influence
whether the gene becomes properly expressed. Integration of the DNA can cause a deleterious
rearrangement of the endogenous DNA at the site of integration potentially leading to
deletions, duplications and translocations which can interfere with coding sequences [186]
[187] [188] [189]. The endogenous genome does seem to have specific areas however, in which
DNA integration is likely to occur termed “integrational hotspots”[189].
The development of genome manipulation and the establishment of stable cell lines is a
pivotal achievement in molecular biology, allowing large scale recombinant protein production,
analysis of gene function and regulation and giving rise to potential new treatment for several
diseases.
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Figure 2.3 Outline of stable and transient transfection principals
Diagram showing a stable transfection (A) with foreign DNA (red wave) passing through the cell
membrane and into the cell nucleus where it becomes integrated into the host genomic DNA
(black wave) and expressed sustainably. In a transient transfection foreign DNA in introduced to
the nucleus and translated, but not integrated into the host genome. Foreign mRNA may also
be transfected and transcribed in a transient transfection. Hexagons represent expressed
proteins from transfected nucleic acids. [177]
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2.1.5 RNA interference (RNAi)

RNA-mediated interference (RNAi), also referred to as post transcriptional gene silencing
(PTGS), is a simple and rapid method of silencing gene expression. The silencing of a gene is a
consequence of degradation of RNA into short RNAs that activate ribonucleases to target
homologous mRNA. The first observations of the RNAi pathway was in the 1980s by Ecker et al
1986, who observed the transcription of antisense RNA was found to effectively block the
expression of target genes in transgenic plants. Fire and Mello were the first to identify the
process by which gene silencing occurred and to identify double stranded RNA as being the
causative agent in gene silencing [190]. The experiments of Baulcombe and Hamilton [191]
offered further understanding of the process by identifying that small 21-25 nueclotide RNA
fragments cleaved from the larger double stranded RNA, later named siRNA, were responsible
for gene silencing. While initial studies utilised introduction of exogenous dsRNA, it is now clear
that higher eukaryotes contain a large number of genes that encode small RNAs referred to as
micro-RNAs (miRNAs) [192]. Both miRNAs and exogenous dsRNAs mediate their effects at the
RNA level, miRNAs by inhibiting translation and exogenous dsRNAs through degradation of
target RNAs [192] [193]. Today RNAi is a commonly used tool in many areas of molecular
biology, medical research and biotechnology.
The process of RNAi begins with activation of a ribonuclease called Dicer that initiates
the cleavage of dsRNA to siRNA (Figure 2.4) [194]. These si-RNA molecules are double-stranded
fragments of 20–25 base pairs with a 2-nucleotide overhang at the 3' end [195]. After
processing by Dicer, mature siRNAs associate with argonaut and other proteins to create an
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RNA-induced silencing complex (RISC) [196]. RISC possess endonuclease activity that degrade
mRNA complementary to the attached siRNA, with argonaut proteins being

primarily

responsible for the endonuclease activity of RISC [196]. RNA molecules produced by the dicer
are double stranded and thus the RISC must bind preferentially to only one of the strands to
prevent degradation of two separate mRNA targets. To prevent this occurring argonaut protein
unwinds the siRNA and binds preferentially to only one strand of the RNA, termed the guide
strand, and the other strand is degraded during RISC activation [197]. The guide strand is
thought to be selected based on the differences on the thermodynamic stability of the 5' end,
with the more stable 5' end forming the guide strand and the strand with the less stable 5' end
being degraded [198].
Because of its specificity and efficiency, RNAi is considered as an important tool not only
for functional genomics, but also for gene-specific therapeutic activities that target the mRNAs
of disease-related genes [199].
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Figure 2.4 Schematic diagram of RNAi pathway, detailing siRNA cleavage by Dicer, RISC
recruitment and site-specific cleavage of target mRNA. [200]
The process of RNA interference begins with cleavage of long double stranded RNA into small
siRNA strands by Dicer. A number of enzymes then associate with the siRNAs to form RNAinduced silencing complex (RISC). RISC unwinds the siRNA into a single stranded RNA molecule
and guides it to its specific mRNA target, resulting in cleavage of the target mRNA.
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2.2 Sample collection and evaluation, selection of cohort
2.2.1 Sample collection

Ethical approval was received from the Rotunda Hospital to collect patient information and
formalin fixed paraffin embedded (FFPE) cervical tissue samples. Ethical approval was also
obtained from Dublin Institute of Technology ethics committee for this program of research to
proceed. Under the terms of the ethical approval, access only the patient number and disease
state of the sample were granted and no follow up or patient outcome information was
provided. Before collection of any tissue blocks, haemotoxylin and eosin (H&E) stained sections
cut by the pathology laboratory Rotunda Hospital, from retrospective cervical biopsy samples
(sent between 2005 and 2007), were examined in order to identify tissue blocks that contained
normal cervical tissue, pre-cancerous and invasive lesions and had large enough lesions to allow
for tissue microarray production. Following microscopic examination of the H&Es, samples
with at least two blocks that contained sufficient lesions were identified (one block for tissue
microarray production, one for evaluation of HPV status) and their corresponding patient and
block numbers recorded. The appropriate tissue blocks were then retrieved from the hospitals
archival storage area. As patient information is confidential, all patient samples were assigned
an arbitrary number for the duration of this study.
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2.2.2 Haematoxylin and Eosin staining and lesion identification

The tissue blocks collected from the hospital had previously been sectioned by the pathology
laboratory, Rotunda Hospital, and in order to ensure that the area containing the lesion was still
present in the tissue blocks, it was necessary to cut a new section and perform a haemotoxylin
and eosin stain from each block. 5µm tissue sections were cut, floated onto a glass slide and
melted for 2 hours in an oven at 60˚C. The sections were then de-waxed for 5 minutes each in
two separate xylene baths, two separate absolute alcohol baths and a spirit bath before being
placed in water. Sections were placed in Mayer’s haematoxylin for 1 minute before being
washed in warm water for 1 minute. Sections were placed in an acid-alcohol solution for 2
seconds before being immediately washed in water for 1 minute. Sections were then placed in
a 1% eosin solution for 5 minutes before being washed in water for 1 minute. Following this,
the sections were dehydrated by placing sections for 5 minutes each in spirit, absolute alcohol
(two baths) and xylene (two baths). Sections were mounted with DPX and left to dry on a flat
surface. Upon examination of the sections, 188 cases were deemed to have adequate lesions
present of which 160 with the greatest amount of lesion present were selected for TMA
production and evaluation of HPV status, as each TMA required 40 cases and 4 TMAs were
produced.
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2.3 Construction of tissue microarrays and immunohistochemical
staining
2.3.1 Tissue microarray instrument/design

The instrument used in the production of the tissue micro-arrays was a Beecher Instruments
Manual Tissue Array MTA-1 (Beecher Instruments, Wisconsin, USA). The needles used to
produce the cores were model number MP10, 1.0mm Manual Tissue Array Needles, produced
by Beecher Instruments. Each tissue micro-array was designed to have: 12 cases of cervical
carcinoma, 12 cases of high-grade squamous intraepithelial lesion, 12 cases of low-grade
squamous intra-epithelial lesion and 4 cases of non-neoplastic cervical epithelium, giving a total
of 40 cases per TMA. In turn, each case was sampled in triplicate giving a total of 120 cores per
TMA.

2.3.2 Identification of lesion and tissue block orientation

Sampling the correct area is of critical importance during tissue-microarray production. To
ensure the correct area is sampled, H&Es from every donor tissue block were examined and the
area of interest was clearly circled on the glass slide. During construction of tissue microarrays
the slide was overlaid on the tissue block to ensure proper orientation, and to ensure the area
of the tissue block was correctly sampled.
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2.3.3 Tissue microarray (TMA) production

A blank recipient paraffin block was placed in the receptacle of the array machine (figure 2.1),
before then being secured by tightening of the clamp screws. A core was removed from the
recipient paraffin block and the tissue extraction needle was selected. Next the donor block
bridge (figure 2.1) was placed above recipient block clamp before the desired tissue block with
appropriate overlying H&E slide was placed on the bridge. The punch was aligned to the area of
interest on the tissue block using the overlying H&E template. When correctly aligned, the
punch was pushed down steadily to remove the area of interest from the donor block. The
bridge holding the donor block was then removed before the needle was slowly lowered to just
above the previously punched hole in the recipient block. Once aligned, the stylus of the needle
was pushed down to force the core into the hole in the recipient block, leaving the core
protruding approximately 1mm above the surface of the recipient paraffin block. The paraffin
extraction needle was then selected before the horizontal axis of the micrometer (figure 2.1)
was adjusted to a position 1.5mm beside the previous punch. This process was then repeated
until all the required samples had been added to the recipient block. When all the samples had
been added, the recipient block was placed in a 56˚C oven for 15-20 minutes until the wax had
softened. A glass slide was then placed on the surface of the block and pushed down firmly and
evenly to ensure all cores are embedded evenly and surface of the block was flat.
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Figure 2.5 Schematic diagram of the Beecher Instruments MTA-1 tissue micro-array machine.
The instrument contains a receptacle into which the recipient paraffin block is placed and
secured. The small punch needle is used to remove a core from the recipient block while the
large punch removes a sample from the donor block, to a depth controlled by the depth stop.
The micrometer is used to set the distance between each sample inserted into the recipient
block.

77

2.3.4 Antibody Optimisation

Optimal staining conditions were determined for all antibodies listed in table 2.1. Various
antibody dilutions (ranging from 1:25 up to 1:1000 depending on the antibody) were used with
a number of different antigen retrieval methods to assess which dilution worked best with
which antigen retrieval technique. A number of different antigen retrieval techniques were
used, protease induced epitope retrieval (PIER), heat induced epitope retrieval (HIER) (using a
microwave oven) and a combination of these two methods. The buffers used for HIER were
10mmol/l citrate buffer (pH6) and 1mmol/l EDTA buffer (pH8)
Table 2.1 Antibodies utilised in this study for IHC based detection of biomarkers.
Protein

Antibody Clone

Company

Raised In

E-cadherin

NCH-38

Dako

Mouse (Monoclonal)

Beta-Catenin

Β-catenin-1

Dako

Mouse (Monoclonal)

p120-Catenin

EPR357(2)

Epitomics

Rabbit (Monoclonal)

N-cadherin

EPR1792Y

Epitomics

Rabbit (Monoclonal)

Snail

Ab63371

Abcam

Rabbit (Polyclonal)

Claudin-1

51-9000

Invitrogen

Rabbit (Polyclonal)

Claudin-7

34-9100

Invitrogen

Rabbit (Polyclonal)

Occludin

33-1500

Invitrogen

Mouse (Monoclonal)

Table displays the clone, manufacturer and the species the antibody was raised in for all of the
antibodies used in this study.
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Antigen Retrieval
(i) Protease Enzyme Treatment
After dewaxing, sections were covered with 0.1% protease (Sigma) in PBS that had been heated
to 37˚C. Sections were incubated at 37˚C for 5 minutes. After incubation sections were washed
in distilled water before continuing with ABC protocol
(ii) Microwave Oven Treatment
After dewaxing, sections were placed in 10mmol/l citrate buffer pH6 (appendix) or 1mmol/l
EDTA buffer (appendix). Sections were then heated in a microwave for 12 minutes and left to
cool for 20 minutes. Sections were washed in distilled water before continuing with the
standard ABC protocol.
(iii) Microwave + Protease treatment
Sections were treated as per microwave oven protocol as described in 2.3.4 (ii). Following
washing with distilled water, 0.1% protease in PBS (appendix) was applied to sections for 30
seconds. Sections were washed with PBS before continuing standard ABC protocol.

2.3.5 Avidin-biotin Complex Immuno-Peroxidase method

Using a standard histology microtome (Lecia), 5µm cervical sections were cut from
formalin-fixed paraffin tissue blocks. Folds or creases were removed by placing the sections in a
42°C water bath for 10 to 15 seconds before mounting sections on Superfrost Plus glass slides
(Thermo-fisher). Sections were then placed in a 60oC oven for one hour in order to melt the
paraffin, before being dewaxed in two washes of xylene for 5 minutes each. Sections were then
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rehydrated by placing slides in two washes of 100% ethanol, one wash of 95% ethanol and one
wash of distilled water for five minutes each. Antigen retrieval, using the methods previously
described, was then carried out. The optimum antigen retrieval method that was determined
for each antibody can be seen in table 3.1. Following antigen retrieval, sections were washed in
distilled water before blocking of endogenous peroxidases was carried out by treating sections
with 3% hydrogen peroxide in methanol for 5 minutes. Sections were then washed in
phosphate buffered saline (PBS) 3 times, before being treated with the Vectastain Elite ABC kit
(Vector laboratories). Normal horse serum, diluted 1:200 in PBS, was applied to the sections
for 5 minutes. Sections were drained and approximately 500µl of specific primary antibody was
applied and incubated at room temperature for 1 hour. Following 3 washes with PBS, the
biotinylated secondary antibody (diluted 1:100 in PBS) was applied for 15 minutes. Sections
were washed in PBS 3 times before being treated with ABC reagent (diluted 1:100 in PBS) and
then again washed in PBS 3 times. Peroxidase labeling was visualised using 0.06% 2,4diaminobenzidine (Sigma) diluted in PBS and 0.03% hydrogen peroxide (BDH). Sections were
lightly counterstained by application of Mayers haematoxylin for 40 seconds and then blued in
distilled water. Sections were then dehydrated by way of 95% ethanol for 30 seconds, two
washes of 100% ethanol for 5 minutes each and 2 washes of xylene for 5 minutes each. Finally,
sections were coverslipped in DPX.
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2.4 Detection and genotyping of HPV DNA in cervical tissue
2.4.1 Extraction of DNA

DNA was extracted from all samples using the Qiagen DNeasy Blood & Tissue Kit protocol.
Included in this protocol was a xylene dewaxing pretreatment step for FFPE tissue that was
recommended by the manufacturer. Five 10µm sections from each block were cut on a
microtome and placed into a sterile 1.5ml eppendorf tube. To prevent contamination between
blocks a different blade was used for each block, the microtome was cleaned with 70% alcohol
(appendix) and finally DNAway solution (Sigma) was applied to the microtome between each
sample. To remove the paraffin wax 1200µl of xylene (BDH) was added to the eppendorf tube
and vortexed vigorously. The sample was centrifuged at 14,000rpm for 5 minutes before the
supernatant was removed and 1200µl of 100% ethanol (Sigma) was added. The sample was
vortexed vigorously before being centrifuged at 14,000rpm for 5 minutes. The supernatant was
removed and another ethanol wash then performed. After removing the supernatant, being
careful not to remove any pellet, the eppendorf tube was left open in a 37˚C oven until any
residual ethanol was evaporated. The pellet was then re-suspended in 180µl of ATL buffer
(Qiagen) and 20µl of Proteinase K. The sample was vortexed vigorously before being incubated
overnight at 56˚C in an oven. Following overnight incubation the sample was briefly vortexed,
200µl of AL Buffer (Qiagen) was added, before being briefly vortexed again and adding 200µl of
ethanol (Sigma). The sample was then vortexed vigorously for 30 seconds, before transferring
the entire sample to the upper well of a QIAamp spin column (Qiagen). The sample was the
centrifuged for 1 minute at 8000rpm. The spin column was placed in a new collection tube and
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the tube containing the filtrate was discarded. 500µl of AW1 buffer (Qiagen) was added to the
spin column and it was centrifuged at 8000rpm for 1 minute. The collection tube containing the
filtrate was discarded and a new collection tube applied to the spin column. 500µl of AW2
buffer (Qiagen) was added to the spin column and it was centrifuged at 14000rpm for 3
minutes. The spin column was placed in a sterile 1.5ml eppendorf tube and 200µl of AE Buffer
(Qiagen) was applied to the spin column. The spin column was left to incubate for 1 minute at
room temperature before being centrifuged at 8000 rpm for 1 minute. Samples were then
stored at -20˚C until required.
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2.4.2 Controls for PCR

With each reaction a positive control was carried out using DNA extracted from the HPV 18
positive cell line HeLa. A negative control reaction with water in place of template DNA was also
included with each batch. To ensure there was no carry over contamination between samples,
skeletal muscle (HPV-) was sectioned on the microtome in between sectioning of cervical
samples. The DNA from the skeletal muscle section was extracted and underwent GP5+/6+ PCR
amplification, to confirm there was no contamination of samples.

2.4.3 PCR Amplification of Cervical DNA

In order to establish whether the DNA extracted from each sample was of sufficient quality for
a PCR reaction, a β-globin PCR was carried out using the PC03/04 primer pair. HPV DNA was
detected using the GP5+/6+ primer pairs. All PCR reactions were carried out in a final volume of
25µl containing 1x reaction buffer (200mmol/l Tris-HCl pH8.4, 500mmol/l KCl) (Invitrogen),
0.2mmol/l dNTPs (Invitrogen), 1U Platinum Taq polymerase (Invitrogen) and 3µl template DNA.
MgCl2 and primer concentration are detailed in table 2.2. The PCR protocol was as follows: an
initial 5 minute denaturation step at 95˚C, followed by 40 cycles of 95˚C for 30 seconds, 48˚C
(GP5+/6+) or 60˚C (PC03/04) for 30 seconds, 72˚C for 30 seconds before an final elongation step
of 72˚C for 5 minutes. All PCR reactions were analysed on a 2% agarose gel (appendix) stained
with 0.5µg/ml ethidium bromide (Fluka). Gels were run at 120V for 1 hour.
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Table 2.2 Primers used for DNA quality assessment and HPV detection.
Primer

Primer Sequence 5’-3’

MgCl2 Concentration

Primer
Concentration

PC03

ACACAACTGTGTTCACTAGC

PC04

CAACTTCATCCACGTTCACC

GP5+

TTTGTTACTGTGGTAGATACTAC

GP6+

GAAAAATAAACTGTAAATCAT

GP5+ M13 TGTAAAACGACGGCCAGTTTTG

Product
Size

1.5mmol/l

40nmol/µl

110bp

2.5mmol/l

40nmol/µl

150bp

2.5mmol/l

40nmol/µl

168bp

TTACTGTGGTAGATACTAC

Primer sequences, magnesium concentrations, primer concentration and product size for
primers used in this study

2.4.4 Purification of PCR amplimers

Purification of PCR products was performed using the High pure PCR purification Kit (Roche).
This product removes excess dNTPs, primers and PCR buffers from PCR reaction solutions. After
amplification, PCR reaction solution was made up to 100µl with distilled water, then mixed with
400µl of binding buffer. The solution was loaded into a provided spin column and centrifuged
for 1 minute at 8000rpm. The eluate from the collection tube was discarded and 400µl of wash
buffer was loaded into the spin column. The spin column was then centrifuged at 8000rpm for 1
minute. The eluate in the collection tube was discarded and 300µl of wash buffer was added to
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the spin column. The spin column was centrifuged at 14000rpm for 1 minute and the collection
tube was then discarded. A new collection tube was attached to the spin column and 20µl of
elution buffer was applied. The spin column was then centrifuged at 8000rpm for 1 minute. The
solution present in the spin column contained the purified DNA and was frozen at -20˚C until
required.

2.4.5 Sequencing of PCR products and BLAST comparison of sequences

After purification of GP5+/6+ PCR amplimers generated from cervical DNA, samples were sent
for sequencing to Eurofins Mwg Operon (Ebersberg, Germany). Samples that were successfully
sequenced were returned to us in FASTA format, which is a text-based file format containing
the complete nucleotide sequence. The sequences were compared to known HPV L1 sequences
using the basic local alignment search tool (BLAST). Using this database, sequence homology in
the PCR amplimers could be found with sequences in the L1 gene of various different HPV
genotypes, thus allowing the identification of the HPV genotype present in cervical samples.
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2.5 Establishment and assessment of stable cell lines
2.5.1 Cell lines and cell Culture
Three cervical cancer cell lines were used during this study. HeLa, a HPV-18 positive cervical cell
line, and SiHa and CasKi both HPV-16 positive. Cell lines were grown in complete RPMI medium
(Sigma), including 2mmol/l L-glutamine (Gibco) 10% foetal calf serum (Sigma) and 40 U
penicillin/streptomycin (Sigma) at 37°C and 5% CO2 in a humidified atmosphere. Cells were
grown to confluence before being trypsinised with 2% trypsin diluted in 0.02% EDTA (Sigma) for
10 minutes at 37°C. 10ml complete RPMI medium was added to the culture dish to inactivate
trypsin. 0.5 x 105 cells were added to a 6mm cell culture dish containing 2ml complete RPMI
were cultured overnight at 37°C and 5% CO2. In addition, 0.5 x 105 cells were added to a 25ml
cell culture flask containing 10ml of complete RPMI medium and incubated at 37°C and 5% CO2
to maintain the cell culture for future use.
2.5.2 Transformation of One Shot® TOP10 chemically competent E. Coli
Two separate expression vectors, one encoding claudin-1 and another encoding claudin-7, were
purchased from Genecopedia (Rockville, MD, USA). An outline of the structure of these
expression vectors can be seen in figure 2.2. 1µg of plasmid was diluted in 2.5µl of H2O and was
added to a 50µl vial of One Shot® TOP10 chemically competent E. Coli (Life Technologies) and
mixed gently. After incubation on ice for 25 minutes the cells were heat-shocked for 30 seconds
at 42°C and placed for 2 minutes on ice. 250µl of pre-warmed S.O.C medium was added and the
tube and the tube was placed in a horizontal shaker at 225 rpm at 37°C for 1 hour. 200µl of the
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transformation solution was spread on a LB agar plate containing 100µg/ml ampicillin and
incubated at 37°C overnight.
2.5.3 Production and isolation of high quality plasmid
In order to prepare purified plasmid DNA in large quantities both plasmids were purified with
the Genopure Plasmid Midi Kit (Roche). Bacterial colonies grown on ampicillin containing agar
plates (from 2.5.2) were picked, inoculated and cultured overnight at 37°C in 100ml LB medium
containing 100µl/ml ampicillin, with vigorous shaking. To pellet the bacteria, the culture
medium was centrifuged for 10 minutes at 3000 x g at 4°C and the supernatant was discarded.
The pellet was air-dryed and resuspended in 8ml suspension buffer. 8ml lysis buffer was added
and mixed gently by inverting the tube and the mixture was then incubated at room
temperature for 2-3 minutes. 8ml of chilled neutralisation buffer was added and mixed
immediately by inverting the tube before being incubated on ice for 5 minutes. The bacterial
lysate was filtered and then loaded into a column and allowed to flow though the column. The
flowthrough was passed though the column again before being discarded. Three separate times
4ml of wash buffer was passed through the column and discarded after each wash. The column
was then inserted into a collection tube capable of withstanding high speed centrifugation and
2.5ml of elution buffer pre-warmed to 50°C was added to the column and allowed to flow
through. The flowthrough was passed though the column again before 3.6ml of isopropanol
was added into the tube to precipitate the eluted plasmid. The plasmid DNA was centrifuged
for 30min at 15000 x g at 4°C. The supernatant was then carefully discarded and the plasmid
DNA was washed with 3ml of chilled 70% ethanol and centrifuged for an additional 10 minutes
at 15000 x g at 4°C. The supernatant was removed and the tube was allowed to air-dry for 15
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minutes. The DNA plasmid pellet was re-dissolved in 50µl nuclease free water buffer and stored
at -20°C.

2.5.4 Transfection of expression vectors and stable clone selection
2 x 106 HeLa cells were plated per well into 35mm plates and incubated overnight at 37°C, 5%
CO2. 100µl of serum free RPMI-1640 media was added to a sterile 1.5ml eppendorf tube. 3µl of
Genejuice (Novagen) per 1µg of DNA was added drop-wise to the media and was mixed
thoroughly by vortexing. The mixture was incubated at room temperature for 5 minutes. For
transient transfections a range of plasmid DNA amounts was used (0.1µg, 0.25µg, 0.5µg, 1µg
and 2µg), for stable transfections 1µg of plasmid DNA was used. The appropriate amount of
plasmid DNA was added to the serum free RPMI/Genejuice solution, mixed by gentle pipetting,
and incubated at room temperature for 15 minutes. The entire volume was then added dropwise to the well of the plate and the plate was rocked to distribute the transfection mixture.
The cells were incubated at 37°C and 5% CO2. For transient transfections, 24 hours post
transfection the medium was removed and the cells were lysed and protein extracted as
described in 2.4.5. For stable cell lines cells were transferred to a 100mm plates and 200µg/ml
of G418 was added to allow genticin selection. Cells were then incubated for 3 weeks to allow
clones of cells expressing the plasmid to grow. After 3 weeks isolated colonies were picked and
subcultured in a 35mm plate.
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Figure 2.6 Outline of expression vector utilised to create C1-HeLa and C7-HeLa stable cell
lines. Expression vector contains a CMV promoter region ahead of an open reading frame
containing either the Claudin-1 or Claudin-7 gene. The expression vector contains an ampicillin
bacterial selection marker for generation of large amounts of plasmid in bacterial cultures and a
neomycin selection marker for selective isolation of mammalian cells expressing the vector.
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2.5.5 DNA Extraction

DNA was extracted from stable cell colonies using the Qiagen DNeasy Blood & Tissue Kit
according to the manufactures protocol. Cells were harvested by trypsinisation and then
centrifuged at 1500 rpm for 5 minutes in a 1.5ml eppendorf tube. The supernatant was
discarded and the pellet resuspended in 200µl PBS, 20µl Protinase K and 200µl buffer AL. The
sample was vortexed vigorously before being incubated for 10 minutes at 56˚C. Following
incubation the sample was briefly vortexed. The sample was then vortexed vigorously for 30
seconds, before transferring the entire sample to the upper well of a QIAamp spin column
(Qiagen). The sample was then centrifuged for 1 minute at 8000rpm. The spin column was
placed in a new collection tube and the tube containing the filtrate was discarded. 500µl of
AW1 buffer (Qiagen) was added to the spin column and it was centrifuged at 8000rpm for 1
minute. The collection tube containing the filtrate was discarded and a new collection tube
applied to the spin column. 500µl of AW2 buffer (Qiagen) was added to the spin column and it
was centrifuged at 14000rpm for 3 minutes. The spin column was placed in a sterile 1.5ml
eppendorf tube and 200µl of AE Buffer (Qiagen) was applied to the spin column. The spin
column was left to incubate for 1 minute at room temperature before being centrifuged at
8000 rpm for 1 minute. The sample was then stored at -20˚C until required.
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2.5.6 PCR verification of stable cell lines

To verify successful uptake of the expression vector in stable cell lines, DNA was extracted from
each colony and a PCR reaction was performed using the primers listed in table 2.3. The
forward primer was complementary to a sequence in the CMV promoter and the reverse
primer was complementary to a sequence in either the CLDN1 or CLDN7 gene. PCR was carried
out according to the method described in 2.3.2, using the primers listed in table 2.3 and
according to the following cycling conditions: an initial 5 minute denaturation step at 95˚C,
followed by 35 cycles of 95˚C for 30 seconds, 59°C for 30 seconds, 72˚C for 30 seconds before
an final elongation step of 72˚C for 5 minutes. All PCR reactions were analysed on a 2% agarose
gel (appendix) stained with 0.5µg/ml ethidium bromide (Fluka). Gels were run at 120V for 1
hour. PCR products were sequenced and matched to the human CLDN1 gene and CLDN7 gene
respectively using BLAST to ensure specificity of primer sets.
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Table 2.3 Table of primers sequences, MgCl2 concentration, primer concentration and PCR product
size used to verify the presence of expression vectors in stable cell lines.

Primer

Primer Sequence 5’-3’

MgCl2
Concentration

CLDN1 Fwd

CAGCCTCCGGACTCTAGC

CLDN1 Rev

GATGTTGTCGCCGGCATAG

CLDN 7 Fwd

CAGCCTCCGGACTCTAGC

CLDN 7 Rev

GCAGTCCATCCACAGCCCC

Primer
Concentration

Product
Size

1.5mmol/l

4ng/µl

200bp

1.5mmol/l

4ng/µl

250bp

2.5.7 Protein extraction

Cells were harvested from 6-well plates by the addition of 200µl trypsin (Sigma) per well. After
cells had detached 800µl of complete medium per well was added. After centrifugation of cells
at 1500rpm for 5 minutes, the supernatant was removed and the pellet resuspended in 1ml of
cold PBS. The cells were washed in PBS another two times and after centrifugation and removal
of the PBS, the cells were lysed in 50µl of RIPA buffer containing 0.1% protease inhibitor
(Calibiochem). The cell lysate was sonicated 5 times, for 10 seconds using a probe sonicator
with the lysate kept on ice at all times. The cell lysate was centrifuged at 14000 rpm for 30
minutes at 4°C. The supernatant was transferred into a fresh eppendorf tube and the protein
concentration was measured in triplicate with a Bradford assay using a BSA standard curve.
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2.5.8 Western Blotting

30µg of sample protein was made up to a total volume of 15µl in distilled water and an
additional 5µl of 4X Laemlli buffer was then added. Samples were heated to 95°C for 5 minutes
and loaded onto a 12% polyacryamide gel (appendix) along with a molecular weight ladder.
Gels were run at 100V for 3 hours. Proteins were then transferred onto a nitrocellulose
membrane (0.45µm pore size) using pre-chilled pH 8.3 transfer buffer (appendix) in a wet tank
apparatus. The tank was kept on ice to keep the buffer chilled and the gel was run at 100V for
70 minutes. After successful transfer of proteins, the membrane was blocked in 5% non-fat dry
milk in TBS-0.1% tween. The appropriate antibody (Table 2.4) was diluted in 5% non-fat dry milk
in TBS-0.1% tween and incubated with membrane for 16 hours at 4°C on a rotary shaker with
gentle agitation. The membrane was washed 5 times in TBS-0.1% tween before being incubated
with appropriate anti-mouse or anti-rabbit secondary HRP-linked secondary antibody (Sigma),
diluted in 5% non-fat dry milk in TBS-0.1% tween for 1 hour at room temperature. The
membrane was then washed in TBS-0.1% tween 5 times. Protein detection was carried out
using the Enhanced Chemiluminescence Kit (Pierce Scientific). ECL solutions were mixed in a 1:1
ratio and applied to the membrane for 5 min. X-Omat film (Kodak) was then overlaid on the
membrane for the appropriate amount of time and the film was developed.
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Table 2.4 Antibodies used in this study for western blotting and the molecular weight of the
proteins they detect.
Antibody

Manufacturer/Clone

Dilution

Molecular weight

Claudin-1

Invitrogen

1:250

23kDa

Claudin-7

Invitrogen

1:250

22kDa

Snail

Cell Signaling (L70G2)

1:1000

29kDa

E-cadherin

Invitrogen (4A2C7)

1:500

97kDa

Beta-Actin

Sigma

1:5000

42kDa

Table shows the manufacturer, clone, working dilution for each antibody and the molecular
weight of the targeted protein.
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2.5.9 Trans epithelial electrical resistance (TEER) Measurements
1.5ml of complete medium was added to each lower well of the plate before 0.5 x 105 cells
were seeded in total volume of 0.5ml of complete medium and added to the insert of 12mm
diameter transwell plate (Corning Costar, Cambridge, MA). An insert with no cells and only
0.5ml of complete medium was also used as blank to measure background resistance. Cells
were then incubated at 37°C until fully confluent and a complete monolayer had formed. After
reaching full confluence, the medium from each transwell insert was removed and replaced
with fresh media. The plates were then incubated at room temperature to allow temperature
equalisation. TEER values were measure using an STX2 electrode (World Precision Instruments)
connected to an Epithlial Voltohmeter (EVOM) (World Precision Instruments) according to the
manufacturer’s instructions. Between each reading the STX2 probe was rinsed with complete
medium. Experiments were carried out in triplicate and on three separate occasions.
Resistance per cm2 was calculated according to the EVOM manual by subtracting the
value of the blank insert from all values then multiplying by the formula for the area of a circle
(πd2/4).
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2.5.10 Cell invasion assay

The Cytoselect 24-well cell invasion assay (Cell Biolabs) was used to evaluate the invasive
properties of stable cell lines. Under sterile conditions the invasion chamber plate was allowed
to incubate at room temperature for 10 minutes. The basement membrane layer of the cell
culture insert was rehydrated by the addition of 300µl of warm, serum-free media to the inner
compartment and incubated at room temperature for 1 hour. The rehydration medium was
removed, taking care not to disturb the basement membrane. 500µl of media containing 10%
fetal bovine serum was added to the lower well of the invasion plate. 300µl of serum free
media containing 0.5 x 106 cells/ml was added to the upper insert and the plate was incubated
at 37°C, 5% CO2 for 48 hours. The media was then carefully aspirated from the upper insert and
the surface of the insert was gently cleaned with cotton-tipped swabs to remove non-migratory
cells. The insert was transferred to a clean well containing 400µl of cell stain solution (0.09%
w/v crystal violet) and incubated for 10 minutes, before being washed several times with
distilled water. Images were then captured of each well under a light microscope, with at least
three individual fields per insert. Each insert was then transferred into an empty well containing
200µl of extraction solution and incubated for 10 minutes on an orbital shaker, before 100µl of
solution was transferred to a 96-well microtiter plate and the absorbance @560nm was
measured. Experiments were carried out three times on three separate occasions.
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2.5.11 Gap closure/Wound healing assay
Cells were seeded at 0.5 x 106 cells per well in a 6 well plate and grown to full confluence. Cells
were examined under an inverted microscope to ensure a continuous monolayer had formed.
Gently and slowly the monolayer was scratched with a p200 pipette tip in a straight line across
the center of the well, in a horizontal direction. While scratching across the surface of the well,
the long-axial of the tip was kept perpendicular to the bottom of the well. Another line was
then scratched though the center of the monolayer, this time in a vertical direction, to create a
cross shaped gap in the monolayer. The cells were then washed twice with PBS before 2ml of
complete medium was added to each well. Under a phase contrast microscope an appropriate
area of the gap was identified and an image captured (0 hour timepoint). This coordinates of
the area was noted for future orientation. The plate was placed in an incubator at 37°C, 5% CO2
until the next timepoint. At 24 hour and 48 hour timepoints the plate was removed and
another image was captured at the appropriate coordinates. The experiment was performed on
three separate occasions.
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2.5.12 MTT assay
Cells were seeded in 96 well plates (1X104 cells per well) and cultured at 37°C, 5% CO2. At 24, 48
and 72 hour time points the assay was performed in triplicate and in three separate
experiments according to the following protocol. A stock MTT solution was prepared at a
concentration of 5mg/ml by dissolving 50mg MTT (Sigma Aldrich, St. Louis, MO, USA) in 10ml
ddH20. A working solution of MTT reagent was prepared by diluting the stock solution 1:10 in
RMPI-1640 media and filter sterilising the solution. At the appropriate time point the media
was removed from each well and 100µl of working MTT solution added to the wells and the
cells were incubated for 3 hours. After 3 hours, the cells were washed 3 times with sterile PBS
and after the last wash all residual liquid was removed from the well. 100µl of DMSO was then
added to each well and the plate was shaken on a rotary shaker for 10 minutes. The absorbance
of each well at 595nm was then recorded using a spectrophotometer.
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2.6 siRNA mediated knockdown of SNAIL in HeLa and SiHa cells
2.6.1 Transfection of siRNA plasmid
Predesigned Silencer® Select siRNAs (Life Technologies) were used in this study to examine
knockdown of SNAIL expression in HeLa and SiHa cells. Two different siRNAs (s13185) and
(s13187) were obtained (Life Technologies), both targeting the SNAIL mRNA, and co-transfected
in to cells according to the following protocol. 0.5 x 10 6 HeLa cells were plated per well into
35mm plates and incubated overnight at 37°C, 5% CO2. 100ul of serum free RPMI-1640 media
was added to a sterile 1.5ml eppendorf tube. 3µl of Lipofectamine RNAiMAX (Life Technologies)
per 10nM of siRNA was added drop-wise to the media and was mixed thoroughly by vortexing.
The mixture was incubated at room temperature for 5 minutes. The appropriate amount of
siRNA was added to the serum free RPMI/ Lipofectamine RNAiMAX solution, mixed by gentle
pipetting, and incubated at room temperature for 15 minutes. The entire volume was then
added drop-wise to the well of the plate and the plate was rocked to distribute the transfection
mixture. The cells were incubated at 37°C and 5% CO2 for 24 hours. Cells were transfected with
a scrambled siRNA as a negative control. Scrambled siRNA contain sequences that are noncomplementary to any known RNA sequences, and thus would not lead to the specific
degradation of any cellular message.
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2.6.2 RNA isolation

RNA was isolated from transfected cells using Trizol solution (Life Technologies). Cells were
harvested by trypsinisation and then centrifuged at 1500 rpm for 5 minutes in a 1.5ml
eppendorf tube. The supernatant was discarded, 1ml of Trizol solution was added and the
solution was mixed thoroughly and incubated at room temperature for 5 minutes. 0.1ml of
bromocholoropropane was added; the solution was mixed thoroughly and then incubated at
room temperature for 5 minutes. The sample was then centrifuged at 12000 x g for 15 minutes
at 4°C to allow phase separation. The upper aqueous phase of the sample was removed by
angling the tube at 45° and pipetting the solution out, taking care to avoid drawing any of the
interphase or organic layer into the pipette, and transferred to a new eppendorf tube. The
interphase and organic phase were discarded. 0.5ml of 100% isopropanol was added to the
aqueous phase and incubated on ice for 10 minutes, before being centrifuged at 12,000 × g for
10 minutes at 4°C. The supernatant was removed and discarded and the pellet resuspended in
1 ml of 75% ethanol. The sample was mixed briefly, then centrifuged at 7500 × g for 5 minutes
at 4°C. The supernatant was removed and the sample allowed to air dry for 10 minutes before
being resuspended in 50µl of RNase-free water. The sample was then heated to 55°C for 10
minutes, before being treated with DNase (Life Technologies) and stored at -80°C.
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2.6.3 Reverse transcription of extracted RNA to cDNA

Creation of cDNA from RNA was achieved using the Enhanced Avian HS RT-PCR Kit (Sigma). In
brief, 1µl of dNTP mix (500µm of each dNTP mix), 1µl of anchored oligo (dT)23 (3.5µM) and
2µg of template DNA were made up to 10ul with RNase free water and placed in a thermal
cycler at 70°C for 10 minutes. The tube was removed from the thermal cycler and 2µl of 10X
AMV-RT buffer, 1µl of enhanced AMV-RT (1U/µl), 1µl of RNase inhibitor and 6µl of RNase free
water was added. The tube was incubated at 48°C for 50 minutes. The cDNA was then either
utilised in a PCR reaction or stored at -20°C.

2.6.4 Real time PCR

Real-time PCR was carried out on reverse transcribed cDNA products using the GAPDH and
SNAIL primers listed in table 2.5. All data on CT values (threshold cycle – the point at which
fluorescence crosses the threshold) was normalised to an internal housekeeping gene, GAPDH,
in order to control for differences in starting cDNA concentration. All PCRs were carried out
using the Lightcycler Fast Start DNA Master SYBR Green Kit (Roche). 18µl of PCR reaction mix
(without template cDNA) was prepared as detailed in table 2.6 and added to pre-cooled light
cycler capillaries (Roche). 2µl of template cDNA was added to each capillary (blank containing
2µl of water) and the capillaries were sealed and centrifuged, before being transferred into the
lightcycler machine. The real time PCR cycles were as follows: an initial denaturation step at
95°C for 10 minutes, 45 cycles of 95°C for 10 seconds, 59°C for 10 seconds, 72°C for 10 seconds.
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A melt curve analysis was performed on all reactions, up to 95°C, with an increase in
temperature of 0.1°C/sec. All real time PCRs were analysed for specificity by melt curve analysis
to ensure only specific peaks for expected products were present. SNAIL primer sequences
were retrieved from Medici et al., 2008 [201] and GAPDH sequences from Paulukat et al., 2001
[202].
Table 2.5 Primers used for real time PCR in this study
Primer

Primer Sequence 5’-3’

GAPDH Fwd

ACCACAGTCCATGCCATCAC

GAPDH Rev

TCCACCACCCTGTTGCTGTA

SNAIL Fwd

ACCACTATGCCGCGCTCTT

SNAIL Rev

GGTCGTAGGGCTGCTGGAA

MgCl2

Primer

Product

Concentration

Concentration

Size

1.5mmol/l

4ng/µl

453bp

1.5mmol/l

4ng/µl

120bp

Forward and reverse primer sequences for GAPDH and SNAIL primers along with MgCl2 and
primer concentrations and the expected product size for each primer set.
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Table 2.6 Reaction mix for real-time PCR.
Component

Volume

Final Conc.

Water

16.2µl

-

MgCl2

0.8µl

2mM

PCR primer mix

1µl

50ng/µl

Lightcycler Faststart DNA 2µl
master SYBR Green Mix

1X

Total

-

18ul

2.7 Data analysis and statistics
SPSS (Statistical Package for the Social Sciences) software was used to perform statistical
analysis, including one way ANOVA tests to examine data for statistical significance and Fisher
least standard difference for post-hoc testing. Microsoft Excel was used for constructing bar
charts and all other graphs.
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3. Examination of tight and adherens junction protein
expression in cervical lesions
3.1 Introduction
Epithelial tissues are characterised by their cohesive structure and by their barrier and gate
function in selectively regulating the flow of ions, cytokines, growth factors and other
molecules through the epithelium and into the underlying tissue. The loss of cohesive structure
and of the barrier and gate function associated with normal epithelium are two of the main
features of epithelial malignancies such as cervical cancer [109]. Tight and adherens junctions
are two distinct but complementary structures within epithelial tissues that play a key role in
initiating and maintaining cell-cell contacts and cohesion [72]. As 90% of cancer deaths are
caused by malignant cells losing their cohesive structure and disseminating away from their
original site to form distant metastasis [203], understanding the mechanisms through which
cells can lose their cohesive structure is of key importance. Identifying aberrant expression of
tight and adherens junction proteins in cervical lesions may help identify some of the
mechanisms by which junctional breakdown occurs, and may also help identify biomarkers that
could indicate which pre-invasive cervical lesions are more likely to progress into invasive
malignancies with the potential to metastasise.
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3.2 Aims


To select a cohort of cervical tissue samples, including all grades of cervical neoplasia
and to utilise selected cervical samples to create tissue micro arrays (TMAs).



To examine the expression of several integral adherens and tight junction proteins in
cervical TMAs using immunohistochemistry.



To analyse the expression profile of each protein and look for changes in expression
between different grades of neoplasia that are statistically significant, possibly
identifying biomarkers associated with the progression of neoplasia.

3.3 Antibody optimisation
In order to determine ideal staining conditions for formalin-fixed paraffin embedded tissue
sections, IHC reactions were carried out using a range of different antibody dilutions for each
antibody and under various different antigen unmasking methods. Antibody dilutions ranged
from 1:20 up to 1:1000 (optimised dilutions can be seen in table 3.1) and unmasking techniques
involved different levels of microwave heat treatment using citrate and EDTA buffers, and
protease treatment. Cervical tissue samples were included in all optimisation steps, along with
another tissue sample that had been reported to have high expression of the protein of
interest. To ensure that any staining observed was due to specific binding of the primary
antibody to the antigen, negative controls that replaced the primary antibody with PBS were
performed simultaneously on the same tissue. All antibodies were successfully optimised on at
least one tissue sample with the exception of occludin, with no staining observed on control
tissues at any antibody dilution or using any antigen retrieval method. The manufacturer of this
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antibody did not specify a recommended positive control tissue but stated the reactivity of the
antibody had been verified on Madine Darby Canine Kidney cells. Human skin tissue was
selected as a positive control tissue as other studies had previously identified occludin as being
present in the stratum granulosum of human epidermis [204]. As the manufacturer of this
antibody had only confirmed the reactivity of this antibody on a cell line it is possible that the
process of formalin fixation may adversely affect the antigen that it is directed against. This
antibody may therefore only be useful for immunohistochemistry using non-formalin fixed
samples such as fresh frozen tissue (cryostat sections) or cell lines. A summary of the optimised
conditions for each antibody can be seen in table 3.1. Images of the positive control and
negative control tissues stained under their optimised conditions can be seen in figure 3.1.
Table 3.1 Outline of optimised antibody dilution, retrieval method, and positive control tissue
for each antibody used in this study.
Protein
E-cadherin

Optimised Antibody
Diluton
1:100

N-cadherin

1:100

Claudin-1

1:50

Claudin-7

1:50

p120-catenin

1:125

SNAIL

1:1000

Occludin

Unable to optimise

Optimised Retrival
Method
12 min MW Citrate
Buffer
12 min MW Citrate
Buffer
12 min MW Citrate
Buffer + 30 seconds
protease
12 min MW Citrate
Buffer + 30 seconds
protease
12 min MW Citrate
Buffer
12 min MW Citrate
Buffer

Optimised Positive
control tissue
Normal Cervix

Unable to optimise

Skin/Normal Cervix
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Liver
Skin

Cervix (HSIL lesion)

Cervix (HSIL lesion)
Cervix (HSIL lesion)/
Breast Carcinoma

Figure 3.1 Images of positive and negative controls for each of the antibodies used in this
study.
Optimised antibody dilutions, antigen retrieval methods and tissue type can be seen in table 3.1
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3.4 Evaluation of tissue microarrays
In total 5 tissue microarray blocks were constructed, 4 arrays containing cervical tissue
samples and 1 array containing control tissue samples for each antibody (Figure 3.3). Each
cervical tissue microarray was designed to have a total of 40 samples each in triplicate, which
would ultimately yield a total of 160 cervical samples. After the tissue microarrays were
constructed a section was cut and a H&E stain was performed to analyse the morphology of
each core (Figure 3.2). A pathologist at the Rotunda Hospital, Dr Eibhlis O’Donovan, analysed
each core to decide if there was adequate epithelium present and, if so, to define what grade
the lesion was.

Figure 3.2 H&E stain of cervical tissue microarrays
A = No evidence of malignancy, B = Low grade squamous intra-epithelial lesion, C = High grade
squamous intra-epithelial lesion, D = Squamous cell carcinoma
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After analysis by the pathologist 126 cases were identified that had adequate lesion
present, a summary of which can be seen in table 3.2. This amount was lower than the
intended 160 samples but still included a large number of samples in all disease grades and was
more than sufficient for subsequent experiments. The tissue blocks used for TMA productions
had previously been used for diagnostic purposes in the Rotunda hospital, therefore a variable
amount of tissue was present on each core sampled. As a result, when the TMAs were
sectioned for use in this study, some cores were lost faster than others and thus all 126 samples
were not always present for each biomarker. A greater number of N.E.M samples, 36, were
present on the final TMAs than the intended 16. This was a result of inaccurate punch sampling
of N.E.M tissue adjacent to the targeted lesion during TMA construction.

Figure 3.3 Image of the 4 cervical TMA blocks used in this study
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Table 3.2 Number of cases selected for TMA construction and final number of cases on
completed TMAs.

Lesion Grade

Number of cases selected for TMA Final number of cases present on
construction
TMAs

N.E.M

16

36

LSIL

48

35

HSIL

48

45

SCC

48

10

Total

160

126
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3.5 Evaluation of biomarker expression in cervical lesions
Following the optimisation of each antibody, the immunohistochemical expression of each
protein was analysed on the cervical tissue microarrays. To evaluate the expression of all
biomarkers except SNAIL, a 4-tier grading system validated for scoring HER-2 expression in
gastric cancer was used [205]. No reactivity in any cell was graded as 0, faint or barely
perceptible membranous reactivity was graded as 1+, weak to moderate basolateral or lateral
membranous reactivity was graded as 2+, strong complete membranous reactivity was graded
as 3+. For SNAIL a 4 tier grading system was used with no nuclear or cytoplasmic reactivity in
any cell graded as 0, faint or barely perceptible nuclear or cytoplasmic reactivity was graded as
1+, weak to moderate nuclear or cytoplasmic reactivity was graded as 2+, strong complete
nuclear or cytoplasmic reactivity was graded as 3+. In consultation with the pathologist it was
decided for LSIL and HSIL cases only the dysplastic cells of the lesions would be graded, to avoid
non dysplastic cells in the epithelium giving an erroneous grading score. Examples of staining
patterns and grading scores for each antibody were presented to the pathologist to confirm
samples were being accurately graded.
A one way ANOVA was performed to determine the statistical significance of the
grading results for each protein across normal cervical tissue and all disease grades, with a p
value of <0.05 deemed significant. For post hoc testing, a Fisher least standard difference (LSD)
test was used to assess the significance of results between individual disease states (e.g NEM vs
LSIL, NEM vs HSIL) etc. In all cases a p value <0.05 was deemed significant. As each sample was
in triplicate staining scores presented were averages of the three scores.
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3.5.1 E-cadherin

Normal cervical epithelium displayed moderate membranous staining of cells in the basal and
intermediate layers of the epithelium. Low grade lesions showed little or no staining of
dysplastic cells in the basal layer of the epithelium with some moderate staining in the
intermediate and superficial layers of the epithelium. High grade lesions predominately had no
staining or some infrequent weak staining of the dysplastic cells in the basal and intermediate
layers with the superficial layer often showing some weak staining (Figure 3.5). In cases of
squamous cell carcinomas a weak staining pattern or an absence of staining was most often
observed (figure 3.5). The significance of any differences in E-cadherin expression in normal
tissue compared to different disease grades were determined using a one way analysis of
variance (ANOVA) test (table 3.4) and a fisher least standard difference (LSD) post-hoc test,
with a p value <0.05 deemed significant (figure 3.5).

Figure 3.4 Bar chart showing the mean expression of E-cadherin according to pathological grade with
error bars showing the standard error for each grade. Significant differences in expression

between normal tissue and different disease grades (p<0.05) highlighted on chart using *. NEM
= no evidence of malignancy, LSIL = low grade squamous intra-epithelial lesion, HSIL = high
grade squamous intra-epithelial lesion, SCC = squamous cell carcinoma. n = number of samples
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Figure 3.5 Expression of E-cadherin in cervical epithelium detected using immunohistochemistry
A = No evidence of malignancy (N.E.M), B = Low grade squamous epithelial lesion (LSIL), C = High grade

squamous epithelial lesion (HSIL), D = Squamous cell carcinoma (SCC)
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Table 3.3 Evaluation of E-cadherin IHC staining intensity in normal cervical epithelium and neoplasia
Staining Intensity
Grade (n=sample no.)

0

1+

2+

3+

N.E.M (n=33)

3 (9%)

10(30%)

14 (43%)

6 (18%)

LSIL (n=25)

14 (56%)

8 (32%)

2 (8%)

1 (4%)

HSIL (n=35)

15 (43%)

9 (26%)

7 (20%)

4 (34%)

SCC (n=9)

3 (33%)

5 (56%)

1 (11%)

0 (0%)

Table shows the scoring results for E-cadherin IHC staining of cervical TMAs. Staining intensity was
assessed using a 0-3 scoring system as described in 3.5. As each cervical tissue specimen was sampled in
triplicate, the results displayed in this table are the average of the three scores rounded to the nearest
whole number.

Table 3.4 Statistical analysis of E-cadherin staining in normal cervical epithelium and neoplasia.

Groups
NEM
LSIL
HSIL
SCC

Statistical analysis of E-cadherin staining results
Count
Sum
Average
Variance
SD
33
54.332
1.646424
0.798182
0.8934
25
14
0.56
0.6525
0.8077
35
34.25
0.978571
1.089601
1.0438
9
7
0.777778
0.444444
0.6666

SE
0.1555
0.1615
0.1595
0.2222

ANOVA
SS
df
MS
F
P-value
F crit
Between Groups
18.52644
3
6.175481
7.398154
<0.05
2.697423
Within Groups
81.8038
98
0.834733
Total
100.3302
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SD = Standard Deviation, SE = Standard Error, SS = Sum of Squares, DF = Degrees of freedom, MS =
Mean Square, F = F-Statistic, Fcrit = F-Critical value

The IHC E-cadherin scoring data from table 3.3 was assessed using SPSS to determine the standard
deviation and standard error within each group. A one way ANOVA analysis was performed to
determine any statistically significant difference between the staining score of the different disease
groups, with a p value of <0.05 considered significant.
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3.5.2 N-cadherin

N-cadherin displayed weak membranous staining in normal cervical epithelium, predominantly
in the basal and intermediate layers. Low grade lesions displayed moderate membranous
staining in the dysplastic cells of the basal layers, with weaker staining in the differentiating
cells of the intermediate and superficial layers. High grade lesions displayed moderate
membranous staining throughout the epithelium. Squamous cell carcinoma cells showed
predominantly moderate membranous staining with some weak cytoplasmic positivity (figure
3.7). The significance of changes in E-cadherin expression in normal tissue compared to
different disease grades were determined using a one way analysis of variance (ANOVA) test
(table 3.5) and a fisher least standard difference (LSD) post-hoc test, with a p value <0.05
deemed significant (figure 3.6).

Figure 3.6 Bar chart showing the mean expression of N-cadherin according to pathological grade with
error bars showing the standard error for each grade. Significant changes in expression between
normal tissue and different disease grades (p<0.05) highlighted on chart using *. NEM = no evidence of
malignancy, LSIL = low grade squamous intra-epithelial lesion, HSIL = high grade squamous intraepithelial lesion, SCC = squamous cell carcinoma. n = number of samples
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Figure 3.7 Expression of N-cadherin in cervical epithelium detected using immunohistochemistry
A = No evidence of malignancy (N.E.M), B = Low grade squamous epithelial lesion (LSIL), C = High grade

squamous epithelial lesion (HSIL), D = Squamous cell carcinoma (SCC)
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Table 3.5 Evaluation of N-cadherin staining intensity in normal cervical epithelium and neoplasia
Staining Intensity
Grade (n=sample no.)

0

1+

2+

3+

N.E.M (n=26)

8 (31%)

8 (31%)

8 (31%)

2 (7%)

LSIL (n=27)

1 (4%)

3 (11%)

15 (56%)

8 (29%)

HSIL (n=37)

3 (8%)

8 (22%)

9 (24%)

17 (46%)

SCC (n=10)

1 (10%)

3 (30%)

4 (40%)

2 (20%)

Table shows the scoring results for N-cadherin IHC staining of cervical TMAs. Staining intensity was
assessed using a 0-3 scoring system as described in 3.5. As each cervical tissue specimen was sampled in
triplicate, the results displayed in this table are the average of the three scores rounded to the nearest
whole number.
Table 3.6 Statistical analysis of N-cadherin staining in normal cervical epithelium and neoplasia
Statistical analysis of N-cadherin staining results
Sum
Average
Variance
SD
29.583
1.137808
0.890545
0.943687

Groups
NEM

Count
26

SE
0.185

LSIL

27

56.5

2.092593

0.577635

0.760023

0.1463

HSIL

37

77

2.081081

1.021021

1.010456

0.1562

SCC

10

17

1.7

0.9

0.948683

0.3

ANOVA

SS

df

MS

F

P-value

F crit

Between
Groups

16.73562

3

5.57854

6.51993

<0.05

2.699393

Within Groups

82.1389

96

0.855614

Total

98.87452
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SD = Standard Deviation, SE = Standard Error, SS = Sum of Squares, DF = Degrees of freedom, MS =
Mean Square, F = F-Statistic, Fcrit = F-Critical value

The IHC N-cadherin scoring data from table 3.5 was assessed using SPSS to determine the standard
deviation and standard error within each group. A one way ANOVA analysis was performed to
determine any statistically significant difference between the staining score of the different disease
groups, with a p value of <0.05 considered significant.
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3.5.3 Claudin 1

Claudin-1 displayed weak membranous staining in normal cervical epithelium, predominantly in
the basal and intermediate layers. Low grade lesions showed moderate membranous staining
in the dysplastic cells of the basal layers, with weaker staining in the differentiating cells of the
intermediate and superficial layers. High grade lesions showed moderate to strong
membranous staining throughout the epithelium. Squamous cell carcinoma cells showed strong
membranous staining with some weak cytoplasmic activity (figure 3.9). The significance of
changes in claudin-1 expression in normal tissue compared to different disease grades were
determined using a one way analysis of variance (ANOVA) test (table 3.8) and a fisher least
standard difference (LSD) post-hoc test, with a p value <0.05 deemed significant (figure 3.8).

Figure 3.8 Bar chart showing the mean expression of claudin-1 according to pathological grade with
error bars showing the standard error for each grade. Significant changes in expression between
normal tissue and different disease grades (p<0.05) highlighted on chart using *. NEM = no evidence of
malignancy, LSIL = low grade squamous intra-epithelial lesion, HSIL = high grade squamous intraepithelial lesion, SCC = squamous cell carcinoma. n = number of samples
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Figure 3.9 Expression
immunohistochemistry

of

Claudin-1

in

cervical

epithelium

detected

using

A = No evidence of malignancy (N.E.M), B = Low grade squamous epithelial lesion (LSIL), C = High grade

squamous epithelial lesion (HSIL), D = Squamous cell carcinoma (SCC)
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Table 3.7 Evaluation of claudin-1 staining intensity in normal cervical epithelium and neoplasia
Staining Intensity
Grade (n= sample no)

0

1+

2+

3+

N.E.M (n=33)

3 (9%)

19 (53%)

11 (36%)

0 (0%)

LSIL (n=31)

0 (0%)

13 (42%)

12 (32%)

6 (26%)

HSIL (n=40)

0 (0%)

4 (10%)

17 (43%)

19 (47%)

SCC (n=10)

0 (0%)

1 (10%)

1 (10%)

8 (80%)

Table shows the scoring results for claudin-1 IHC staining of cervical TMAs. Staining intensity was
assessed using a 0-3 scoring system as described in 3.5. As each cervical tissue specimen was sampled in
triplicate, the results displayed in this table are the average of the three scores rounded to the nearest
whole number

Table 3.8 Statistical analysis of claudin-1 staining in normal cervical epithelium and neoplasia

Groups
NEM

Statistical analysis of Claudin-1 staining results
Count
Sum
Average
Variance
SD
33
39.166
1.186848
0.345045
0.587406

SE
0.1022

LSIL

31

54.5

1.758065

0.581183

0.762353

0.1369

HSIL

40

93

2.325

0.48141

0.693837

0.1067

SCC

10

27

2.7

0.455556

0.674949

0.2134

Source of Variation

SS

df

MS

F

P-value

F crit

Between Groups

30.95731

3

10.3191

22.10436

<0.05

2.687139

Within Groups

51.35193

110

0.466836

Total

82.30924
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SD = Standard Deviation, SE = Standard Error, SS = Sum of Squares, DF = Degrees of freedom, MS =
Mean Square, F = F-Statistic, Fcrit = F-Critical value
The IHC claudin-1 scoring data from table 3.7 was assessed using SPSS to determine the standard
deviation and standard error within each group. A one way ANOVA analysis was performed to
determine any statistically significant difference between the staining score of the different disease
groups, with a p value of <0.05 considered significant.
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3.5.4 Claudin-7

Claudin-7 displayed weak membranous staining in normal cervical epithelium, predominantly in
the basal and intermediate layers. Low grade lesions displayed weak to moderate membranous
staining in the dysplastic cells of the basal layers, with less staining in the differentiating cells of
the intermediate and superficial layers. High grade lesions displayed moderate to strong
membranous staining throughout the epithelium. Squamous cell carcinoma cells displayed
moderate membranous staining with some weak cytoplasmic positivity (figure 3.11). The
significance of changes in claudin-7 expression in normal tissue compared to different disease
grades were determined using a one way analysis of variance (ANOVA) test (table 3.10) and a
fisher least standard difference (LSD) post-hoc test, with a p value <0.05 deemed significant
(figure 3.10).

Figure 3.10 Bar chart showing the mean expression of claudin-7 according to pathological grade with
error bars showing the standard error for each grade. Significant changes in expression between
normal tissue and different disease grades (p<0.05) highlighted on chart using *. NEM = no evidence of
malignancy, LSIL = low grade squamous intra-epithelial lesion, HSIL = high grade squamous intraepithelial lesion, SCC = squamous cell carcinoma. n = number of samples
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Figure 3.11 Expression
immunohistochemistry

of

Claudin-7

in

cervical

epithelium

detected

using

A = No evidence of malignancy (N.E.M), B = Low grade squamous epithelial lesion (LSIL), C = High grade

squamous epithelial lesion (HSIL), D = Squamous cell carcinoma (SCC)
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Table 3.9 Evaluation of claudin-7 staining intensity in normal cervical epithelium and neoplasia
Staining Intensity
Grade (n=sample no.)

0

1+

2+

3+

N.E.M (n=29)

13 (45%)

12 (41%)

4 (14%)

0 (0%)

LSIL (n=30)

7 (21%)

13 (45%)

4 (14%)

6 (20%)

HSIL (n=31)

2 (7%)

5 (16%)

9 (29%)

15 (48%)

SCC (n=10)

1 (10%)

5 (50%)

1 (10%)

3 (30%)

Table shows the scoring results for claudin-7 IHC staining of cervical TMAs. Staining intensity was
assessed using a 0-3 scoring system as described in 3.5. As each cervical tissue specimen was sampled in
triplicate, the results displayed in this table are the average of the three scores rounded to the nearest
whole number.

Table 3.10 Statistical analysis of claudin-7 staining in normal cervical epithelium and neoplasia

Groups
NEM

Statistical analysis of Claudin-7 staining results
Count
Sum
Average
Variance
SD
29
19.5
0.672414
0.504926
0.710582

SE
0.132

LSIL

30

39

1.3

1.13793

1.055364

0.1055

HSIL

31

66

2.129032

0.882796

0.939572

0.1581

SCC

10

16

1.6

1.155556

1.074968

0.34

Source of Variation

SS

df

MS

F

P-value

F crit

Between Groups

34.09222

3

11.36407

16.10223

<0.05

2.698398

Within Groups

68.45729

97

0.705745

Total

102.5495

100

SD = Standard Deviation, SE = Standard Error, SS = Sum of Squares, DF = Degrees of freedom, MS =
Mean Square, F = F-Statistic, Fcrit = F-Critical value
The IHC claudin-7 scoring data from table 3.9 was assessed using SPSS to determine the standard
deviation and standard error within each group. A one way ANOVA analysis was performed to
determine any statistically significant difference between the staining score of the different disease
groups, with a p value of <0.05 considered significant.
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3.5.5 p120-catenin

p120-catenin showed weak membranous staining in normal cervical epithelium, predominantly
in the basal and parabasal layers. Low grade lesions showed moderate membranous staining in
the dysplastic cells of the basal layers, with less staining in the differentiating cells of the
intermediate and superficial layers. High grade lesions showed strong membranous staining
throughout the epithelium. Squamous cell carcinoma cells showed strong membranous and
cytoplasmic staining (figure 3.13). The significance of changes in p120-catenin expression in
normal tissue compared to different disease grades were determined using a one way analysis
of variance (ANOVA) test (table 3.12) and a fisher least standard difference (LSD) post-hoc test,
with a p value <0.05 deemed significant (figure 3.12).

Figure 3.12 Bar chart showing the mean expression of p120-catenin according to pathological grade
with error bars showing the standard error for each grade. Significant changes in expression between
normal tissue and different disease grades (p<0.05) highlighted on chart using *. NEM = no evidence of
malignancy, LSIL = low grade squamous intra-epithelial lesion, HSIL = high grade squamous intraepithelial lesion, SCC = squamous cell carcinoma. n = number of samples
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Figure 3.13 Expression
immunohistochemistry

of

p120-catenin

in

cervical

epithelium

detected

using

A = No evidence of malignancy (N.E.M), B = Low grade squamous epithelial lesion (LSIL), C = High grade

squamous epithelial lesion (HSIL), D = Squamous cell carcinoma (SCC)

125

Table 3.11 Evaluation of p120-catenin staining intensity in normal cervical epithelium and neoplasia
Staining Intensity
Grade (n=sample no.)

0

1+

2+

3+

N.E.M (n=30)

7 (23%)

12 (40%)

8 (27%)

3 (10%)

LSIL (n=28)

7 (25%)

1 (4%)

14 (50%)

6 (21%)

HSIL (n=32)

0 (0%)

3 (9%)

4 (13%)

25 (78%)

SCC (n=10)

0 (0%)

1 (9%)

4 (36%)

6 (55%)

Table shows the scoring results for p120-catenin IHC staining of cervical TMAs. Staining intensity was
assessed using a 0-3 scoring system as described in 3.5. As each cervical tissue specimen was sampled in
triplicate, the results displayed in this table are the average of the three scores rounded to the nearest
whole number

Table 3.12 Statistical analysis of p120-catenin staining in normal cervical epithelium and neoplasia

Groups
NEM

Statistical analysis of p120-catenin staining results
Count
Sum
Average
Variance
SD
30
36
1.2
0.803448
0.896353

SE
0.1636

LSIL

28

47

1.678571

1.189153

1.090483

0.206

HSIL

32

86

2.6875

0.415323

0.644455

0.1127

SCC

10

27

2.454545

0.472727

0.687552

0.2073

Source of Variation

SS

df

MS

F

P-value

F crit

Between Groups

39.13415

3

13.04472

17.33115

<0.05

2.698398

Within Groups

73.00942

97

0.752674

Total

112.1436

100

SD = Standard Deviation, SE = Standard Error, SS = Sum of Squares, DF = Degrees of freedom, MS =
Mean Square, F = F-Statistic, Fcrit = F-Critical value

The IHC p120-catenin scoring data from table 3.11 was assessed using SPSS to determine the standard
deviation and standard error within each group. A one way ANOVA analysis was performed to
determine any statistically significant difference between the staining score of the different disease
groups, with a p value of <0.05 considered significant
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3.5.6 Snail

In normal cervical epithelium an absence of staining was most often observed. In low grade
lesions weak nuclear and cytoplasmic staining of dysplastic cells in the basal layer was observed
with no staining of cells in the intermediate and superficial layers. In high grade lesions weak to
moderate nuclear and cytoplasmic staining was observed of dysplastic cells in the basal and
intermediate layers of the epithelium. In squamous cell carcinoma cases moderate nuclear and
cytoplasmic staining of malignant cells was observed (figure 3.15). The significance of changes
in SNAIL expression in normal tissue compared to different disease grades were determined
using a one way analysis of variance (ANOVA) test (table 3.14) and a fisher least standard
difference (LSD) post-hoc test, with a p value <0.05 deemed significant (figure 3.14).

Figure 3.14 Bar chart showing the mean expression of SNAIL according to pathological grade with
error bars showing the standard error for each grade. Significant changes in expression between
normal tissue and different disease grades (p<0.05) highlighted on chart using *. NEM = no evidence of
malignancy, LSIL = low grade squamous intra-epithelial lesion, HSIL = high grade squamous intraepithelial lesion, SCC = squamous cell carcinoma. n = number of samples
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Figure 3.15 Expression of SNAIL in cervical epithelium detected using immunohistochemistry
(N.E.M) No evidence of malignancy, (LSIL) Low grade squamous epithelial lesion, (HSIL) High grade squamous
epithelial lesion, (SCC) Squamous cell carcinoma
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Table 3.13 Evaluation of Snail staining intensity in normal cervical epithelium and neoplasia
Staining Intensity
Grade (n=sample no.)

0

1+

2+

3+

N.E.M (n=27)

19 (70%)

7 (26%)

1 (4%)

0 (0%)

LSIL (n=28)

8 (29%)

13 (46%)

7 (25%)

0 (0%)

HSIL (n=29)

2 (7%)

13 (45%)

11 (38%)

3 (10%)

SCC (n=9)

0 (0%)

4 (40%)

2 (30%)

3 (30%)

Table shows the scoring results for SNAIL IHC staining of cervical TMAs. Staining intensity was assessed
using a 0-3 scoring system as described in 3.5. As each cervical tissue specimen was sampled in
triplicate, the results displayed in this table are the average of the three scores rounded to the nearest
whole number.

Table 3.14 Statistical analysis of Snail staining in normal cervical epithelium and neoplasia

Groups
NEM

Statistical analysis of Snail staining results
Count
Sum
Average
Variance
SD
27
8.333
0.30863
0.232272
0.476968

SE
0.0928

LSIL

28

26

0.928571

0.531746

0.729209

0.1378

HSIL

29

43

1.482759

0.597906

0.773244

0.14

SCC

9

17

1.888889

0.861111

0.927961

0.3093

Source of Variation

SS

df

MS

F

P-value

F crit

Between Groups

26.43769

3

8.812564

17.64647

<0.05

2.709402

Within Groups

43.44738

87

0.499395

Total

69.88508

90

SD = Standard Deviation, SE = Standard Error, SS = Sum of Squares, DF = Degrees of freedom, MS =
Mean Square, F = F-Statistic, Fcrit = F-Critical value

The IHC SNAIL scoring data from table 3.13 was assessed using SPSS to determine the standard deviation
and standard error within each group. A one way ANOVA analysis was performed to determine any
statistically significant difference between the staining score of the different disease groups, with a p
value of <0.05 considered significant.
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3.6 Correlation between expression of different biomarkers
In order to assess any possible correlation between the expression of different biomarkers in
cervical lesions, the mean expression for each biomarker in each disease grade was entered
into microsoft excel and a correlation test was performed. The correlation co-efficient is
expressed within a range of -1 to +1 inclusive, with -1 indicating a high inverse correlation and
+1 indicating a high positive correlation between two biomarkers. E-cadherin was inversely
correlated to all other biomarkers, as E-cadherin was the only biomarker with highest
expression in NEM tissue and reduced expression in neoplastic lesions, with its strongest
inverse correlation to N-cadherin (-0.85821). Apart from its strong inverse correlation to Ecadherin, N-cadherin also had a high positive correlation to Claudin-7 (0.784817). Claudin-1
expression was very highly correlated with both p120-catenin (0.92857) and SNAIL expression.
(0.99966). Claudin-7 also displayed a strong correlation with SNAIL (0.820169) and p120-catenin
(0.923247). Correlation coefficients for all biomarkers can be seen in table 3.15.
Table 3.15 Correlation coefficients between different biomarker staining results.
ECAD

NCAD

CLDN1

CLDN7

p120

ECAD

1

NCAD

-0.85821

1

CLDN1

-0.62422

0.546993

1

CLDN7

-0.56719

0.784817

0.822935

1

p120

-0.50664

0.630428

0.92857

0.960345

1

SNAIL

-0.64353

0.559515

0.99966

0.820169

0.923247

SNAIL

1

Coefficent of +1 indicates strong correlation. Coefficient of -1 indicates strong negative correlation
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3.7 Summary & Key findings
A cohort of cervical tissue samples containing normal cervical tissue and all grades of
cervical neoplasia were selected and retrieved from the Rotunda Maternity Hospital. Sections
from all of the tissue blocks were cut and a H&E stain was performed to identify the area
containing the lesion. Several tissue microarrays were then produced using the cervical tissue
blocks, and these TMAs were imunohistochemically stained to examine the expression of
several adherens and tight junction proteins in cervical tissue.



The expression of several tight and adherens junction proteins is altered in pre-invasive
and invasive cervical lesions
o Reduction in the expression of E-cadherin in all grades of neoplasia compared to
normal cervical epithelium
o Increase in the expression of N-cadherin, claudin-1, claudin-7, p120-catenin, and
SNAIL



Change in expression for many proteins was observed even in low-grade lesions
indicating some of these proteins may be of use as biomarkers for differentiating
between borderline normal and LSIL lesions and also in identifying pre-invasive lesions
more likely to progress to invasive cancers.



Identified aberrant expression profile of AJ and TJ proteins in this study may offer
further insight into the pathogenesis of cervical malignancies, potentially uncovering
new targets for future therapies.
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3.8 Discussion
This study aimed to examine the expression profiles of a range of adherens and tight junction
proteins in normal cervical epithelium and in different grades of cervical neoplasia. To this end
we utilised a cohort of cervical tissue samples from the Rotunda Maternity Hospital to create
several tissue microarrays, each containing normal cervical tissue and all grades of neoplasia.
We examined the expression of several adherens and tight junction proteins and a significant
change in expression of these proteins was observed in both pre-invasive and invasive lesions.
A change in expression of many adherens and tight junction proteins was observed in both low
grade and high grade pre-cancer lesions and in invasive cancer. In particular, a reduction in the
expression of E-cadherin and a reduction in the expression of N-Cadherin, claudin-1, claudin-7,
p120-cateninand SNAIL was observed in all grades of neoplasia. This may indicate that some of
these proteins could be of use as biomarkers for disease progression, potentially helping the
identification of pre-cancerous lesions that are more likely to progress to invasive cancers, and
also help to differentiate pre-cancerous lesions from other non-cancer related conditions in the
cervical epithelium, such as metaplasia. To fully assess the usefulness of these proteins as
markers of disease progression, it would be necessary to compare the expression of each
protein to patient follow up information, such as patient outcomes. Unfortunately, due to
ethical constraints, this information was not made available to this study. As a result of not
having access to patient follow up information, this study was unable to assess if there is any
relationship between changes in expression of a particular adherens or tight junction protein
and aspects of patient outcome, such as prognosis. Further studies are therefore required to
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determine if any of these proteins would be of use in a clinical setting as prognostic indicators
or biomarkers for disease progression.
One limitation of this study, however, was the lower number of invasive cancer samples
analysed compared to NEM, LSIL, and HSIL samples. Initially, during TMA design, it was
intended to include 48 samples each of LSIL, HSIL and invasive cancer in the study.
Unfortunately, inclusion of 48 invasive cancer samples was not possible as this study only had
access to patient samples from the Rotunda Hospital that were treated between 2005-2007
and an insufficient number of invasive cancer samples were processed in the hospital during
this period. Although in Ireland there are on average 180 cases of cervical cancer per year
(WHO 2012), these cases are treated throughout all the maternity hospitals in the state, thus an
individual hospital may only have a small number of patients presenting with cervical cancer
per year. As a result, this study was limited to analysing 10 samples of invasive cancer. The
sample number of this study was similar to the 12 SCC samples used by Wang et al., 2005 to
assess p16 expression in cervical neoplasia, and was still sufficient to assess the expression
profile of tight and adherens junction proteins in invasive cancer and to allow comparisons of
expression of these proteins in normal cervical tissue and low and high grade lesions.
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4. Detection and genotyping of HPV in cervical tissue samples
4.1 Introduction
The causal role of HPV in the development of cervical cancer had been well established and is
highlighted by the fact that HPV DNA is detected in 99% of invasive cervical tumours [3].
Significant diversity exists within the HPV family, with over 120 HPV genotypes currently
identified and 12 subgroups within the α-papillomvirus genus alone [14]. In a clinical setting
HPV genotypes are classified into ‘high-risk’ and ‘low-risk categories depending on their ability
promote oncogenic changes within the cervical epithelium. HPV-16 and HPV-18 subtypes in
particular are strongly associated with the development and persistence of pre-invasive cervical
lesions, and subsequent development of invasive cervical cancer [207]. The viral proteins E6
and E7 are two of the main promoters of oncogenic change in cervical cells primarily though
their interaction with p53 and pRb respectively, with HPV-16 E6 shown to have a higher affinity
for p53 than other subtypes [31]. However, malignant transformation of cervical cells is a
complex process involving more than interaction with p53 and pRb alone, and it is likely that
the virus also possesses mechanisms for disrupting tight and adherens junctions and thus cell
cohesion and polarity. It is possible that high risk HPV subtypes may also possess a more
effective mechanism for disrupting cell cohesion and thus cervical lesions infected with a high
risk HPV genotypes may display a different tight and adherens junction expression profile
compared to lesions with a lower risk subtype.
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4.2 Aims


To investigate the prevalence of different HPV genotypes in the selected cohort of FFPE
cervical tissue samples.
o Extracting DNA from the samples and utilising a PCR based method to amplify
any HPV DNA present in the samples.
o HPV amplimers will then be sequenced and compared to known HPV sequences
to discover the HPV genotype present in each sample.



To investigate if there is a correlation between specific HPV genotypes and aberrant
expression profiles of tight and adherens junction proteins, by comparing the detected
genotypes to the results in chapter 3.

.
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4.3 Optimisation of PCR
Optimization of PCR conditions for the amplification of the β-Globin gene (used as a control to
assess DNA quality) and the HPV L1 gene using the PC03/04 and GP5+/6+ primer sets (table 4.1)
respectively were performed using DNA extracted from cultured HPV-18+ HeLa cells. All PCR
reactions were performed using the T Professional Basic thermocycler (Biometra). A series of
PCR reactions were performed using different annealing temperatures and magnesium chloride
concentrations to determine the conditions for optimum amplification of target genes. To aid
in sequencing of the PCR products a M13 (uni -21) primer sequence was added to 5’ end of the
forward (GP5+) primer, producing a 168bp amplimer. This would allow sequencing of PCR
products without having to send sample of primer and should aid in the successful sequencing
of amplimers.
Table 4.1 Primers used for DNA quality assessment and HPV detection
Primer

Primer Sequence 5’-3’

Primer

Product Size

Concentration
PC03

ACACAACTGTGTTCACTAGC

PC04

CAACTTCATCCACGTTCACC

GP5+

TTTGTTACTGTGGTAGATACTAC

GP6+

GAAAAATAAACTGTAAATCAT

GP5+ M13

TGTAAAACGACGGCCAGTTTTGTTACTGTG

40nmol/µl

110bp

40nmol/µl

150bp

40nmol/µl

168bp

GTAGATACTAC
Primer sequences, primer concentration and product size for primers used in this chapter. GP5+/6+
sequence was retrieved from de Roda Husman et al. 1995 [208], PC03/04 sequence retrieved from de
Roda Husman, Snijders, et al. 1995 [209]
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4.3.1 PC03/04

The PC03/04 primer set amplifies a 110bp region of the β-Globin gene. Several PCR reactions
were performed with this primer set using annealing temperatures from 58˚C to 60˚C and with
MgCl2+ concentration ranging from 1.5mM to 3.5mM. It was found that annealing temperature
of 60°C and a magnesium concentration of 1.5mM MgCl2+ was optimal and gave the strongest
amplimer (Fig 4.1).

DNA extracted from HeLa cells was used as the template for this

optimisation reaction. Negative controls for optimisation reactions used H2O instead of
template DNA.

Figure 4.1 Optimisation of annealing temperature and MgCl 2+ concentration for PC03/04
primer set.
A range of temperatures from 58˚C to 60˚C and MgCl2+ concentrations were examined with
60˚C and a MgCl2+ concentration of 1.5mM determined to be optimum
137

4.3.2 GP5+/6+

HPV DNA was detected in cervical tissue samples using the GP5+/6+ primer set. This primer set
amplifies a section of the L1 gene, producing a 150bp amplimer. Optimisation of this primer set
was performed using magnesium chloride concentrations of 0 to 3.5mM (at 48°C) (Fig 4.2) and
annealing temperature ranges of 48˚C to 55˚C (using 2.5mM MgCl2) (Fig 4.3). It was found that
an annealing temperature of 48°C and MgCl2+ concentration of 2.5mM were optimum. DNA
extracted from HeLa cells was used as the template for this optimisation reaction. Negative
controls for optimisation reactions used H2O instead of template DNA.

Figure 4.2 Optimisation of MgCl2+ concentration for GP5+/6+ primer set.
Optimisation using a range of 0 to 3.5mM MgCl2+ with 2.5mM determined to be the optimum
concentration for this primer set.
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Figure 4.3 Optimisation of annealing temperature for GP5+/6+ primer set.
Optimisation of annealing temperature for GP5+/6+ primer set was performed using a
temperature range of 48˚C to 55˚C. An annealing temperature of 48˚C was determined to be
optimum.
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4.4 Extraction of DNA from formalin fixed paraffin embedded cervical
tissue.
From the 160 cases examined using the H&E stain DNA was extracted from 101 samples. During
the sectioning of cervical tissue samples for DNA extraction the blade was changed after each
sample and muscle tissue block was sectioned after every 10 cervical sections. Muscle tissue
should not contain HPV DNA, as HPV is epitheliotropic [210] thus DNA extracted from muscle
tissue ensured that no HPV DNA contamination was occurring during the DNA extraction
process (Fig 4.4). With each reaction a positive control was carried out using DNA extracted
from the HPV 18 positive cell line HeLa. A negative control reaction with water in place of
template DNA was also included with each batch.

Figure 4.4 PCR amplification using GP5+/6+ primers on negative controls
Lane 1: 100bp ladder, Lane2: Muscle DNA 1, Lane 3: Muscle DNA 2, Lane 4: HeLa DNA (positive
control), Lane 5: Negative Control (H2O instead of template DNA)
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In total DNA was extracted from 101 cervical samples. The presence of amplifiable DNA
was detected using the PC03/04 primers, of which 85/101 (85%) samples were positive (Figure
4.5), while in the remaining 16 samples DNA of sufficient quality could not be extracted. Of the
85 samples in which amplifiable DNA was detected, HPV DNA was detected in 60 of these
samples using the GP5+/6+ primer set (figure 4.6), while in the remaining 25 samples either no
GP5+/6+ PCR product was detected, or the product was not of sufficient quality for sequencing.
The HPV-genotypes detected in the 60 GP5+/6+ positive samples can be seen in table 4.3 and
figure 4.9.
In N.E.M cervical samples DNA was extracted from 9 samples of which 8/9 samples
produced amplifiable DNA. HPV DNA was detected in 5 of these samples (63%) while in 3 of the
samples no HPV DNA could be detected. In 22/28 LSIL samples, DNA of sufficient quality for PCR
was extracted, with HPV DNA detected in 12 of these 22 samples (55%). For HSIL samples DNA
of sufficient quality for PCR was extracted from 45 of 54 samples. Of these 45 samples, HPV
DNA was detected in 34/45 (73%) of samples. In all 10 SCC samples amplifiable DNA was
extracted and HPV DNA was detected in 9/10 of these samples. For a summary of these results
see (Table 4.2)
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Figure 4.5 β-globin amplification of DNA extracted from cervical tissue
Lane 1: 100bp ladder, Lane 2-11: Cervical sample number 1-10, Lane 12: Negative Control, Lane
13: Positive Control

Figure 4.6 PCR detection of HPV DNA in cervical tissue samples using GP5+/6+ primer set.
Lane 1: 100bp ladder, Lane 2-9: Cervical sample number 1-8, Lane 10:, Positive Control, Lane
11: Negative Control.
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Table 4.2 Detection of HPV DNA in cervical tissue samples using GP5+/6+ primers
Disease staus

No. of Samples tested

HPV+

HPV-

β-Globin Neg.

N.E.M

9

5 (63%)

3 (37%)

1

LSIL

28

12(55%)

10 (45%)

6

HSIL

54

34 (76%)

11 (24%)

9

SCC

10

9 (90%)

1 (10%)

0

Total

101

60 (71%)

25 (29%)

16

Summary of the results from PCR detection of HPV DNA in cervical tissues. SCC samples had the
highest % positivity for HPV DNA.
N.E.M = No evidence of malignancy, LSIL = Low grade squamous intraepithelial lesion, HSIL =
High grade squamous epithelial lesion, SCC = Squamous cell carcinoma.

4.5 HPV genotyping
Sequencing was performed by Eurofins DNA MWG Operon, Ebersberg, Germany. After PCR
reactions were performed the products were purified by spin column, sequenced, and an
electropherogram was produced (Figure 4.7). The electropherogram shows the absorbance
peak of each nucleotide in the DNA strand and thus sequence of the strand. The sequenced PCR
products were then matched for sequence homology with known L1 sequences of specific HPV
genotypes using the Basic Local Alignment Search Tool (BLAST) (Figure 4.8). 60 samples were
successfully sequenced, with HPV-16 the most common genotype detected (Figure 4.9)
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Figure 4.7 Example of an electropherogram produced from a GP5+/6+ amplimer.
Each nucleotide is tagged with a different fluorescent dye and detected simultaneously by a
laser, allowing determination of base pair sequence in the DNA fragment.

Figure 4.8 Example of results from BLAST analysis of sequenced HPV amplimers, showing
level of sequence homology with known HPV sequences.
BLAST is an algorithm that allows comparison of an unknown DNA sequence with database of
published sequences. In this case the query sequence matched published sequences from the
HPV-16 L1 gene, indicating that the original sample contained HPV-16 DNA.

HPV DNA was successfully detected and genotyped in a total of 60 cervical tissue
samples. HPV-16 was the most common genotype detected, with a total of 44/60 (73.3%) of
successfully sequenced samples being HPV-16 positive. HPV-18 was the second most common
genotype detected, with 11/60 (18.3%) of samples being HPV-18 positive. In total, 4 other HPV144

strains were detected with HPV-33 being present in 2/60 (3.3%) and HPV-6, HPV-58 and HPV-67
each detected in 1/60 (1.7%) of cases. HPV-16 and HPV-18 together were detected in 91.6% of
overall cases and both genotypes were detected in cases of NEM and across all grades of
neoplasia. Both HPV-33 genotypes detected were identified in HSIL lesions, as well as the only
detected HPV-58 genotype. The low risk, HPV-6 genotype, was identified in a sample containing
a LSIL lesion, as was the high risk HPV-67 genotype (Table 4.3)

HPV-genotypes detected
11
21
HPV-16
11

HPV-18
HPV-33
HPV-6
HPV-58
44

HPV-67

Figure 4.9 Pie chart displaying the prevalence of different HPV genotypes detected
HPV-16 was the most prevalent subtype detected with a 44 cervical samples testing positive for
this genotype. HPV-18 DNA second most prevalent subtype, with 11 samples testing positive. A
small number of samples tested positive for other genotypes including 2 for HPV-33 and 1 each
for HPV-6, HPV-58 and HPV-67.
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Table 4.3 Number of different HPV genotypes detected and their overall distribution per
pathological grade

Pathological Grade

HPV-6

HPV-16

HPV-18

3

2

9

1

HSIL (n=34)

24

7

SCC (n=9)

8

1

44 (73.3%)

11 (18.3%)

N.E.M (n=5)

LSIL (n=12)

Total (n=60)

1

1 (1.7%)

HPV-33

HPV-58

HPV-67

1

2

1

2 (3.3%)

1 (1.7%)

1(1.7%)

HPV-16 and HPV-18 were most frequently observed genotypes in all disease grades and the
only subtypes detected in N.E.M tissue and invasive cancer samples. In low grade lesions HPV-6,
HPV-18 and HPV-67 subtypes were also detected. In high grade lesions, HPV-33 was detected in
2 samples and HPV-58 in 1 sample in addition to 24 HPV-16 and 7 HPV-18 samples. (N.E.M) =
No evidence of malignancy (LSIL) = Low grade squamous epithelial lesion, (HSIL) = High grade
squamous epithelial lesion, (SCC) = Squamous cell carcinoma

146

4.6 Biomarker expression per HPV-genotype
Of the 60 cervical samples that were successfully genotyped, 31 of these had cores
present on the tissue microarrays that could be graded. HPV-16 and HPV-33 positive samples
had on average low expression of E-cadherin along with moderate to high expression of Ncadherin, claudin-1, claudin-7, p120-catenin and SNAIL (table 4.4). HPV-18 positive samples
displayed on average moderate expression of E-cadherin, weak expression of N-cadherin,
claudin-1, claudin-7 and SNAIL and high expression of p120-catenin. HPV-6 and HPV-67 positive
samples both displayed high E-cadherin expression, moderate N-cadherin expression, weak
claudin-1 expression and an absence of p120 catenin expression (table 4.4).
Table 4.4 Comparison of biomarker expression per HPV genotype
Genotype

ECAD

NCAD

CLDN-1

CLDN-7

p120

SNAIL

3

2

1

3

0

N/A

0.824

2.316

2.425

1.75

2.526

1.7

1.583

0.8666

1.3

1.1

2.6

0.7666

0.5

2.5

2.5

1.5

3

1.5

3

2

1

0

0

0

(number of samples, lesion grade)

HPV-6
(1 LSIL)

HPV-16
(4 LSIL, 10 HSIL, 7 SCC)

HPV-18
(1 NEM, 4 HSIL, 1 SCC)

HPV-33
( 2 HSIL)

HPV-67
(1 LSIL)

Mean IHC staining intensity for each biomarker per HPV genotype. Staining intensity was
graded from 0-3 with 0 indicating no staining and 3 indicating strong staining intensity. HPV-16
and HPV-33 samples displayed on average the lowest expression of E-cadherin and highest
expression of N-cadherin, claudin-1 and SNAIL compared to other HPV subtypes. HPV-6 and
HPV-67 subtypes displayed the strongest E-cadherin expression and weakest claudin-1 and
p120-catenin expression compared to other HPV subtypes.
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4.7 Summary & Key Findings
DNA was extracted from the cohort of cervical tissue samples and the presence of HPV
DNA in the samples was assessed using a PCR based method. A modified GP5+/6+ primer set
producing an amplimer of 168bp was used, with the PC03/04 β-globin primer set used to assess
the quality of the extracted DNA. For any samples that successfully produced an amplimer using
the GP5+/6+set, this amplimer was sequenced and compared to known HPV sequences to
determine the HPV genotype present in the sample.


HPV DNA was detected in 60/101 (59%) of the cervical tissue samples
o In 25/101 (25%) samples HPV DNA could not be detected, while in the remaining
16 samples (16%) no amplifiable DNA could be detected.



The highest detection rate of HPV was in squamous cell carcinoma samples (90%), while
the lowest detection rate was in LSIL samples, with HPV DNA detected in 12/22 (55%) of
samples in which amplifiable DNA was detected.



6 different HPV genotypes were detected with HPV-16 being by far the most prevalent
genotype, with 44/60 (73%) of samples containing HPV-16 DNA.
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4.8 Discussion
This study aimed to examine the prevalence of HPV genotypes in the cohort of FFPE
tissues used in the earlier study. A PCR based method using the GP5+/6+ consensus primer set
was utilised in this study to detect HPV DNA in FFPE cervical tissue samples. Amplimers were
sequenced and compared with published HPV sequenced using BLAST to assess the HPV
genotype present in the sample. While this is a sensitive and reliable method for detecting HPV
DNA, this method has some limitations. Infection with multiple HPV types is relatively common
occurrence in normal cervical tissue and in cervical neoplasia with Huang et al., 2004 finding
28.9% of invasive cervical tumours co-infected with multiple HPV genotypes. Co-infection with
multiple HPV types can have a significant effect on patient outcomes, with Munagala et al.,
2009 finding that patients with multiple infections up to have a poorer response to treatment
compared to patients with infected with a single HPV type. As the HPV detection method used
in this study was unable to detect more than one HPV genotype in a sample, this study was
unable to assess any relationship between HPV co-infection any expression of tight and
adherens junction proteins. PCR systems using multiple primers such as PGMY09/11 and SPFPCR are more robust in detecting multiple infections than systems using single consensus
primers such as GP5+/6+. This may especially be true in cases of mixed infections where one
type is present in a high viral load compared to the other genotype. Methods that use reverse
line blot assays such as the commercial INNO-LiPA kit produced by Roche, instead of DNA
sequencing are also more effective in determining the presence of multiple HPV genotypes in a
single sample, however, for this study the cost of using such a kit was prohibitive.
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One of the aims of this study was to assess if particular HPV genotypes are associated
with a greater degree of aberrant AJ and TJ protein expression compared to other HPV
gentoypes. This study was limited in its ability to compare and contrast the expression profile of
AJ and TJ proteins across a large range of HPV genotypes, due to the predominance of HPV-16
and HPV-18 in the cohort of samples. In this study 73% of samples tested positive for HPV-16
and 18% tested positive for HPV-18. A small number or other HPV genotypes, such as HPV-6,
HPV-33 and HPV-67 were detected although often only a single sample tested positive for these
other genotypes, and overall only 9% of the sample tested positive for a non HPV-16 or HPV-18
genotype. With a small sample number of genotypes other than HPV-16 and -18 this study was
limited in its ability to make meaningful or significant comparisons of AJ and TJ protein
expression between different HPV genotypes. The high prevalence of HPV-16 and -18 in precancerous and invasive cervical lesions has been well established with most studies identifying
HPV-16 and -18 being responsible for around 70% of invasive cancers. This study detected and
genotyped HPV from 60 cervical samples but higher number of samples would need to be
analysed in order to have an adequate number of other HPV genotypes to offer a significant
comparison between expression pattern of the different AJ and TJ proteins. This study was
limited in the number of samples it could analyse due to ethical approval only granting access
to retrospective cervical samples sent to the Rotunda hospital between 2005 and 2007.
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5. The role of SNAIL in E-cadherin expression and investigation
into the role of claudin-1 and claudin-7 on cervical cell
tumourigenesis

5.1 Introduction
Changes in the expression of adherens and tight junction proteins are often observed in
epithelial malignancies [116]. In chapter 3 of this study, an increase in expression of claudin-1,
claudin-7 and SNAIL was observed in cases of cervical neoplasia. Claudin-1 and claudin-7 are
both integral tight junction proteins and have both been implicated as having pro and anti
tumourigenic properties depending on the tumour cell line [113], [124], [125], [211]. SNAIL is a
zinc fingered transcriptional repressor protein and has been shown to be a potent repressor of
E-cadherin expression when overexpressed in the epithelial MDCK cell line [212]. To the best of
our knowledge, there is a lack of studies in the literature about the effect of claudin-1 and
claudin-7 overexpression, or of the role SNAIL may play in the regulation E-cadherin expression,
in cervical cell lines. In this chapter we will attempt to elucidate what role claudin-1, claudin-7
and SNAIL may play in cervical tumourigenesis.
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5.2 Aims



To determine the significance of the increased claudin-1, claudin-7 and snail expression
observed in cervical neoplasia tissue samples in chapter 3 of this study.



To elucidate the role these proteins may play in cervical tumourigenesis by performing a
number of experiments in cervical cell lines.
o To transfect two cervical cell lines that display high expression of SNAIL and no Ecadherin expression, HeLa and SiHa cells, with two siRNAs targeting SNAIL and
the effect of SNAIL knockdown on E-cadherin expression would be examined.
o To investigate the role of claudin-1 and claudin-7 overexpression by generating
claudin-1 and claudin-7 overexpressing HeLa cell lines. The characteristics of
these stable cell lines would then be assessed, in terms of cell
proliferation/viability, permeability, invasion and migration.
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5.3 siRNA mediated knockdown of SNAIL in HeLa cells
HeLa cells were transiently co-transfected two different siRNAs targeting SNAIL in order
to establish knockdown of SNAIL expression in these cells. Two different siRNAs both targeting
SNAIL were selected in order to maximise the level of gene knockdown. Endogenous expression
of SNAIL in HeLa cells had previously been reported by Zhao et al., 2007 [213] and was
confirmed by western blot before proceeding with siRNA experiments (data not shown) Cells
were co-transfected with both siRNAs at concentrations of 100nM, 50nM, 20nM, 10nM, 5nM
for 24 hours. A commercially purchased scrambled siRNA sequence (Ambion) that has no
homology to any known mammalian gene was used as a negative control. The scrambled siRNA
was validated by the manufacturer to ensure minimal non specific effects and to ensure that
comparison of the gene-specific siRNA to the negative control gives a true picture of the effects
of target-gene knockdown on gene expression and phenotype. No reduction of SNAIL protein
expression was observed at all utilised siRNA concentrations, compared to the scrambled siRNA
control (Figure 5.1). No detectable changes in cell morphology were observed at 24 hours post
transfection, although cell viability was not assessed. The siRNAs used in this study were
commercially purchased and were predesigned by the manufacturer, although not validated.
One possibility for the lack of SNAIL knockdown was that siRNA sequences were not fully
complementary to SNAIL mRNA sequences and therefore the mRNA was not efficiently
targeted for degradation. The manufacturer offers several different siRNA variants that target
SNAIL and offers to replace siRNAs that don’t achieve significant knockdown with alternate
siRNAs. To assess if the problem was with a lack of siRNA specificity or another factor, a similar
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cervical cell line (SiHa) was transfected with the siRNA to see if knockdown could be achieved in
this cell line.

Figure 5.1 Western blot of HeLa cells transiently transfected with SNAIL siRNA
Lane 1: 100nM siRNA,

Lane 2: 50nM siRNA,

Lane 3: 25nM siRNA,

Lane 5: 5nM siRNA

Lane 6: Scrambled siRNA

Lane 4: 10nM siRNA,

5.4 siRNA mediated knockdown of SNAIL in SiHa cells
After being unable to achieve significant knockdown of SNAIL expression in HeLa cells,
another cervical cancer cell line, SiHa, was selected to evaluate the role SNAIL in the expression
of E-cadherin. SiHa cells, like HeLa cells, do not express E-cadherin and display high SNAIL
expression. Endogenous expression of SNAIL in SiHa cells was previously reported by Haaberg
et al., 2008 [51] confirmed by western blot before proceeding with siRNA experiments (data
not shown).

SNAIL siRNAs were co-transfected at 100nM, 50nM, 5nM and also with a

scrambled siRNA sequence as a negative control for 24 hours. No detectable changes in cell
morphology were observed at 24 hours post transfection, although cell viability was not
assessed. A reduction of SNAIL expression at the protein level was observed compared to the
scrambled siRNA negative control, at all concentrations of siRNA (Figure 5.2).
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Figure 5.2 Western blot of SiHa cells transiently transfected with SNAIL siRNA.
Lane 1: 100nM siRNA, Lane 2: 50nm siRNA,

Lane 3: 5nm siRNA,

Lane 4: Scrambled siRNA

Although knockdown of SNAIL protein had already been confirmed by western blot, a
preliminary real time PCR reaction was carried out on SiHa cDNA using SNAIL and GAPDH
primers, to confirm knockdown of SNAIL mRNA. The CT value (cycle threshold) value is the cycle
at which fluorescence achieves a certain threshold, and is inversely correlated to the amount of
nucleic acid that was in the original sample. To account for any differences in overall cDNA
concentration, the GAPDH housekeeping gene was used to normalise the SNAIL CT values and
the relative expression was assessed using the 2-∆∆CTmethod as described by Livak et al., 2001
[214]. An decrease in relative SNAIL expression was observed for all concentrations of siRNA ,
compared to the scrambled siRNA samples. The lowest observed relative expression was at the
100nM siRNA concentration, although both 50nM and 5nM concentrations were below the
scrambled siRNA control (Figure 5.3).

155

Percentage change in realtive expression

SNAIL knockdown by siRNA in SiHA cells
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Figure 5.3 Bar chart of relative change in expression of SNAIL in SiHa cells transfected with
different concentrations of siRNA. A reduction in relative SNAIL expression was observed at all
concentration of siRNA compared to the scrambled siRNA control. The greatest reduction was
observed at 100nm with just below 20% of relative expression observed.

5.5 Detection of E-cadherin in siRNA transfected SiHa
After determining that knockdown of SNAIL expression had been achieved at the mRNA
and protein level, an investigation of the relationship between SNAIL and E-cadherin expression
was performed. To assess if siRNA mediated knockdown of SNAIL affected E-cadherin protein
expression, protein was extracted from transfected SiHa cells and a western blot was
performed. As a positive control extracts from the CasKi cell line, that strongly expresses Ecadherin, were used.
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Figure 5.4 Western blot detection of E-cadherin protein in SNAIL siRNA transfected SiHa cells
Lane 1: 100nM SNAIL siRNA,

Lane2: 50nM SNAIL siRNA,

Lane3: 5nM SNAIL siRNA

Lane 4: Scrambled siRNA

Lane 5: Positive Control (CasKi cell extracts)

No expression of E-cadherin was observed at any of the concentrations of transfected SNAIL
siRNA or, as expected, in the scrambled siRNA negative control (Figure 5.4). CasKi cell extracts
were used as a positive control for this experiment as they have high endogenous expression of
E-cadherin. The lack of E-cadherin expression observed in SNAIL knockdown cells could be due
to a number of reasons. It is possible that level of SNAIL knockdown achieved was not sufficient
to nullify its effects in repressing E-cadherin expression. The highest concentration of siRNA
used for transfection was 100nM, which is well above the range recommended by the
manufacturer of 5-30nM. Another siRNA delivery method such as lentivirus particles may offer
a greater level of SNAIL knockdown and perhaps have a greater effect on the level of E-cadherin
expression. It is also possible that in SiHa cells there may be other factors, such as deletions in
the E-cadherin gene itself that may negatively regulate E-cahderin and prevent its expression.
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5.6 Transient transfection of HeLa cells with CLDN expression vectors.
An initial transient transfection of HeLa cells was carried out with the claudin-1 and
claudin-7 expression vectors in order to establish whether claudin protein expression could be
achieved in this cell line. Each vector contained a CMV promoter ahead of either a claudin-1 or
claudin-7 ORF and a neomycin selection marker (Figure 5.7). Varying amounts of each plasmid
were transfected, from 0.1µg to 2µg, to determine the optimum plasmid concentration.

Figure 5.5 Western blot of HeLa cells transiently transfected with a range of Claudin-1 plasmid
concentrations.
Lane 1: Untransfected HeLa, Lane 2: 0.1µg of plasmid, Lane 3: 0.25µg of plasmid, Lane 4: 0.5µg of
plasmid, Lane 5: 1.0µg of plasmid, Lane 6: 2.0µg of plasmid.
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Figure 5.6 Western blot of HeLa cells transiently transfected with a range of Claudin-7 plasmid
concentrations.
Lane 1: Untransfected HeLa, Lane 2: 0.1µg of plasmid, Lane 3: 0.25µg of plasmid, Lane 4: 0.5µg of
plasmid, Lane 5: 1.0µg of plasmid, Lane 6: 2.0µg of plasmid.

HeLa cells transiently transfected with the Claudin-1 expression vector showed expression of
Claudin-1 protein at all ranges of transfected plasmid, from (0.1µg to 2.0µg). Increased
expression of Claudin-1 protein was observed with increasing plasmid concentration, with the
highest expression observed with 0.5µg, 1.0µg and 2.0µg of plasmid (Figure 5.5). A very faint
band was observed in the untransfected HeLa lane, likely as a result of an overflow of sample
from an adjacent lane.
In HeLa cells transiently transfected with the claudin-7 expression vector, no expression
of claudin-7 protein was observed in cells transfected with 0.1µg, 0.25µg, or 0.5µg of plasmid.
Expression of claudin-7 protein was observed in HeLa cells transfected with 1.0µg and 2.0µg of
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plasmid, with a similar level or protein expression observed for both plasmid concentrations
(Figure 5.6).

5.7 PCR screening of claudin-1 stable clones
After transfection of HeLa cells with the claudin-1 expression vector, genticin selection was
performed using G418 (Roche). Cells that survived genticin selection were cultured until
isolated colonies of cells had formed. 50 colonies were picked, although only 42 successfully
grew when subcultured, and DNA was extracted from each sample. To determine successful
uptake of the expression vector and to ensure vector fidelity in each colony, a PCR was
performed (figure 5.8) using primers listed in table 2.3. An outline of the area amplified by the
claudin-1 primers within the expression vector can be seen in figure 5.7. For PCR reactions a
sample of the expression vector was used as a positive control, and DNA extracted from
untransfected HeLa was used as a negative control.

Figure 5.7 Outline of expression vector used for the production of stable cell lines.
Area of expression vector amplified by claudin primers is indicated, spanning from the CMV
promoter to the claudin ORF.
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Figure 5.8 PCR screening of stably transfected claudin-1 colonies
100bp = 100 base pair DNA ladder,

Lane 1-42: Colonies 1-42 respectively

Lane 43: Positive control (plasmid DNA)

Lane 44: Negative control
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After PCR screening the claudin-1 stable colonies, 8 different colonies were identified
that successfully produced an amplimer : Colony#7, Colony#11, Colony#14, Colony#16,
Colony#24, Colony#27, Colony#34, Colony#42 (figure 5.8), indicating that the expression vector
had been successfully integrated and that the CMV-CLDN1 ORF area of the vector was intact.
Amplimers were sequenced and compared to published CLDN1 ORF sequences using BLAST to
ensure the area being amplified was homologous to the CLDN1 ORF (Figure 5.9). These colonies
were then selected for western blotting analysis to assess if the claudin-1 was being expressed
at the protein level. The overall length of the sequence analysed using BLAST was shorter than
length of the amplicon as the sequencing method used ‘clips’ the sequence or automatically
removes the low-quality sections at the start and end of the amplimer by using sequence
quality scores.

Figure 5.9 BLAST analysis of amplimer from claudin-1 stable colony showing sequence
homology with published claudin-1 sequences
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5.8 Western blot analysis of claudin-1 stable colonies
Following, the identification of colonies that had successful uptake of the expression
vector, an assessment of the level of claudin-1 protein expression in each colony was carried
out using western blotting.

Figure 5.10 Western blot detection of claudin-1 in stable colonies
Lane 1: Colony #7

Lane 2: Colony# 11

Lane3: Colony # 14

Lane4: Colony#16

Lane 5: Colony #24

Lane 6: Colony# 27

Lane7: Colony# 34

Lane8: Colony #42

Lane 9: Positive Control Lane 10: Untransfected HeLa

Western blot analysis showed varying levels claudin-1 expression in different colonies
(figure 5.10). Colony #11 and #27 displayed very low expression, while moderate expression
was observed in colonies #24 and #14. The highest observed expression was in colony#7 and
therefore this colony was selected for use in further experiments and designated as C1-HeLa.
Beta-actin bands in lanes 1 and 2 were slightly weak, likely as result of the chemluminescent
substrate draining off the edge of the membrane. Equal loading of proteins was ensured
however, by using a Bradford assay to match protein concentration before loading.
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5.9 PCR screening of claudin-7 stable clones
After transfection of HeLa cells with the claudin-7 expression vector, genticin selection was
performed using G418. Cells that survived genticin selection were cultured until isolated
colonies of cells had formed. 50 colonies were selected, however only 42 colonies continued to
grow when subcultured, and DNA was extracted from each of these colonies. To determine
successful uptake of the expression vector and to ensure the vector fidelity in each colony, a
PCR was performed (figure 5.11) using primers listed in table 2.3.

Figure 5.11 PCR screening of stably transfection claudin-7 colonies
100bp = 100 base pair DNA ladder

Lane1-42: Colonies 1-42 respectively

Lane 43: Positive control (plasmid DNA)

Lane 44: Negative control
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After PCR screening the claudin-7 stable colonies, 8 different colonies were identified that
successfully produced an amplimer : Colony#6, Colony#16, Colony#18, Colony#20, Colony#21, ,
Colony#23, Colony#24, Colony #31, indicating that the expression vector had been successfully
integrated and that the CMV-claudin-7 ORF area of the vector was intact. Amplimers were
sequenced and compared to published claudin-7 ORF sequences using BLAST to ensure the area
being amplified was homologous to the claudin-7 ORF (figure 5.12). These colonies were then
selected for western blotting analysis, to assess if the claudin-7 was being expressed at the
protein level. The overall length of the sequence analysed using BLAST was shorter than length
of the amplicon as the sequencing method used ‘clips’ the sequence or automatically removes
the low-quality sections at the start and end of the amplimer by using sequence quality scores.

Figure 5.12 BLAST analysis of amplimer from claudin-7 stable colony showing sequence
homology with published claudin-7 sequences.
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5.10 Western blot analysis of claudin-7 stable colonies

Following, the identification of colonies that had successful uptake of the expression
vector, an assessment of the level of claudin-7 protein expression in each colony was carried
out using western blotting.

Figure 5.13 Western blot detection of claudin-1 in stable colonies
Lane 1: Colony #6

Lane 2: Colony# 16

Lane3: Colony # 18

Lane4: Colony#20

Lane 5: Colony #21

Lane 6: Colony# 23

Lane7: Colony# 24

Lane8: Colony #31

Lane 9: Positive Control Lane 10: Untransfected HeLa

Western blot analysis showed varying levels claudin-7 expression in different colonies
(figure 5.13). Colony #31 displayed very low expression, while moderate expression was
observed in colonies #16, #18, #20, #21, #23, and #24. The highest observed expression was in
colony#6 and therefore this colony was selected for use in further experiments and designated
as C7-HeLa.
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5.11 Assessment of the effect claudin-1 and claudin-7 expression on cell
viability
The effect of claudin-1 and claudin-7 expression on the viability and proliferation of C1-HeLa
and C7-HeLa stable cell lines was assessed using the MTT assay. Non-claudin transfected HeLa
(Null HeLa) was used as a negative control to assess the endogenous level of viability in HeLa
cells and to allow comparison with claudin transfected cell lines. Results indicate that Claudin-1
and Claudin-7 expression had no effect on the proliferative ability of Hela cells. Claudin-1 and
Claudin-7 transfected cells showed a high level of proliferation at the 48hrs and 72 hrs
timepoints of the assay, with absorbance values roughly doubling at each timepoint. The assay
results from Claudin-1 and Claudin-7 stable cells lines closely matched those of non claudin
expressing HeLa cells (Figure 5.14) indicating that Claudin-1 or 7 expression did not affect the
viability or proliferation of the cells. In addition, no changes in cell morphology were observed.
All experiments were carried out in triplicate on three separate occasions and one way ANOVA
analysis indicated results were not statistically significant.
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Figure 5.14 Graph showing proliferation of C1-Hela, C7-Hela and Hela-Null cell lines using MTT
assay at 24hr, 48hr and 72 hr time points. Error bars show + or – one standard deviation.
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5.12 The effect claudin-1 and claudin-7 expression on cell invasion
The effect of claudin-1 and claudin-7 expression on the invasive ability of HeLa cells was
assessed using the C1-HeLa and C7-HeLa stable cell lines. The ability of cells to digest
extracellular matrix components and permeate through a basement membrane was assessed
using a boyden chamber assay. Non-claudin transfected HeLa (Null HeLa) was used as a
negative control to assess the endogenous level of invasive ability in HeLa cells and to allow
comparison with claudin transfected cell lines. C1-HeLa cells showed a very low invasive ability
as evidenced by the low absorbance reading observed upon staining and lysis of invaded cells
(Figure 5.15A). This result correlated with the observation of very few cells on the membrane
when observed under a light microscope (Figure 5.15B). C7-Hela displayed a similar invasive
ability to C1-Hela cells, with both a low number invaded cells observed when the membrane
was observed under a light microscope (Figure 5.15C) and low absorbance reading observed
when invaded cells stained and lysed (Figure 5.15A) Null-Hela, showed slightly higher invasive
ability compared to C1-Hela and C7-Hela although overall the level of invasion was still very low
(Figure 5.15A, 5.15D). A one way ANOVA test indicated results were not significant with a p
value >0.05.
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Figure 5.15 Cell invasion assay results for claudin-1 and claudin-7 stable cell lines
(A) Graph showing quantification of invaded Claudin-1, Claudin-7 transfected and untransfected
Hela cells at 560nm following staining and extraction, error bars indicate + or – one standard
deviation (B) Brightfield image of invaded claudin-1 transfected (C) claudin-7 transfected and
(D) null-HeLa x40 magnification (arrows indicate invasive cells)
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5.13 Effect of claudin-1 and claudin-7 expression on permeability
The effect of claudin-1 and claudin-7 expression on the permeability of HeLa cells was assessed
using the C1-HeLa and C7-HeLa stable cell lines. Non-claudin transfected HeLa (Null HeLa) was
used as a negative control to assess the endogenous level transepithlial electrical resistance in
HeLa cells and to allow comparison with claudin transfected cell lines. To assess the
permeability of stable cell lines, monolayers were cultured on transwell plates and the
transepithelial electrical resistance was measured. Claudin-1 transfected cells displayed
increased TEER values compared with non-transfected HeLa cells, with an average resistance of
27.55 Ω per cm2 compared to 12.89 Ω per cm2 for untransfected HeLa cells. Claudin-7
transfected cells had an average resistance of 28.26 Ω per cm2 which is significant increase
compared to the resistance of claudin null HeLa (Figure 5.16) and comparable to value
observed for Claudin-1 transfected cells (Figure5.16). Results were analysed using a one way
ANOVA test and were deemed to be statistically significant (P<0.05).
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Figure 5.16 TEER reading for claudin-1, claudin-7 stable cell lines and null-HeLa
Graph showing average resistance per cm2 in ohms for cultured monolayers of Claudin-1 transfected,
Claudin-7 transfected and untransfected HeLa cells. Error bars indicate + or – one standard deviation.
Significance (p<0.05) indicated using *.
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5.14 Effect of claudin-1 and claudin-7 transfection on cell migration
The effect of Claudin-1 and Claudin-7 expression on the migratory ability of HeLa cells
was assessed using a wound healing/gap closure assay. Non-claudin transfected HeLa (Null
HeLa) was used as a negative control to assess the endogenous level of migratory ability in HeLa
cells and to allow comparison with claudin transfected cell lines. After creating the gap in the
cell monolayer, the size of the gap was measured using image j© software to ensure the gaps
were close to equal size. The gap in the C1-HeLa, C7-HeLa and Null-HeLa were 840µm, 870µm,
850µm respectively at the beginning of the experiment (0 hours). Images of Null-HeLa show
significant migration of cells into the gap after 24 hours and complete closure of the gap after
48 hours (Figure 5.17). The size of the gap had reduced after 24 hours for C1-HeLa although not
to the same extent as the Null-HeLa at 24hours and the gap had not shown complete closure
after 48 hours, in contrast to the Null-HeLa cells.
C7-HeLa showed a similar pattern to C1-HeLa with partial closure occurring after 24 hours but
with gap closure still incomplete after 48 hours, unlike the HeLa-null cells which completely
infiltrated and filled the gap after 48 hours (Figure 5.17). These results indicate that Claudin-1
and Claudin-7 transfection may have an effect on the migratory ability of HeLa cells, possibly
impeding the motility of cells and their ability to detach from a group of cells and disperse.
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Figure 5.17 Cell migration assay images for claudin-1 and claudin-7 stable cell lines and
untransfected HeLa
Gap closure assay showing migration of cells over 48hr time period. Initial width of gap was
measured at 0 hour timepoint as being 840µm, 870µm and 850µm for C1-HeLa, C7-HeLa and
Null-Hela respectively. Null-Hela showed partial migration of cells into the gap after 24 hours
and complete gap closure at 48 hour timepoint. C1-HeLa showed partial gap closure at 24 hours
and 48 hours but incomplete gap closure over 48 hour period. C7-HeLa showed a similar
pattern to C1-HeLa with partial but incomplete gap closure after 48 hour time period.
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5.15 Summary and Key findings
SNAIL has been shown to be a potent repressor of E-cadherin [141] and in this study an
increase in SNAIL expression was observed in cases of cervical neoplasia. To assess what role
SNAIL might have on E-cadherin expression in a cervical context, siRNA was purchased from Life
Sciences and used to knockdown expression of SNAIL in two cervical cell lines, SiHa and HeLa.
An increase in claudin-1 and claudin-7 expression in cases of cervical neoplasia was also
observed in this study. To elucidate the role claudin overexpression may play in cervical
neoplasia, HeLa cells were stably transfected with expression vectors containing the claudin-1
and claudin-7 genes to produce two separate stable cell lines expressing claudin-1 and claudin7 respectively. The effect of claudin-1 and claudin-7 overexpresion on these cells, in terms of
cell proliferation/viability, permeability, invasion and migration, was then assessed.


Knockdown of SNAIL in SiHa cells had no effect on E-cadherin expression



Claudin-1 and claudin-7 overexpression both had a similar effect on HeLa cells
o Reduction in the migratory ability of transfected cells
o Increase in trans-epithelial electrical resistance of cell monolayers, indicating
decreased permeability.
o No significant effect on cell invasion
o No significant effect on cell proliferation/viability
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5.16 Discussion
This study assessed the role SNAIL may play in the regulation of E-cadherin expression in
two cervical cell lines, SiHa and HeLa. Both cell lines have high endogenous expression of SNAIL
and do not express E-cadherin. As SNAIL has been shown to be a potent repressor of E-cadherin
expression, this study used siRNAs targeting SNAIL to see if knockdown of SNAIL could be
achieved and if it had an effect on E-cadherin expression in these cells lines. siRNA is widely
used to tool in gene expression and silencing studies , however, the technique has limitations
that must be considered. The transduction of siRNA into cells leads to only a transient
knockdown of the gene of interest, with the duration of gene knockdown being determined by
the rate of cell growth and the dilution of the siRNAs below a crucial threshold level that is
necessary to maintain the inhibition of gene expression. As a result, the half-life of the target
protein must be considered to ensure that protein does not outlast the duration of gene
knockdown achieved by the siRNA. As SNAIL protein has a reported half-life of 20-45 minutes
[215], cells were harvested after 24 hours in order to try and minimize dilution of the siRNA
during cell growth and maximise knockdown of the SNAIL protein.
Another common limitation is of siRNA based techniques are the potential for off target
effects. Off target effects occur through partial complementarity of the siRNA with unintended
mRNA targets leading to down-regulation of non-target genes. The two siRNAs used in this
study were purchased commercially and designed by Ambion using off-target effect prediction
algorithms to ensure specificity for SNAIL mRNA only and to minimise any cross
complementariness with other mRNA sequences.
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Another limitation of siRNA based studies is the need for an effective delivery system, as
siRNAs are naturally repelled by the negatively charged cell membrane. This study utilised a
commercial lipofectamine, RNAi Max (Ambion), reagent to transfect siRNA into the target cells.
This reagent had been specifically designed for transfection of siRNA and had been validated for
use on HeLa cells by the manufacturer, which should have ensured effective transfection of
siRNAs into target cells during the experiments performed in this study.
To investigate the effect of claudin-1 and claudin-7 transfection on HeLa cells a number
of assays were used to assess cell behavior, such as migration, invasion, viability and
permeability. To assess cell migration a wound-healing or gap closure assay was performed.
This assay involves manually scraping a gap in a cultured monolayer and measuring the rate at
which surrounding cells migrate into the space and fill the gap. The main limitation of this assay
is the lack of precision associated with manually scratching the gap in the monolayer and the
variability that can occur in the total area of the gap using this method. To minimise any
variability in the size of the gap, the size of the gap was measured using image j software to
ensure uniformity in the gap size and all assays were performed a minimum of 3 times. To
assess the invasive ability of cells a boyden chamber assay was used. This assay measures the
ability of cells to digest an extracellular matrix and pass through a semi-permeable membrane.
A limitation of this method is that it lacks sensitivity when only a small number of cells invade
through the membrane and thus with a weakly invasive cell line like HeLa, it is difficult to detect
any statistically significant changes in invasive ability. It is therefore possible that if claudin
transfection had only a minor effect on cell invasion, due to the low invasive ability of HeLa
cells, this assay may lack the sensitivity to detect these changes. To measure the effect of
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claudin transfection on cell monolayer permeability, TEER readings of cells cultured on a porous
filter membrane were measured using a voltmeter. The ability of the voltmeter to accurately
and reliably measure the resistance across the membrane is dependent on the correct and
consistent positioning of the electrode in the transwell plate. TEER readings were measured 10
times and experiments performed in triplicate on 3 separate occasions, to ensure results were
as accurate as possible any variability in resistance readings associated the positioning of the
electrode was minimised.
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6. Discussion
Adherens and tight junctions play a key role in maintaining the cohesive structure of
epithelial tissue. Loss of cell-cell cohesion is a key mechanism in the development of epithelial
malignancies, allowing cells to leave their site of origin and spread throughout the body,
forming distant metastasis [216]. The significance of the process of metastasis is highlighted by
the fact that 90% of cancer deaths are due to the formation of distant metastasis [203]. Since
adherens and tight junctions in epithelial cells are important for maintaining tissue homeostasis
by regulating epithelial barriers, and are important for cell adhesion and for cohesive structure,
aberrant expression of the proteins that make up these structures is frequently observed in
epithelial malignancies [116] [217] [218]. The aims of this study were to examine if various AJ
and TJ proteins are aberrantly expressed in cases of cervical neoplasia, if these aberrant
expression profiles are associated with any specific HPV subtype, and to analyse what effects
aberrant AJ and TJ protein expression may have on dysplastic cervical cells.
To examine AJ and TJ protein expression several tissue microarrays were constructed
containing normal cervical tissue and all grades of neoplasia. These tissue microarrays were
stained using immunhistochemistry and assessed to see if there was any change in AJ and TJ
protein expression in cases of cervical neoplasia. E-cadherin is an important part of adherens
junctions being one of the main trans-membrane proteins in the junction and initiating cell-cell
adhesion through trans-cadherin interactions between neighbouring cells. In this study normal
cervical tissue displayed moderate E-cadherin staining in the basal and intermediate layers of
the epithelium with weaker staining observed in the superficial layers of the epithelium, and
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this is a staining pattern also observed by Vessey et al. 1995 [219] . E-cadherin expression is
thought to be reduced in the superficial layers of the epithelium as the cells terminally
differentiate, allowing these cells to be sloughed off and for new cells to move up through the
epithelium [220]. Low grade lesions displayed significantly less staining than normal epithelium.
Dysplastic cells in basal portion of the epithelium frequently displayed a lack of staining, while
some weak staining was observed in the intermediate and superficial layers of the epithelium.
High grade lesions often displayed a complete absence of staining with occasional weak staining
observed in the superficial portion of the epithelium. The weak staining observed in the
superficial sections of the epithelium most likely reflect the immature dysplastic cells beginning
to mature further up the epithelium than in normal epithelium, where cells begin to mature in
the basal and intermediate layers of the epithelium. Two different patterns were observed in
squamous cell carcinoma samples with some samples displaying an absence of staining while
others displayed weak staining. The dichotomy between weak and absent staining of sqaumous
cell carcinomas most likely reflects the level of differentiation within the tumour, with Wu et
al., 2000 showing that well differentiated squamous tumours often retain some level of Ecadherin expression while poorly differentiated tumours tend to lose all expression completely.
The findings of this study are in agreement with other studies Munhoz, et al., 2009 [221] ,
Branca, et al., 2006 [222] that have observed a reduction of E-cadherin in cases of cervical
intraepithelial neoplasia and squamous cell carcinomas compared to normal cervical
epithelium., indicating that loss of E-cadherin expression may play an important role in cervical
tumourigenesis.
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This study found N-cadherin displayed predominantly weak membranous staining in
normal cervical epithelium, mostly in the basal and intermediate layers. Low grade lesions
displayed moderate membranous staining in the dysplatic cells of the basal layers, with weaker
staining in the differentiating cells of the intermediate and superficial layers. High grade lesions
showed moderate to strong membranous staining throughout the epithelium. Squamous cell
carcinoma cells showed strong membranous staining with some weak cytoplasmic activity.
Currently there are few studies of N-cadherin expression in cervical malignancies to directly
compare the results of this study to. An immunohistochemistry based study by Fan et al. 2012
[223] found an increase in N-cadherin expression in LSIL, HSIL and invasive cancer compared to
normal cervical epithelium, which is similar to the findings in this study. Another
immunohistochemistry based study found increased expression of N-cadherin in oral squamous
cell carcinoma samples, and that N-cadherin expression correlated with poor patient outcome
[224]. The role of N-cahderin in tumourigenesis has been extensively studied in cell models
which may offer insight into its potential role in cervical neoplasia. N-cadherin has been shown
to promote motility and invasiveness in breast [132] and melanoma cells lines [225], which may
indicate the increased expression observed in cases of cervical neoplasia in this study could be
associated with cervical tumourigenesis.
This study observed an increase in staining of Claudin-1 and Claudin-7 in cervical
neoplasia compared to normal cervical epithelium. A gradual increase in staining intensity for
Claudin-1 was observed, with low grade lesions showing a slight increase, high grade lesions a
more pronounced increase and squamous cell carcinoma samples showing the highest level of
staining. Claudin-7 displayed a similar staining pattern to claudin-1 except the most intense
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staining was observed in high grade lesions. The results of this study concur with other studies
that have observed increased Claudin-1 and Claudin-7 expression in cervical neoplasia. Lee, et
al., 2005 [226] observed gradually increased expressions of claudins-1 and -7 in accordance
with progression from LSIL to HSIL and invasive carcinoma. Lee et al., 2005 [226] however, did
not observe Claudin-1 or -7 expression in normal cervical epithelium and found the highest
expression levels of Claudin-7 in invasive carcinoma samples, contrary to our findings. Sobel et
al., 2005 [227] observed Claudin-1 and -7 expression in normal cervical epithelium with an
increase in expression in low and high grade lesions and invasive carcinoma in concordance
with our results. Sobel, et al., 2005 observed the highest level of expression for Claudin-7 in
HSIL lesions, which concurs with this study, although they observed the highest expression of
Claudin-1 in HSIL lesion whereas this study observed the greatest expression in invasive
carcinoma samples. Claudins-1 and -7 are closely related TJ proteins [228], which may explain
the similarities in staining patterns observed for both proteins in this study. Parallel up and
down regulation of structurally similar claudin proteins has been observed in other cancer types
such as prostatic adenocarcinomas [121]. Overexpression of Claudin-1 has been suggested to
destabilise the tight junctions and lead to a loss of adhesion in oral squamous carcinoma cell
lines [112], although in lung adenocarcinoma Claudin-1 has been observed to be a metastasis
suppressor [115]
This study observed an increase in staining of p120 catenin in cervical neoplasia
compared to normal cervical epithelium. HSIL lesions displayed the most intense staining
pattern while both LSIL and squamous cell carcinoma displayed greater staining intensity than
normal epithelium. p120 catenin is an integral part of adherens junctions with p120 binding
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promoting the stabilisation of cadherin complexes on the plasma membrane and thus
strengthens cell-cell adhesion [87]. The E-cadherin/p120-catenin complex is important for
formation and maintenance of the adherens junctions, and Stairs, et al., 2011[229] found that
in mouse models p120-catenin loss in the mouse oral cavity and esophagus leads to squamous
cancers and suggested p120-catenin functions as a tumour suppressor gene.
p120 overexpression, however, can induce dramatic changes in cell morphology and
increase cell motility [230]. These effects are apparently mediated by the ability of p120 to
suppress RhoA activity and induce the activities of the related Rho GTPases, Rac1 and Cdc42
[230]. The dual role of p120, both promoting and inhibiting tumourigenesis, is thought to occur
as a result of the interactions between p120 and E-cadherin. Endogenous p120 promotes the
transformed growth of E-cadherin–deficient tumours by promoting Rac1 activation and
inducing MAPK signaling. In contrast, p120 potently suppresses the growth of tumour cells
expressing endogenous or exogenous E-cadherin [91]. In this study LSIL, HSIL and SCC samples
frequently displayed a lack of positive staining for E-cadherin while strong positive staining for
p120-catenin was observed for all grades of neoplasia. These findings suggest p120 may play a
role in the pathogenesis of cervical neoplasia, although detection of the Rac1 and Cdc42 Rho
GTPases in SIL and SCC samples would be needed to confirm this.
This study observed an increase in staining of SNAIL in cases of cervical neoplasia as
compared to normal epithelium. Very few cases of normal cervical epithelium showed any
staining with a gradual increase in staining observed in accordance with progression from LSIL
to HSIL and invasive carcinoma. As yet, few studies have been published looking at SNAIL
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expression in cervical neoplasia. Zhao et al., 2008 [231] analysed SNAIL expression at the
transcriptional level finding SIL lesions and invasive carcinoma samples had much greater
expression of SNAIL mRNA than normal cervical tissue. Increased expression of SNAIL in cervical
neoplasia may be of significance, as SNAIL has been shown to a potent repressor of E-cadherin
in epithelial cell lines [212]. This study attempted to gain further insight into the role that SNAIL
might play in suppressing E-cadherin in cervical neoplasia, by performing siRNA mediated
knockdown of SNAIL expression in two malignant cervical cell lines, HeLa and SiHa that lack Ecadherin expression. In HeLa cells we were unable to achieve significant knockdown of SNAIL
expression, however, significant reduction in SNAIL was observed at the protein and mRNA
level in SiHa cells. This reduction in SNAIL expression did not correspond to an increase in Ecadherin expression in transfected cells, for which there could be several explanations. It is
possible that the potency of SNAIL is such that the level of knockdown we achieved in this study
is insufficient to inhibit its repression of E-cadherin. It is also possible that there is another
mechanism involved in repression of E-cadherin in the SiHa cell line and in cervical neoplasia.
Loss of E-cadherin expression is observed in many different tumour types, and SNAIL mediated
suppression is only one possible mechanism by which repression of E-cadherin may occur. Ecadherin promoter methylation [232] and the action of other transcriptional repressor proteins
, Slug [233], SIP1 [234], and ZEB1 [235] may also play a role in suppressing E-cadherin
expression. Further experiments are necessary to fully reveal the role that SNAIL may play in
cervical tumorigenesis, however, the immunohistochemistry staining results in our cervical
tissue samples indicate that its expression is associated with disease progression and thus it
may be useful as a biomarker for disease progression. The role of HPV in promoting EMT is still
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not fully understood although a number of studies are beginning to uncover interactions
between HPV oncoproteins and key EMT pathways. Over expression of HPV16 E7 causes
molecular changes indicative of a mesenchymal transition in normal human foreskin
keratinocytes [236]. Expression of HPV16 E7 in normal human epithelial cells caused increased
levels of vimentin and fibronectin and N-cadherin, all markers associated with a mesenchymal
phenotype, whereas E-cadherin, a marker of the epithelial phenotype, was expressed at
decreased levels [236]. In a similar study, many epithelial features were gradually eliminated
and some mesenchymal traits were established in HPV16-transformed keratinocytes during
HPV induced transformation [237]. These studies indicate that HPV proteins likely play a key
role in driving EMT in cervical cancer.
After identifying aberrant expression of tight and adherens junction protein in cases of
cervical neoplasia, the prevalence of different HPV genotypes in our samples was analysed. This
would offer insights into the prevalence of HPV in the Irish population, and also allow
comparisons between infection with certain HPV-genotypes and the expression profile of tight
and adherens junction proteins. This study utilised a PCR based method to identify the
presence of HPV DNA in FFPE cervical tissue samples. The GP5+/6+ consensus primer set was
selected as it is capable of amplifying DNA from a broad spectrum of HPV types and produces a
150bp amplimer that can be subsequently sequenced to determine the HPV genotype of the
sample. Other primer sets, such as SPF10 and MY09/11, can also be utilised in the detection and
genotyping of HPV, however, they were not utilised for a number of reasons. The degradation
of DNA in formalin-fixed samples hinders the PCR amplification of DNA fragments over 200bp
[238]. As the MY09/11 primer set amplifies a 450bp part of the L1 genome it was not utilised in
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this study. The SPF10 primer set is capable of detecting more HPV genotypes than the GP5+/6+
primer set and is more sensitive, however, as it uses multiple forward and reverse primer and
amplifies a short 65bp sequence of the genome, that is unsuitable for sequencing, it was not
utilised in this study.
This study detected HPV DNA in 60 of 101 samples examined (60%). HPV DNA was
detected in 9 of 10 (90%) squamous cell carcinoma samples examined , in 12 of 28 (43%) of LSIL
samples and 33 of 54 (61%) HSIL samples. For 16 of the 101 (16%) samples no beta-globin
amplimers could be produced, indicating an absence of amplifiable DNA. It has previously been
reported that HPV DNA is present in up to 99% of cervical cancers and 94% of CIN lesions [3].
This discrepancy in the levels of HPV DNA detection in this study and other studies may be due
to a number of factors. Overall FFPE tissue is not ideal for PCR studies because of the damage
done to DNA during the formalin fixation process, that causes fragmentation and cross linking
of the DNA strands. The damage caused to DNA by formalin fixation is highlighted by the fact
that in 16% of the analysed samples no amplifiable DNA could be detected at all using the betaglobin primers. For N.E.M samples that were beta-globin positive but GP5+/6+ negative it is
possible that in these samples there was simply no HPV DNA present; in the vast majority of SIL
samples however HPV DNA would be expected to be present. One factor that may explain why
some SIL samples had amplifiable DNA present but still failed to produce an amplimer using the
GP5+/6+ primers, is due to the relative lower level of HPV DNA compared to genomic DNA is
the samples. In samples with SIL, the lesions may only cover a small area and overall only
contain a few cells. While PCR amplification for β-globin may be successful in a given sample
due to the fact that every cell within the tissue should contain a copy of the beta-globin gene,
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the number of cells containing HPV DNA may be much lower, making detection of HPV more
difficult. This effect is highlighted by the fact that the highest HPV detection rate was in invasive
carcinoma samples, in which the majority of cells would be expected to contain HPV DNA.
A study by Steineau, et al., 2011 [239] using the same DNA extraction method as this
study, was able to detect HPV DNA in 62.7% cases of formalin-fixed cervical neoplasia and other
HPV induced carcinomas, which is comparable to the 60% detection rate of this study.
Interestingly this study noted that by using an additional heating step during DNA extraction
that HPV DNA detection was increased to 73.3% of samples. This study also found that they
were unable to detect amplifiable DNA in 19% of their samples, which is comparable to the 16%
of this study, and they also noted that with heat treatment this figure lowered to 5%. A study
by Odida et al., 2010 [240] found a HPV DNA detection rate of 88.9% in formalin fixed paraffin
embedded invasive cervical carcinoma samples , which contrasts with the 60% detection rate of
this study. The study by Odida et al., 2010 utilised the SPF10 primer set which is capable of
detecting a greater number of HPV types than the GP5+/6+ primer set utilised in this study, and
also produces a shorter amplimer that is more effective in FFPE tissue, which may explain the
greater detection rate compared to this study. Ideally all samples that were beta-globin
negative or SIL lesions that were beta-globin positive but GP5+/6+ negative would have had the
DNA extraction step repeated using more tissue, and possibly using the heating step described
by Steineau et al., 2011 in order to try and increase the HPV DNA detection rate. Unfortunately
this was not possible due to ethical constraints, as the tissue samples were only available for a
limited time before they had to be returned to the hospital.
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After detection of HPV DNA in samples, the amplified PCR products were sent for
external sequencing by Eurofins MWG Operon, Ebersberg, Germany. Of the 60 samples
successfully sequenced HPV-16 was by far the most common genotype detected with 77.3% of
samples being HPV-16 positive. The second most common genotype detected was HPV-18 with
18.3% of samples, with HPV-16 and HPV-18 combined accounting for the vast majority, over
90%, of HPV genotypes detected. A large scale meta-study by Smith et al. 2007 [241] of HPV
genotype global distribution in invasive cervical cancer and high-grade squamous intraepithelial
lesions (HSIL) identified the highest prevalence of HPV16/18 in invasive carcinoma was in
Europe, North America and Australia, with a prevalence 74-77% and global prevalence of 68%.
All samples of invasive carcinoma in which HPV was detected in the study were HPV-16/18
positive; the discrepancy between the HPV-16/18 prevalence in this study is likely due to the
relatively low sample number compared to the meta-study. The detection rate of HPV in HSIL
lesions globally in the meta-study by Smith et al. 2007 was 84.9%, compared to the 61%
detection rate of this study. One aspect that may explain the lower HPV detection rate in this
study compared to the meta-study is the fact the meta-study compiled results from various
different studies using a variety of tissue types, including FFPE tissue and fresh samples
collected for cytological analysis, and a variety of HPV detection methods. This study examined
FFPE tissue exclusively and, as has previously been discussed, it is likely that that this
contributed to the lower detection rate compared to the meta-study. The prevalence of HPV16/18 in the meta-study was 52% compared to 90% observed in this study. The higher
prevalence observed in this study is likely due to the nature of samples utilised. Most tissues
sample used in this study would have been referred for biopsy after several abnormal smear
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tests, thus were likely cases with persistent lesions. HPV-16 infection in particular is strongly
associated with persistent lesions [242], thus it is likely that our samples would be more
inclined towards HPV-16 infected lesions. A significant number of samples in the meta-study
(44%) were derived from thin-prep cytological preparations, which may not contain as many
persistent lesions and therefore may contain a lower number of HPV-16 positive samples,
compared to this study. Of the other subtypes detected HPV-6 was the only low risk genotype
detected and was found in a LSIL sample. Low risk HPV subtypes are typically associated with
benign condylomas and may also infrequently be associated with a LSIL lesion, with Clifford et
al., 2005 [243] finding approximately 10% of HPV positive LSIL cases containing HPV-6 DNA. A
small number of other high risk subtypes were detected, HPV-33 HPV-58 and HPV-67, with both
HPV-33 samples associated with high grade lesions, HPV-58 positive sample didn’t have a
gradable core on the TMA and HPV-67 was associated with a LSIL sample. HPV-67 is a genotype
from the same alpha-9 subgroup as many highly oncogenic HPV subtypes, such as HPV-16 and 33, however, it’s association with cancer is less clear with only a few reports of HPV-67 being
identified in cervical cancer cases [244] [245]. A combination of low frequency, lack of data on
active transcription and it’s transforming potential in model systems, has led HPV-67 to be
classified as only probable/possible carcinogen [246]. A number of NEM samples also tested
positive for HPV. HPV infection can often be asymptomatic, presenting with no discernable
dysplasia. A study of 996 liquid cytology samples from Irish women aged between 16 and 72 by
Keegan et al., 2007 found that 11.4% of samples with normal cytology tested positive for HPV,
highlighting that infection with even high-risk HPV subtypes does not necessarily lead to the
development of dysplasia.
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One of the aims of this study was to examine if there was any association between an
individual HPV genotype and aberrant expression of particular adherens and tight junction
proteins. After successfully genotyping 60 samples, only 31 of these samples were available for
comparison on the corresponding TMAs. The reasons for this discrepancy were twofold. Firstly,
some samples were damaged during TMA construction process, meaning the cores were
ungradable after IHC staining. Secondly, inaccurate punch sampling during TMA construction
meant that in a number of cases the area containing the desired lesion was missed and an
adjacent area of the epithelium was incorporated into the TMA instead. While this adjacent
area of the epithelium was still graded by the pathologist and used for IHC staining, it could not
be used for comparison with detected HPV genotypes, as it had been adjacent to another part
of the epithelium containing a lesion with a different disease grade. Other methods that would
have allowed detection of HPV directly in our TMA sections, such as chromatic in-situ
hybridization (CISH), were explored however this method only distinguishes between high-risk
low-risk subtypes and doesn’t allow for comparison between specific subtypes of HPV.

After determining that several adherens and tight junction proteins were expressed
aberrantly in cervical neoplasia, it was decided to examine further the role that claudin-1 and
claudin-7 overexpression may play in cervical tumourigenesis. Claudin-1 and claudin-7 were
selected for further analysis for a number of reasons. Firstly, the role of claudins in
tumourigenesis is far from fully understood and is currently an area of significant research. The
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difficulty in fully elucidating the role of claudins in cancer is highlighted by the fact that both up
and downregulation of claudins is frequently observed in tumours. [116].
Secondly, while the results of this study and others [227],[247] have observed increased
Claudin-1 and Claudin-7 in pre-invasive cervical lesions and in cases of cervical carcinoma, to
the best of our knowledge, there have been no studies studying the effect of claudin-1 and
claudin-7 overexpression in cervical cell lines. This study aimed to investigate the effect of
Claudin-1 and 7 overexpression on the cervical carcinoma cell line HeLa, and to elucidate what
role Claudin-1 and -7 overexpression may play in cervical carcinoma. To this end, stable cell
lines expressing claudin-1 and claudin-7 were generated and their invasive, migratory,
permeability and proliferative ability assessed.
This study found that Claudin-1 or Claudin-7 over expression had no significant effect on
the invasive ability of HeLa cells. Studies have identified that Claudin-1 overexpression is
associated with an increased invasiveness in oral carcinoma cells through upregulation of
several matrix metalloproteases [112] [113]. Claudin-1 expressing colon carcinoma cells that
underwent siRNA mediated knockdown of Claudin-1 displayed significantly decreased
anchorage-independent growth and invasion with a significant decrease in MMP-9 activity.
Conversely, claudin-1 overexpression suppresses metastasis and invasion in lung cancer cells
[115]. The interaction between claudins and MMPs is likely to have a key influence on the
invasive ability of malignant cells as the role of MMPs in digesting the extracellular matrix and
promoting invasion has been well established [248] and claudins have previously been shown
to promote activation of matrix metalloproteinase-2 in Human Embryonic Kidney cells [249].
Studies have previously reported that HeLa cells lack the alphavbeta3 integrin receptor [250]
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which through its interaction with membrane type-1 metalloproteinase-2 (MT1-MMP), and
tissue inhibitor of metalloproteinase-2 (TIMP-2) aids the activation of MMP-2 [251]. A lack of
MMP-2 activation in HeLa cells may explain why they show low invasive ability and why the
Claudin-1 and -7 overexpression in HeLa cells had no significant effect on the invasive ability of
HeLa cells in this study.
The association between Claudin-1 and Claudin-7 expression and cell migration is also
highly dependent on tumour type, with Claudin-1 expression associated with increased cell
migration in breast cancer cells [252] and, conversely, associated with an inhibition of cell
migration in lung cancer cells [211]. Claudin-7 expression is associated with increased migratory
ability in ovarian carcinoma cells [125] but is associated with reduced migratory ability in lung
carcinoma cells[124]. This study found that Claudin-1 and Claudin-7 overexpression reduced
the migratory ability of HeLa cells. These results suggest there may be some establishment of
homotypic claudin interaction between neighbouring cells leading to increased adhesion, or
that claudin-1 and -7 transfection had a downstream effect on another motility related
pathway. The exact mechanisms by which claudins contribute to cell migration and motility is
still not fully understood. A recent study by Webb et al. 2013 [253] found that second
extracellular loop of claudin-4 is able to interact with the extracellular environment to promote
cell motility. Another mechanism through which claudins may influence cell motility and
migration is through the N-WASP (neuronal Wiskott–Aldrich Syndrome protein) and ROCK (Rhoassociated Coiled-coil Kinase) pathways. N-WASP is a key regulator of actin cytoskeleton
remodeling which is an essential process for cell motility [254] [255], while ROCK is also
involved in regulation of cell motility through modulation of the cytoskeleton [256] [257]. Loss
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of claudin-5 in the breast cancer cell line MDA-MB-231 inhibited cell motility through
involvement in signaling pathway of N-WASP and ROCK [258], while transfection of claudin-5
into a human endothelial cell line also reduced the motility of transfected cells through the
same pathways [259]. Similar to claudin-5, it is possible that claudin-1 and claudin-7 may also
interact with the N-WASP and ROCK signaling pathways to reduce cell motility, although further
experiments would be needed to confirm this.
Aside from contributing to disruption in cellular cohesion, tight junction breakdown is
thought to contribute to tumorigenesis through disorganised paracellular permeability allowing
an unregulated flow of various potentially oncogenic molecules, such as growth factors and
cytokines, through the epithelium [260]. This study found that claudin-1 and claudin-7
transfected cells showed increased TEER readings suggesting decreased permeability. Claudin-1
and claudin-7 are reported to increase TEER when transfected into cultured epithelial cells
[109] although Claudin-1 transfected colon carcinoma cells showed reduced TEER readings
[114]. The increased in TEER readings observed in claudin-1 and claudin-7 stable cell lines, along
with the decreased migratory ability of these cells suggests that some level of claudin-claudin
interaction may be re-established in these cell lines.
The role of claudins in tumourigenesis is still not fully understood, part of which relates
to the fact that in certain tumours an increase in expression a particular claudin is associated
with tumourigenesis, while in another tumour type a reduction of the same claudin is
associated with tumourigenesis. Immunohistochemistry based studies of pre-invasive cervical
lesions and cases of cervical carcinoma found an increase in expression of claudin-1 and
claudin-7 compared to normal cervical epithelium[227],[247], which would suggest that in the
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case of cervical malignancies claudin-1 and claudin-7 may be involved in oncogenic progression.
The findings of this study, that claudin-1 and claudin-7 expression reduces HeLa cell migration,
increases TEER and has no significant effect on cell invasion or proliferation, suggest that
alteration in claudin-1 and claudin-7 expression alone are not responsible for tumourigenesis in
cervical malignancies, but likely play a role as part of a larger process of tight junction
disruption and cellular transformation. The process of tight junction dysregulation is a complex
process likely involving the aberrant expression of several tight junction proteins. Claudin-1,-2,4,-7 have been previously reported to be overexpressed in cervical pre-invasive lesions and
cases of carcinoma[247]. Other non tight junction related proteins that are involved in cellular
adhesion, such as E-cadherin and beta-catenin, are also reported to be aberrantly expressed in
cervical malignancies [261]. The nature of any possible interactions between these proteins and
how they contribute to tumourigenesis in cervical malignancies is yet to be fully understood,
although experiments in other cell models may offer some insights. In colon carcinoma cell lines
claudin-7 forms a complex with epithelial cell adhesion molecule (EpCAM), CD44v6 and COO29, that confers a higher degree of apoptosis resistance than lines devoid of any one of the
four molecules [262]. A recent study also found that claudin-7 associates with claudin-1 and
facilitates incorporation of claudin-1 into EpCAM-containing complexes, and that TJ formed
readily after EpCAM knockdown; the acquisition of trans-epithelial electroresistance was
enhanced, and TJ showed increased resistance to disruption by calcium chelation [263].
This study identified a change in expression of a number of key tight and adherens
junction proteins in pre-invasive and invasive cervical lesions. The change in expression of a
number of these proteins, often observed even in low grade lesions, suggest that disruption of
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tight and adherens junction may be an early step in the oncogenic transformation of epithelial
cervical cells. As such, many of these proteins may be of use as prognostic indications or
biomarkers for disease progression. This study did not have access to patient follow up
information, such as patient outcomes, and thus was unable to fully assess if there is any
relationship between changes in expression of particular proteins and factors related to
prognosis. Future studies with access to full patient follow up information, should seek to
examine whether changes of tight and adherens protein expression in cases of cervical
neoplasia are associated with any difference in various factors relating to prognosis, such as
disease recurrence, resistance to treatment or survival rates. Further studies of this type would
allow a more complete evaluation of the potential role that these proteins may play as
biomarkers for disease progression or prognostic indicators. This may allow for the
identification of pre-invasive lesions more likely to progress to invasive cancers or identify
cancers more likely have poorer responses to treatment and thus give more information to
physicians when assessing treatment options for patients.
This study detected and genotyped HPV DNA in number of cervical samples, with HPV
16 and 18 being by far the most prevalent subtypes detected, and aimed study aimed to assess
whether infection with a particular HPV subtype was associated with an aberrant expression
profile of adherens and tight junction proteins. Due to the predominance of HPV-16 in the
sample cohort (73% of samples) and the low prevalence of other HPV genotypes, this study was
limited in its ability to make significant comparisons of protein expression profiles between the
different genotypes. Future studies with a larger cohort of non HPV-16 samples could offer
greater insight into whether infection with different HPV genotypes is associated with differing
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adherens and tight junction expression profiles. This may allow identification of HPV subtypes
more associated with disruption of adherens and tight junction function and thus potentially
with a greater risk of disease progression. If particular HPV genotypes are associated with a
greater degree of aberrant protein expression, future studies may also aim to uncover the
different mechanisms by which particular HPV genotype effect the expression of adherens and
tight junction proteins in infected cervical cells.
Future studies may also examine the interactions between different tight and adherens
junction proteins and explore if several proteins can act synergistically to promote
tumourigenesis. The results of this study indicated that claudin-1 and claudin-7 expression
alone in HeLa cells did not increase cell invasion and reduced the migratory ability of
transfected cells. Other studies have begun to uncover the complex interactions between
claudins and other proteins, within and outside of tight junctions, and how these interactions
can promote invasion and other features associated with tumourigenesis. Studies by Kuhn et
al., 2007 and Wu et al., 2013 have indicated claudins can interact with EpCam and other
claudins to destabilise tight junctions and confer increased resistance to apoptosis in a
synergistic mechanism that is reliant on co-expression of several proteins simultaneously. This
study identified changes in expression of several adherens and tight junction protein in cervical
tissue samples and future studies may focus on how co-expression of several of these proteins
effects cell behaviour, such as invasion, migration and proliferation. By uncovering any
potential mechanisms through which claudins can co-operate to promote invasion, it may
identify new pathways that can be used for targeted therapies in cervical cancer treatment.
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The future outlook for cervical cancer prevention is relatively positive due to a number
of recent advancements. Early detection of pre-invasive lesions before they have a chance to
progress to invasive cervical lesions has played a key role in the reduction of cervical cancer
incidence. The introduction of cervical screening programmes in several countries, including
Ireland, has helped greatly increase the detection rate of preinvasive lesions, which once
detected can usually be removed without complication. Another recent development which
should greatly reduce the incidence of cervical cancer is the introduction of vaccination
programmes. Two vaccines are currently available, Cervarix which offers protection from HPV16 and HPV-18, and Gardasil that offers protection from HPV-6,-11,-16 and -18. With HPV-16
and HPV-18 being responsible for approximately 70% of cervical cancer cases, a large reduction
in the incidence of cervical cancer should be observed in countries with organised vaccination
programmes. In Ireland the full benefits of the vaccination programme, in terms of lower
cervical cancer incidence will not be seen immediately, but over a longer period of time. This is
due to the fact vaccine is only effective in pre-sexually active women and is therefore currently
mostly being administered to girls aged 12 to 14.
While the outlook for cervical cancer prevention is positive in most developed nations,
the outlook for developing countries is less encouraging. Over 85% of cervical cancer deaths
occur in developing countries (WHO 2012) and this is projected to rise to 90% by 2020 [264].
There are huge divergences in mortality rates between developing and developed nations. For
example, in Malawi the mortaility rate is 38.3 per 100,000 people, compared to 1.8 per 100,000
in France (WHO 2012). The massive difference in mortality rates is principally down to a lack of
funding for cervical screening and vaccination programmes in developing countries. There have,
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however, been some encouraging signs recently that the burden of disease in developing
countries may be eased. The Global Alliance for Vaccines and Immunisation (GAVI) is a publicprivate health charity that aims to increase access and availability of vaccines in developing
countries. GAVI is currently trailing a HPV vaccination programme is in several developing
countries with the aim of vaccinating 30 million girls by 2020. Although this programme will not
completely address the overall burden of disease, it is hoped that it will pave the way for
further implementation of vaccination programmes in developing countries and ultimately lead
to significant reduction in cervical cancer incidence worldwide.
In summary, cervical cancer continues to be a significant cause of cancer deaths
worldwide, although the successful implementation of screening and vaccination programmes
should help reduce the burden of disease. Understanding the mechanisms by which HPVinduced cervical lesions acquire the ability to invade and metastasise and identifying
biomarkers that may predict this process remains critically important. This study identified
changes in expression of several adherens and tight junction proteins in cases of cervical
neoplasia, and identified a possible association between aberrant adherens and tight junction
expression and specific HPV genotypes. In order to elucidate how aberrant adherens and tight
junction expression may promote cervical tumourigenesis, this study examined the
overexpression of claudin-1 and claudin-7, and the knockdown of SNAIL, in cervical cell models.
This study observed that SNAIL knockdown in cervical cancer cell lines is insufficient to induce
E-caherin expression, which is a novel finding and indicates that another mechanism may be
responsible for the repression of E-cadherin expression observed in cases of cervical neoplasia.
Despite the increased expression of claudin-1 and claudin-7 observed in cases of cervical
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neoplasia, claudin-1 or claudin-7 overexpression did not contribute to increased tumourigenesis
in HeLa cells. On the contrary this study identified claudin-1 and claudin-7 overexpression
reduces cell migration and decreases permeability in cervical cell models, which is a novel
finding, and suggests that the development of invasive and metastatic characteristics in
malignant cervical cells is likely reliant on the synergistic aberrant expression of several
adhesion proteins.
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Appendix
Mayer’s Haematoxylin
2g haematoxylin (Merck)
100g aluminium sulphate (BDH)
0.4g Sodium Iodate (EMD Chemicals)
Make up to 2 litres with distilled water and leave overnight
2g citric acid (BDH)
Mix and Boil for 5 minutes
Allow to Cool and filter before use

1% Eosin
1g eosin powder (Merck) dissolved in 100ml water

Spirit (96%)
960ml absolute alcohol (Merck) made up to 1 litre with distilled water

70% Alcohol
700ml absolute ethanol (Merck) made up to 1 litre with distilled water
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2% agarose gel
2g agarose powder (Invitrogen)
100ml of TBE (invitrogen)
Boil in microwave until dissolved
Cool to 60˚C
Add 0.5μg/ml Ethidium Bromide (Fluka)
Mix and gently poor into template
6x DNA loading buffer (50ml)
0.25% bromophenol blue (BDH)
0.25% xylene cyanol (BDH)
30% glycerol (BDH)

0.01mol/l citrate buffer (pH6)
2.1g citric acid (BDH)
Add approximately 800ml distilled water
Adjust to pH 6 using 2M NaOH
Make solution up to 1 litre

0.01mol/l EDTA buffer (pH8)
3.7g EDTA (BDH)
Add approximately 800ml distilled water
Adjust pH to pH 8 using 2M NaOH
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Phosphate Buffered Saline (PBS)
Add 1 PBS tablet (Sigma) to 100ml distilled water.

0.1% protease
0.1g protease type 24 (Sigma) in 100ml PBS

3% Hydrogen Peroxide in methanol
1ml 30% hydrogen peroxide (BDH)
9ml Methanol (Fluka)

0.06% 2,4 diaminobenzidine (DAB)
16ml PBS injected into 1 container of DAB (Sigma)
1XTBS (Tris-buffered saline)
1.21g Tris + 4.38g NaCl in 500ml dH2O

T-TBS 1X
To 1 liter of TBS 1X, add 1 mL of Tween 20.
1X Running Buffer
1.5g Tris + 7.2g glycine + 0.5g SDS in 500ml H2O
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1X Transfer Buffer
0.6g Tris
2.882g glycine
adjust to pH 8.3 in 200ml H2O

APS 10%
0.1 g

Ammonium Persulfate

1 mL distilled H2O
LB Broth
5g Tryptone (Lab M)
5g NaCl (Merck)
2.5g Yeast extract (Lab M)
Mix with 500ml distilled water and autoclave
0.1M CaCl2
5.5g CaCl2 (Fisher Scientific)
Mix with 250ml distilled water
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